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1 INTRODUCTION 
1.1 Obesity 
1.1.1 Introduction 
Over the past four decades, we have transitioned from a world in which underweight prevalence was 
more than double that of obesity to one in which people are more obese than underweight (NCD et 
al., 2016). The World Health organization (WHO) estimates that, more than 1.9 billion adults were 
overweight in 2014, of which 600 million were obese (13% of the global population) (WHO, 2016).  
Obesity is a chronic metabolic disease which results from an imbalance between energy uptake and 
energy expenditure (EE). In adults, obesity is defined by the body mass index (BMI). The BMI, 
originally named Quetelet index after its Belgian inventor, is calculated by dividing the body mass in 
kilograms by the square of the body height in meters. The BMI divides the population into 
underweight (BMI < 18.5), normal-weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30), obese (30 ≤ 
BMI < 40) and morbidly obese (BMI ≥ 40) populations. 
Obesity leads to an excessive accumulation of intra-abdominal fat, which can have adverse health 
consequences like the development of insulin resistance and type 2 diabetes (T2DM). The 
mechanisms linking obesity to insulin resistance involve several factors that are released by the 
adipose tissue like non-esterified fatty acids (NEFAs), glycerol, hormones, pro-inflammatory cytokines 
and other factors (Kahn et al., 2006). In obesity, the production of many of these products is 
increased, leading to insulin resistance. This insulin resistance can result in a decreased pancreatic 
insulin production which can impair adipocyte metabolism, resulting in increased lipolysis and 
elevated NEFA levels, which further fuel the development of T2DM. Thus the process may slowly 
feed forward, explaining why the onset of T2DM is usually a slow process that takes many years. 
Obesity is not only linked to insulin resistance but also contributes to 33% of heart diseases, 50% of 
hypertensive incidents and 75% of diabetes prevalence (Forouzanfar et al., 2015). Associated with 
this, the life expectancy of morbidly obese patients is reduced by 10 years (Fontaine et al., 2003).  
The comorbidities of obesity, such as cardiovascular disease ($193-315 billion) (Maahs et al., 2014) 
and T2DM ($105-245 billion) (Dall et al., 2009) result in medical obesity-related costs as high as $210 
billion. This accounts for more than 20% of all annual healthcare spending in the US (Cawley and 
Meyerhoefer, 2012).  
1.1.2 Origin 
Obesity has reached epidemic proportions in populations whose environment promotes physical 
inactivity and increases consumption of energy dense, low-fiber foods. However, not all people in 
similar environmental conditions will become obese or suffer from the same health problems. 
Besides behavioral factors, genetics also determine our predisposition to become obese in an 
Introduction 
 
4 
 
obesogenic environment. Genetic studies in twins and families shows that genetic influences 
contribute up to 60% to abdominal adiposity (Wardle et al., 2008).  
In rare cases (5%) obesity will not have a multifactorial, but a monogenetic cause. The absence of the 
leptin gene or leptin receptor for instance will cause obesity (Zhang et al., 1994). Other monogenetic 
obesity disorders are related to mutations in pro-opiomelanocortin (POMC) (Krude et al., 1998), the 
melanocortin 4 receptor (MC4R) (Vaisse et al., 1998) or prohormone convertase 1 (Jackson et al., 
1997). 
1.1.3 Treatment 
Obesity treatment must begin with long-term lifestyle changes, including increased physical activity, 
dietary modifications using low-energy diets and behavioral therapy. Artificial sweeteners or 
functional food ingredients could be used as sugar replacers. When lifestyle changes alone are 
insufficient, pharmacotherapy can be added, although their side-effect profile and the modest nature 
of weight loss that can be achieved with these drugs should be taken into account. A last strategy for 
effective weight reduction is bariatric surgery.  
1.1.3.1 Lifestyle changes 
1.1.3.1.1 Lifestyle modification programs 
A program for lifestyle modification includes diet, exercise and behavioral therapy and is considered 
the first step to achieve successful weight loss. How do we define ‘successful weight loss 
management’? Wing and Hill proposed the following definition; ‘An intentional weight loss of at least 
10% of the body weight that keeps off for at least 1 year’ (Wing and Hill, 2001). 
Dietary interventions; low-energy diets 
A reduction of 500 kcal/day below energy requirements will provide health benefits (Ryan and 
Heaner, 2014). Many studies have focused on the amounts of dietary fat, protein and carbohydrates 
in the low-energy diets in an attempt to find the ‘magic’ weight-loss diet. However, these low-fat, 
low-carbohydrate or high-protein diets did not differ in their capacity to induce weight loss, 
indicating that the amount of calories is more important than the macronutrient composition of the 
diet (Johnston et al., 2014, Sacks et al., 2009). Therefore, the best practice is to provide low-energy 
diets that can be maintained by the patient and subsequently will provide health benefits. 
Dietary interventions; artificial sweeteners 
Sugar replacers, such as high-intensity sweeteners (HIS), can help to reduce the caloric content of 
meals without affecting its taste. So far sucralose (acceptable daily intake (ADI) 5 mg/kg/day, relative 
global market share (RGMS) 27.9%), aspartame (ADI 50 mg/kg/day, RGMS 27.9%), saccharin (ADI 15 
mg/kg/day, RGMS 13.1%), acesulfame potassium (ADI 15 mg/kg/day, RGMS 5.2%), neotame (ADI 0.3 
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mg/kg/day, RGMS 1.4%) and advantame (ADI 32.8 mg/kg/day, RGMS 1.4%) have been approved by 
the Food and Drug Administration (FDA) as HIS (FDA, 2014, Research, 2011). Stevia has not yet been 
approved by the FDA as a HIS but has a RGMS of 8.7%. The global market for HIS totaled up to $13.5 
billion in 2014. These products are mainly used in food products like soft drinks, coffee, breakfast 
cereals and chewing gum, but also in pharmaceutical products.  
HIS are several times sweeter than sucrose (normal table sugar) but are non-caloric. Two opposite 
views exist on the link between HIS and obesity. The first view hypothesized that HIS might 
dysregulate appetite control due to the mismatch between the sweet taste and lack of consumed 
energy. This question was popularized by studies linking sweetened beverages and increased hunger 
ratings (Rogers and Blundell, 1989, Blundell and Hill, 1986, Rogers et al., 1988) and was underbuilt by 
epidemiological studies (Blum et al., 2005, Forshee and Storey, 2003). However, these 
epidemiological studies did not take dietary patterns and lifestyle modifications into account, leading 
to confounding results. Furthermore, no big randomized controlled trials were performed to support 
this hypothesis. 
The second view stated that HIS are metabolically inert and might be used to decrease the caloric 
content of meals in order to decrease body weight. This hypothesis was underbuilt by studies that 
failed to link sweetened beverages and increased hunger ratings (Anderson et al., 1989, Rolls et al., 
1990) and two big randomized controlled trials (de Ruyter et al., 2012, Tate et al., 2012) suggesting 
that replacing sugar-sweetened beverages with non-caloric beverages might be a useful strategy in 
the battle against obesity. 
Dietary interventions; functional food ingredients 
The current typical Western diet is generally lacking sufficient dietary fiber, being composed 
principally of refined grains and other highly digestible sources of starch, sugar, various fats, and 
animal products. Many adults in our Western society consume 5g to 10g of fiber daily, as opposed to 
the 35g to 50g that is recommended for optimal health (Lyon and Kacinik, 2012). Several studies also 
investigated the link between fiber intake and weight gain. A study in 252 women showed that for 
each 1g increase in total fiber consumed, weight decreased by 0.25kg (Tucker and Thomas, 2009). 
Four other cross-sectional reports reported inverse associations between cereal fiber intake and 
body weight measurements (Newby et al., 2007, Lairon et al., 2005, McKeown et al., 2009, van de 
Vijver et al., 2009). Furthermore, two prospective cohort studies found a dose-response relationship 
between fiber intake and weight gain (Koh-Banerjee et al., 2004, Du et al., 2010). 
A specific kind of fibers, namely prebiotic sweeteners were proposed as functional food ingredients 
that may be useful to combat obesity. Prebiotics can be defined as; ‘nondigestible compounds that, 
through their metabolization by microorganisms in the gut, modulate the composition and/or activity 
of the gut microbiota, thus conferring a beneficial physiological effect on the host.’ (Bindels et al., 
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2015). The established prebiotics are; fructooligosaccharides (FOS) (oligofructose (OFS) and inulin), 
arabinoxylanoligosacharides, xylooligosacharides and galactooligosaccharides. OFS and inulin are 
derived from chicory root and differ in their polymerization degree; the average polymerization 
degree of OFS and inulin is estimated at 4 or 11 respectively although the polymerization degree of 
inulin can vary depending on its source and form. 
These prebiotics are not absorbed in the small intestine of healthy individuals but are fermented by 
the gut microbiota to the short-chain fatty acids (SCFAs); acetate, propionate and butyrate (Gibson 
and Roberfroid, 1995). OFS and inulin can be used as natural sweeteners since they have a low 
caloric content (1.5 kcal/g) and a sweetening power of 30-35% in comparison to sucrose (table sugar) 
(Apolinario et al., 2014).  
Supplementing OFS (10%) to a high-fat diet (HFD) for several weeks decreases body weight in 
rodents (Woting et al., 2015, Anastasovska et al., 2012, Delmee et al., 2006, Delzenne et al., 2005, 
Cani et al., 2005a). In contrast, a decrease (Cani et al., 2004a) or no effect (Parnell and Reimer, 2012) 
on body weight is observed when added to a normal chow diet. Moreover, OFS supplementation 
exerts an antidiabetic effect in streptozotocin-treated rats and HFD fed mice (Delzenne et al., 2007, 
Cani et al., 2006). 
In humans the effect of the prebiotics on body weight is dose-dependent. In lean adults, 9g/day of 
inulin for 4 weeks did not affect body weight in a cross-over design (Brighenti et al., 1999). When 
they increase their daily OFS intake gradually every week during 5 weeks from 15g to 55g, >35g 
OFS/day suppressed hunger without altering energy intake (Pedersen et al., 2013). In prediabetic 
patients, 30g/day inulin promoted weight loss during an 18 week study period (Guess et al., 2015), 
while in overweight adults contradictory results have been reported. Some studies investigating the 
effects of OFS or inulin reported a reduced body weight (Yang et al., 2012, Hoeger et al., 1998, 
Parnell and Reimer, 2009), while body weight or energy intake was not altered in others (Savastano 
et al., 2014, Daud et al., 2014). In overweight and obese children, 12 weeks OFS supplementation did 
not affect body weight in a randomized, double-blind, placebo controlled trial (Liber and Szajewska, 
2014). 
The positive effects of these prebiotics on energy homeostasis have been assigned to their 
fermentation products, namely the SCFAs. Indeed, SCFAs may directly affect adiposity by influencing 
lipogenesis and stimulating fatty acid oxidation (den Besten et al., 2015, Gao et al., 2009, Lu et al., 
2016). Furthermore, SCFAs can regulate the release of gut hormones involved in appetite regulation 
(Lin et al., 2012, Freeland and Wolever, 2010). Acetate may also play a role in central appetite 
regulation since; 1) 13C acetate preferentially accumulates in the hypothalamus, 2) a direct 
intracerebroventricular administration of acetate into the third ventricle suppressed food intake in 
rats, 3) an intraperitoneal injection of acetate increased signal intensity, measured via manganese-
enhanced magnetic resonance imaging (MEMRI), in the arcuate nucleus (ARC) and 4) an 
intraperitoneal injection increased POMC and reduced agouti-related peptide (AgRP) expression 
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(Frost et al., 2014). SCFAs have also been shown to improve glucose homeostasis and insulin 
sensitivity via activation of intestinal gluconeogenesis (De Vadder et al., 2014), improvement of 
insulin resistance (Gao et al., 2009) and stimulation of glucagon-like peptide 1 (GLP-1) secretion (Cani 
et al., 2006). 
Dietary intervention studies in humans indicate that SCFAs could regulate energy intake and body 
weight. This has been studied in a randomized-controlled 24-week trial in 60 overweight adults, 
where an inulin-propionate ester was used to specifically deliver propionate to the colon at 
concentrations that cannot be reached by unpalatably high levels of fermentable dietary fibers alone. 
Daily supplementation of 10g of this ester significantly reduced weight gain, intra-abdominal adipose 
tissue distribution, intrahepatocellular lipid content and prevented the deterioration in insulin 
sensitivity compared to the inulin-control group (Chambers et al., 2015).  
Physical activity 
Increasing physical activity is another essential component of lifestyle modification programs. 
Recommendations in the US and UK recommend 150min/week of physical activity (National et al., 
2014). Although more physical activity (30-45min/day) is needed to prevent obesity (Ryan and 
Heaner, 2014) and 60-90min/day may be needed to avoid weight regain (Ryan and Heaner, 2014). 
Furthermore, using physical activity as a weight-loss strategy resulted in a lower relapse and body 
weight regain in a follow-up study (Kayman et al., 1990, Leser et al., 2002). Therefore physical activity 
appears to play an important role in the maintenance of long-term weight loss. 
Behavioral therapy 
Behavioral therapy refers to a combination of techniques that help obese patients to modify their 
eating pattern, activity and thinking habits to control their excessive weight. Some of the core 
strategies of behavioral therapy are; self-monitoring, stimulus control, problem solving, cognitive 
restructuring and relapse prevention training (Diabetes et al., 2002).  
The benefit of lifestyle modification programs 
A systematic review on the outcome of weight loss induced by lifestyle modification programs 
showed that, in case of intense interventions, at 1 year only 28% of the participants obtained a 
weight loss ≥ 10%, 26% decreased their body weight with 5-9.9% and 38% with ≤ 4.9%. In less intense 
interventions 13% lost ≥ 10%, 16% decreased their body weight with 5-9.9% and 27% lost ≤ 4.9% of 
their body weight (Christian et al., 2010). ‘Intense lifestyle modification interventions’ were defined as 
those in which participants were asked to attend sessions where the intervention was delivered for an 
average of 37 h, whereas ‘less intense lifestyle modification interventions’ were those where sessions 
required participants to attend an average of 5 h (Christian et al., 2010). Furthermore, although the 
weight loss after these programs reached its peak within 6 months after the start of the treatment, 
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the trend began to reverse thereafter, with 30% and 50% returning to their original weight after 1 
and 5 years respectively (Curioni and Lourenco, 2005). 
Despite this modest weight loss, lifestyle modification programs can prevent the onset of T2DM with 
58% (Knowler et al., 2002). Moreover, during a follow-up study of 15 years, diabetes incidence was 
still reduced by 27% in the lifestyle intervention group, despite the weight regain (Prevention et al., 
2015). 
1.1.3.2 Pharmacological treatment 
Currently lifestyle modifications are regarded as the cornerstone for the prevention and 
management of obesity. However, the addition of weight-reducing therapies could help to induce 
and maintain body weight loss. 
The indications for adding pharmacotherapy to a weight loss effort are; a BMI ≤ 27 with one or more 
comorbidities or a BMI ≥ 27 (Apovian et al., 2015). A pharmacological treatment is deemed effective 
when a weight loss of 5% or more is achieved within 3 months after the start of the treatment. When 
this criterion is not met, it is recommended that the pharmacotherapy is discontinued and 
alternative drugs or referral for alternative treatment approaches be considered. 
Orlistat is currently the only anti-obesity drug that can be used on a long-term basis. Orlistat is a 
potent and selective inhibitor of gastric and pancreatic lipases (Sternby et al., 2002). Thus it reduces 
the subsequent absorption of monolglycerides and free fatty acids. Orlistat is approved for over-the 
counter use, despite its notorious gastrointestinal side effects such as steatorrhea. Diet pills 
containing 2,4-dinitrophenol (DNP) increased metabolic rate but were withdrawn from the market 
due to their severe side-effect profile which included agranulocytosis, dermatitis and fatal 
hyperthermia. Aminorex, an amphetamine-like drug was withdrawn since it caused chronic 
pulmonary hypertension. Fen-Phen, which is a combination of fenfluramine, a serotonin-
noradrenalin reuptake inhibitor (SNRI) and phentermine, an amphetamine derivative, was withdrawn 
from the market due to its association with valvular heart disease. Rimonabant, a cannabinoid 
receptor 1 antagonist, was previously available but was withdrawn due to an increased risk in 
depression and suicidality. Sibutramine, a SNRI, induced cardiovascular risks (Bray et al., 2016). 
From 2012 on a repertoire of new therapeutic agents to treat obesity became available, which 
included the 4 drugs (Table 1.1); lorcaserin, phentermine/topimarate, naltrexone/bupropion and 
liraglutide. Lorcaserin in a small-molecule agonist of the serotonin 2C (5-HT2C) receptor in the central 
nervous system (CNS). Specifically it stimulates 5-HT2C receptors on the POMC neurons in the ARC, 
which causes the release of α-melanocortin-stimulating hormone (α-MSH) to suppress appetite. 
Phentermine is a sympathomimetic amine which also acts centrally as an appetite suppressant. 
Topimarate is a sulfamate-substituted monosaccharide which was initially approved by the FDA for 
management of seizure disorders, its mechanisms of action for obesity remains unclear. Naltrexone 
is an opioid agonist while bupropion is a dopamine reuptake inhibitor. Liraglutide can induce body 
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weight loss by working as a long-acting GLP-1 receptor (GLP-1R) agonist (Bray et al., 2016). 
Interestingly these new agents are drugs that were previously used for other indications. Some of 
them also pose an extensive side-effect profile (Table 1.1). These drugs can induce at least 5% weight 
loss after 52 weeks (Table 1.1). 
The only anti-obesity drugs on the European market are currently orlistat, naltrexone/bupropion and 
liraglutide (Table 1.1). The central working anti-obesity drugs lorcaserin and phentermine/topimarate 
are not yet approved by the European Medicine Agency. 
 
Table 1.1 Pharmacological treatment of obesity. Drugs for weight management with their mechanisms of 
action, availability, induced effect, advantages and disadvantages (Adapted from Bray, Lancet, 2016). 
Abbreviations: 5-HT, 5-hydroxytryptamine/serotonin; DNRI, dopamine-norepinephrine reuptake inhibitor; ER, 
extended release; SR, sustained release. 
1.1.3.3 Bariatric surgery 
1.1.3.3.1 General 
Bariatric surgery is generally considered when nonsurgical interventions have failed in patients with a 
BMI of ≥35 kg/m2 with one or more comorbidities, or a BMI of ≥40. Bariatric surgery remains the 
most effective and durable therapeutic option for obesity. Common bariatric surgeries include 
adjustable gastric banding (AGB), vertical sleeve gastrectomy (VSG), and Roux-en-Y gastric bypass 
(RYGB) surgery. In 2011, the global percentage of each of those bariatric procedures was as followed; 
AGB 17.8%, VSG 27.8% and RYGB 46.6% (Buchwald and Oien, 2013). 
AGB involves placing a silicone ring around the top of the stomach. VSG is a bariatric procedure that 
reduces the stomach to about 15% of its original size, by surgically removing a portion of the stomach 
along the greater curvature. During RYGB surgery a small pouch is created under the esophagus and 
the remaining stomach and part of the small intestine are bypassed by connecting the jejunum 
directly to the esophagus. The remaining stomach and small intestine are reconnected with a lower 
part of the jejunum (Figure 1.1) (Piche et al., 2015).  
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Figure 1.1 Postsurgical anatomy. The postsurgical anatomy after (A) AGB, (B) VSG and (C) RYGB (Adapted from 
Piché, Can J Cardiol., 2015). Abbreviations: AGB, Adjustable gastric banding; RYGB, Roux-en-Y gastric bypass 
surgery; VSG, Vertical sleeve gastrectomy. 
 
The mean weight loss after these surgical techniques was investigated in the Swedish Obese Subjects 
study involving 4047 obese subjects of which 2010 underwent bariatric surgery and 2037 received 
conventional treatment (matched control group). In this study, weight loss was maximal after 1-2 
years with on average 20% weight loss after AGB, 25% after VSG and 32% after RYGB. After this initial 
drop, patients started to regain weight but this weight regain leveled off after 8-10 years. These 
procedures resulted in a stable weight loss of 14% for AGB, 16% for VSG and 25% for RYGB (Sjostrom 
et al., 2007).  
The beneficial effects of bariatric surgery (AGB, VSG and RYGB) compared to the other treatment 
strategies are not exclusively limited to weight loss but also include resolution of comorbidities 
(T2DM, dyslipidemia, hypertension, sleep apnea) associated with obesity (Patkar et al., 2016). For 
instance, bariatric surgery reduces the long-term incidence of T2DM by 78% in obese patients 
(Carlsson et al., 2012). A randomized non-blinded study showed that 37% of the patients in the VSG 
group and 42% of the patients in the RYGB group reduced their glycated hemoglobin levels to at least 
6%. In contrast, only 12% of the patients in the medical therapy group (which received lifestyle 
counseling, weight management, frequent home glucose monitoring and the use of newer approved 
drug therapies) succeeded in lowering their glycated hemoglobin levels to at least 6% (Schauer et al., 
2012). 
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1.1.3.3.2 Mechanisms of action 
The mechanisms behind the metabolic improvement after bariatric surgery are not fully elucidated 
yet. Some of the proposed mechanisms are; an altered energy expenditure (EE), food restriction, 
food malabsorption, altered gut hormone release, altered bile acid secretion and central effects. 
These effects are summarized in Figure 1.2. 
Figure 1.2 Potential mechanisms of the 
metabolic improvements after RYGB surgery. 
Role of EE, food restriction, food malabsorption, 
gut hormones, bile acids and central 
melanocortin signaling in the metabolic 
improvements after RYGB surgery. 
Abbreviations: AgRP, agouti-related peptide; EE, 
energy expenditure; GLP-1, glucagon-like 
peptide 1; MC4R, melanocortin 4 receptor; NPY, 
neuropeptide Y; PYY, peptide YY; SCFA, short-
chain fatty acid. 
1.1.3.3.3 Energy expenditure 
The EE is the sum of the basal metabolic 
rate, the thermic effect of feeding and the EE of physical activity. The difference between the rates of 
EE and energy intake defines energy balance. 
Human studies conclude that bariatric surgery decreases EE (Das et al., 2003, Carrasco et al., 2007, 
Coupaye et al., 2005). But still, these results remain controversial since it is quite difficult to compare 
different weights and body compositions with their relative rates of EE, as weight loss itself will 
decrease EE. Therefore the question should be posed as; will the effect on EE seen after RYGB 
surgery be different compared to a similar amount of weight loss imposed in another manner? 
1.1.3.3.4 Restriction 
Since AGB, VSG and RYGB are all mechanically restrictive techniques, it was originally hypothesized 
that making a small pouch would physically limit the amount of calories that could be consumed over 
short intervals. Thus an increased gastric pressure would trigger early satiety. However, recent 
studies clearly showed that although AGB, RYGB ad RYGB are all restrictive techniques, the reduction 
in stomach size is not the main cause for weight loss after these procedures. This has been supported 
by several lines of evidence. First of all, Topart et al. showed that the pouch size after gastric bypass 
does not correlate with weight loss outcomes (Topart et al., 2011). Secondly, the stomach volume 
after VSG in humans (150-200ml) is larger than the volume remaining after gastric banding (12-20ml) 
(Gagner and Rogula, 2003), although VSG induces a greater weight loss than gastric banding (Sjoholm 
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et al., 2013). Thirdly, gastric dilatation after VSG does not abrogate the weight loss after this 
procedure (Langer et al., 2006). Finally, after VSG (Stefater et al., 2010) and RYGB surgery (Zheng et 
al., 2009), much smaller and more frequent meals are consumed, therefore meal size will not limit 
the total daily caloric intake.  
1.1.3.3.5 Malabsorption 
RYGB does not only restrict stomach size but also bypasses a part of the absorptive capacity of the 
intestine, which may result in food malabsorbtion. This malabsorption may contribute to the 
profound weight loss after RYGB, but it also puts patients at a higher risk for micronutrient 
deficiencies (Bal et al., 2012, Hammer, 2012). Other classic malabsorptive techniques are the 
biliopancreatic diversion and the biliopancreatic diversion with duodenal switch. These procedures 
have by far the highest long-term complication rates and result in caloric, protein and micronutrient 
deficiencies (Aasheim et al., 2009, Billeter et al., 2014). Most bariatric procedures try to minimize 
these effects, with clinical studies reporting no, or minimal nutrient malabsorption (sugar and fat) 
after bariatric procedures such as RYGB surgery (Wang et al., 2012, Carswell et al., 2014, Kumar et al., 
2011).  
VSG, which is a restrictive, but not a malabsorptive technique, induces comparable weight loss 
compared to RYGB surgery (Sjostrom et al., 2007). This suggests that macronutrient malabsorption 
plays a minor role in the weight loss induced by RYGB or that the mechanisms of weight loss after 
VSG and RYGB differ. 
1.1.3.3.6 Gut hormones 
Altered release of gut hormones is considered as one of the leading candidate mechanisms for the 
metabolic improvement after RYGB surgery. More specifically, RYGB surgery enhances the secretion 
of the anorexigenic hormones GLP-1 and peptide YY (PYY) and, although more controversial, inhibits 
secretion of the orexigenic hormone ghrelin. Figure 1.3. depictures the central mechanisms through 
which gut hormones may induce orexigenic and anorexigenic effects. 
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Figure 1.3 Mechanisms underlying the orexigenic effect of ghrelin and the anorexigenic effect of GLP-1 and 
PYY. Ghrelin stimulates food intake and GLP-1 and PYY inhibit food intake by acting on hypothalamic circuits in 
the ARC and paraventricular nucleus (PVN) (Adapted from Briggs and Andrews, Neuroendocrinology, 2010). 
Abbreviations: ARC, arcuate nucleus; GABA, gamma-aminobutyric acid; GHSR, growth hormone secretagogue 
receptor; GLP-1R, glucagon-like peptide 1 receptor; MC4R, melanocortin 4 receptor; NPY, neuropeptide Y; 
POMC, pro-opiomelanocortin; PVN, paraventricular nucleus. 
Ghrelin 
Ghrelin is mostly (80%) secreted by X/A cells from the stomach. Ghrelin is a 28-amino acid peptide 
with a unique posttranslational modification consisting of an octanoyl group at Ser3 which is 
necessary for the activation of its receptor (growth hormone secretagogue receptor; GHSR) and thus 
for its biological activity. The octanoylation is catalyzed by ghrelin O-acyltransferase (GOAT), a 
member of the 16 hydrophobic membrane bound acyltransferase family (Muller et al., 2015). 
Physiological functions of ghrelin 
Besides its effect on growth hormone release, the most important function of ghrelin is the 
stimulation of food intake and its role in energy metabolism. Plasma ghrelin levels rise preprandially 
and decrease after the meal, indicating that ghrelin is a meal-initiating factor. Indeed, both 
peripheral and central administration of ghrelin dose-dependently increased food intake in rodents. 
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In humans an intravenous or subcutaneous administration of ghrelin also increased food intake and 
enhanced hunger scores (Muller et al., 2015). 
Ghrelin is believed to exert its biological functions on food intake through its receptor present in the 
ARC of the hypothalamus. A humoral and neural pathway has been suggested for the central 
activation of the ghrelin receptor. The neural pathway suggests that ghrelin can stimulate food intake 
indirectly via its receptor on the vagal nerve. GHSRs are synthesized in the neuronal cell bodies in the 
nodose ganglion and transported to the nerve terminals through axonal transport (Date et al., 2002). 
In rats 75% of GHSR containing neurons in the nodose ganglion express other orexigenic receptors 
(cannabinoid and melanin-concentrating hormone receptors) and anorexigenic receptors 
(cholecystokinin; CCK and leptin receptor) (Burdyga et al., 2006, Date et al., 2005, Burdyga et al., 
2002). Furthermore, the CCK-mediated upregulation of the cocaine- and amphetamine-regulated 
transcript (which inhibits food intake) in vagal afferent neurons, was inhibited by ghrelin (de Lartigue 
et al., 2007). Ghrelin also selectively inhibited subpopulations of mechanically sensitive 
gastroesophageal vagal afferents but the subpopulations of afferents inhibited differed between 
mice and ferrets (Page et al., 2007).  
The role of the vagus nerve in the orexigenic effects of ghrelin is controversial but it is generally 
accepted that this orexigenic effect is at least partially mediated through GHSR activation on the 
vagus nerve. Truncal vagotomy and vagal afferent ablation or perivagal application of capsaicin, but 
not subdiaphragmatic vagal differentiation in rodents abolished the stimulatory effect of peripherally 
administered ghrelin on food intake (Asakawa et al., 2001, Date et al., 2002, Arnold et al., 2006). 
Furthermore, ghrelin was unable to stimulate food intake in humans who underwent surgery 
involving vagotomy (le Roux et al., 2005). The expression of GHSR on the vagal nerve may play an 
important physiological role in the setting of excessive nutrition, since its expression in vagal 
afferents is increased in diet-induced obese rats (Paulino et al., 2009). This may maintain ghrelin 
signaling during obesity, when ghrelin levels are decreased (Kentish et al., 2013).  
The humoral pathway suggests that ghrelin released from the stomach can directly, via the 
bloodstream, activate the ghrelin receptor on the orexigenic neuropeptide Y (NPY)/AgRP neuron in 
the ARC. The activation of this neuron by ghrelin has been demonstrated by electrophysiological 
recording studies on hypothalamic slices (Cowley et al., 2003). Furthermore, chronic central 
administration of ghrelin resulted in a higher expression of NPY and AgRP, which stimulated food 
intake (Kamegai et al., 2001). The effect of ghrelin on food intake was completely abolished in double 
knockout mice for NPY and AgRP (Chen et al., 2004). This indicated that NPY and AgRP are both 
necessary for the orexigenic effects of ghrelin. NPY can activate Y1/Y5 receptors in the PVN to 
stimulate food intake. AgRP is an antagonist of the MC4R containing neurons in the PVN which inhibit 
food intake. Additionally, ghrelin also indirectly inhibits the activity of POMC neurons by stimulating 
gamma-aminobutyric acid (GABA) release from NPY/AgRP neurons (Cowley et al., 2003). 
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The ghrelin receptor is also expressed in tegmental and mesolimbic systems that are involved in 
reward (Zigman et al., 2006). Brain imaging studies in humans showed that intravenous 
administration of ghrelin stimulated brain regions involved in reward processing and appetitive 
behavior (Malik et al., 2008). 
Besides initiating food intake and influencing hunger on a short-term basis, ghrelin also promotes fat 
storage resulting in an increased body weight on the long term (Nakazato et al., 2001, Tschop et al., 
2000, Wortley et al., 2004). The effect of ghrelin on adiposity is partially regulated via ghrelin 
receptors in the CNS (Heppner et al., 2014) where ghrelin can regulate the sympathetic nervous 
system activity to influence adiposity (Theander-Carrillo et al., 2006). 
Previous data also indicate that ghrelin has direct peripheral effects on adipocyte and lipid 
metabolism; 1) intravenous ghrelin administration in rats increased white adipose tissue (WAT) mass 
by inducing lipid retention in adipocytes (Davies et al., 2009), 2) ghrelin reduced TNF-α-induced 
apoptosis and autophagy in human visceral adipocytes in vitro (Rodriguez et al., 2012) and 3) ghrelin 
stimulated lipid accumulation in cultured human omental adipocytes in vitro by targetting several fat 
storage-related proteins (Rodriguez et al., 2009, Choi et al., 2003). 
Surprisingly, obese people show significantly lower ghrelin levels compared to lean people (Tschop et 
al., 2001). This probably represents a positive feedback signal to the positive energy balance. The 
only exception to this is the Prader-Willi syndrome, a genetic obesity syndrome which is 
characterized by severe obesity and hyperphagia. These patients have 3-fold increased ghrelin levels 
(Goldstone et al., 2004). Obese patients do not only have a lower basal ghrelin release but also show 
a less pronounced drop in ghrelin levels after food intake which can lead to a persistent hunger signal 
and increased food intake (English et al., 2002). In contrast, ghrelin levels are elevated in anorexia 
patients. These ghrelin levels may reflect its compensating role in energy balance. 
Ghrelin and bariatric surgery 
The role of ghrelin in energy metabolism makes altering postprandial ghrelin levels a plausible 
candidate mechanism for the metabolic improvements after bariatric surgery. However, 
controversial findings have been reported concerning the effect of bariatric surgery on ghrelin levels. 
The first study reported a dramatic decrease in plasma ghrelin levels after RYGB surgery in humans 
(Cummings et al., 2002). This was confirmed in some studies but not in others which reported no 
change or an increase in ghrelin levels (Meek et al., 2016). Furthermore, studies using ghrelin 
deficient mice have shown that the effects of VSG on the metabolic improvements are ghrelin 
independent (Chambers et al., 2013). These results indicate that alterations in ghrelin levels may play 
a minor role in the metabolic improvements after bariatric surgery. 
Introduction 
 
16 
 
GLP-1 
GLP-1 is secreted from intestinal L-cells and the biological active hormones GLP-17-37 and GLP-17-36 
amide are rapidly degraded by the enzyme dipeptidyl peptidase 4 (DPP4) to antagonists (Kieffer et al., 
1995). GLP-17-37 and GLP-17-36 amide are equally potent at activating the GLP-1 receptor. 
Physiological functions of GLP-1 
GLP-1 has numerous physiological actions, including potentiation of glucose-stimulated insulin 
secretion through its binding with the GLP-1 receptor on pancreatic β-cells, β-cell proliferation and 
inhibition of apoptosis, inhibition of glucagon release, delaying gastric emptying and inhibiting food 
intake (Steinert et al., 2016).  
The biological functions of GLP-1 made it an ideal therapeutic target to treat T2DM. Since native GLP-
1 has a short half-life, novel methods have been developed to exploit its anti-hyperglycemic effects. 
They can broadly be classified in short-and long working GLP-1 analogues and DPP4 inhibitors. 
Currently, the GLP-1 analogue liraglutide is approved for the treatment of obesity and several other 
drugs are in the pipeline for this indication (Isaacs et al., 2016). 
The GLP-1R is not only present in the pancreas, but also in the hypothalamic ARC and PVN (Wei and 
Mojsov, 1995). GLP-17-36 amide induced c-fos activation in the PVN of rodents (Larsen et al., 1997b, 
Baggio et al., 2004a) and changed neuronal activity in the prefrontal cortex and hypothalamus of 
humans (Pannacciulli et al., 2007). There have been contradictory findings on whether or not GLP-1 
can cross the blood brain barrier to directly act on these brain regions. Although it has been shown 
that GLP-1 can gain access to these brain regions through simple diffusion (Kastin et al., 2002), a 
fusion protein of albumin and GLP-1 that cannot pass the blood brain barrier can also reduce feeding 
(Baggio et al., 2004b), suggesting that GLP-1 reduces feeding via GLP-1Rs in nodose ganglia. In 
addition, the fact that circulating GLP-1 is rapidly degraded by DPP4 argues against activation of the 
GLP-1R in the CNS by peripheral GLP-1 (Mentlein et al., 1993). Furthermore, central GLP-1R blockade 
did not affect GLP-1-induced anorexia (after intraperitoneal administration) suggesting that central 
GLP-1R activation did not play a role in this effect (Williams et al., 2009). 
The role of the vagus nerve in the satiating effects of GLP-1 has been supported by a study in rodents 
that reported no effect of peripheral administration of GLP-1 on food intake and activation of 
hypothalamic ARC neurons after either bilateral subdiaphragmatic total truncal vagotomy or 
brainstem-hypothalamic transsectioning in rodents (Abbott et al., 2005). Furthermore, capsaicin 
pretreatment prevented the inhibitory effect of Exendin-4 (a GLP-1R agonist) on food intake (Talsania 
et al., 2005).  
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The GLP-1R does not only play a role in the anorexigenic effect of GLP-1, but might also play a role in 
anticipatory food reward. This has been suggested by a study where Exendin-4 increased brain 
responses to receipt of chocolate milk and decreased anticipation of chocolate milk compared with 
placebo. Furthermore, a GLP-1R antagonist largely prevented these brain responses to chocolate 
milk compared with placebo, suggesting that GLP-1R activation plays a role in anticipatory food 
reward (van Bloemendaal et al., 2015). 
GLP-1 and bariatric surgery 
Postprandial GLP-1 levels are dramatically increased after both VSG and RYGB in rodents and humans 
and this postprandial increase persists over several years (Meek et al., 2016). However, studies in 
GLP-1R-/- mice provided no support for a role of GLP-1 in the body weight-lowering effects of VSG and 
RYGB (Ye et al., 2014, Wilson-Perez et al., 2013, Mokadem et al., 2014). In contrast, the decreased 
appetite after RYGB in humans returned when the GLP-1 release was inhibited (le Roux et al., 2007, 
Svane et al., 2016), suggesting an important role for GLP-1 in the RYGB-induced weight loss in 
humans.  
PYY 
PYY is also secreted from intestinal L-cells. Full-length PYY acts on the Y-family receptors Y1, Y2, and 
Y5, whereas digestion of PYY1–36 by DPP4 results in the generation of PYY3–36, a selective agonist for 
the Y2 receptor (Y2R) (Rose et al., 1995). 
Physiological functions of PYY 
PYY can affect satiety by delaying gastric emptying (Savage et al., 1987) and by inducing the ileal 
brake (Lin et al., 1996). Circulating PYY3-36 affects the CNS directly after transport across the blood 
brain barrier (Gustafson et al., 1997), or by activation of the vagus-brainstem-hypothalamic pathway 
(Koda et al., 2005). In the CNS, studies in Y2R-/- mice showed that peripheral PYY stimulates satiety by 
activating Y2Rs on the NPY/AgRP neuron and by increasing activity of the anorectic POMC/α-MSH 
neuron (Batterham et al., 2002). However, this effect of peripheral PYY administration could not be 
repeated by other laboratories (Boggiano et al., 2005). In humans, the therapeutic window of PYY to 
inhibit food intake is small since adverse effects (like nausea) might mediate also mediate the 
inhibition of food intake. Therefore it is difficult to distinguish between the genuine satiating effect of 
PYY and the reductions in appetite due to nausea (Perry and Wang, 2012). Furthermore, studies 
using functional magnetic resonance imaging (MRI), showed that PYY3-36 can switch the regulation of 
food intake from a homeostatic brain region (hypothalamus) to a hedonic brain region (Batterham et 
al., 2007). 
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The Y2R is also synthesized in the rat nodose ganglion and transported to the vagal afferent terminals 
(Koda et al., 2005). Abdominal vagotomy abolished the anorectic effect of PYY3-36 and the PYY3-36 
induced c-fos expression in the ARC of rats (Koda et al., 2005), suggesting a role for the vagal nerve in 
the anorectic effect of PYY3-36. 
PYY and bariatric surgery 
Postprandial PYY levels are rapidly increased after bariatric surgery and persist after one year. 
Several types of bariatric surgery increase PYY levels, such as AGB, VSG and RYGB (Meek et al., 2016). 
Furthermore, the effects of bariatric surgery on body weight loss were absent in PYY-/- mice 
(Chandarana et al., 2011). Nevertheless, central infusion of the selective Y2R-antagonist BIIE0246 had 
no effect on the body weight loss induced by RYGB surgery in mice, suggesting that the Y2R does not 
mediate the effects of RYGB surgery on body weight (Ye et al., 2014). In contrast, a human study 
showed that combined pharmacological blockage of GLP-1 and PYY3-36 increased food intake after 
RYGB, supporting the hypothesis that these hormones have a role in the decreased postoperative 
food intake. This study also revealed that blocking the actions of only one of these hormones 
resulted in the increased secretion of the other, explaining previous findings questioning the role of 
GLP-1 and PYY in the decreased food intake and body weight loss after RYGB (Svane et al., 2016). 
Other hormones have been shown to be altered after bariatric surgery, including CCK, glucose-
dependent insulinotropic peptide (GIP), glucagon and GLP-2 (Meek et al., 2016). Determining the 
relative contribution of these different hormones in the postsurgical weight loss remains an 
important research goal.  
1.1.3.3.7 Bile acids  
Bile acids are potent digestive surfactants that promote lipid absorption. Primary bile acids are 
synthesized in the liver and duodenally secreted in response to fatty acid ingestion. In addition to 
their role in lipid absorption, bile acids can also act in a ‘hormone-like’ manner. They are the natural 
ligand for several receptors amongst which; a cell surface G-protein coupled receptor (TGR5) 
(Maruyama et al., 2002, Kawamata et al., 2003) and a ligand-activated transcription factor farnesoid-
X-receptor (FXR) (Wang et al., 1999) via which they play an important role in the energy-and glucose 
homeostasis. 
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Postprandial bile acid levels correlate inversely with BMI (Suzuki et al., 2014). Furthermore, 
supplementing a HFD with cholic acid (a bile acid) increases EE, oxygen consumption, prevents 
obesity and decreases insulin resistance in a mice model of obesity (Watanabe et al., 2006). In vitro 
experiments in brown adipocytes and skeletal myocytes suggest that these effects are mediated 
through increased cAMP production after TGR5 activation. This in turn will activate the key enzyme 
iodothyronine deiodinase, which converts inactive thyroxine (T4) into intracellular active tri-
iodothyronine (T3), a major component in cellular basal metabolism (Watanabe et al., 2006). The bile 
acid-induced protection against insulin resistance has been attributed to TGR5 mediated GLP-1 
release (Thomas et al., 2009, Duboc et al., 2014). Furthermore, FXR activation can improve glycemic 
control and increase EE by increasing the concentration of fibroblast growth factor 19 (FGF19) (Kir et 
al., 2011, Tomlinson et al., 2002). 
Serum bile acids are elevated after RYGB surgery and VSG (Cole et al., 2015, Steinert et al., 2013), 
normalizing the blunted postprandial bile acids concentrations in obesity (Kohli et al., 2010). The 
increased bile acid levels after bariatric surgery could contribute to the increased postsurgical plasma 
GLP-1 levels through TGR5 activation on L-cells (Thomas et al., 2009, Duboc et al., 2014). 
Furthermore, experiments in WT and FXR knockout mice showed that FXR plays an important role in 
the effect of VSG on body weight and glucose tolerance (Ryan et al., 2014), suggesting that altered 
bile acid signaling may play a role in the metabolic improvements after bariatric surgery.  
1.1.3.3.8 Central control of energy balance 
The brain responds to internal cues from the periphery and relays information about long-term and 
short-term energy availability to regulate body weight maintenance. The ARC of the hypothalamus is 
an important component of this homeostatic system. The ARC contains catabolic POMC-neurons and 
anabolic NPY and AgRP-neurons. POMC is cleaved to produce α-MSH, a hormone which decreases 
food intake and induces weight loss when administered exogenously (Tsujii and Bray, 1989). 
Furthermore, the AgRP is an antagonist of the MC4R which is found in several brains regions such as 
the PVN via which it can induce feeding and weight gain (Fan et al., 1997). Like AgRP, NPY stimulates 
food intake and weight gain (Morley et al., 1987). 
Given the importance of central melanocortin signaling in energy homeostasis, the decrease in body 
weight after bariatric surgery may result from changes in this axis. RYGB is still effective in patients 
with a heterozygous mutation in the gene encoding MC4R (Aslan et al., 2011), suggesting that one 
functional copy of MC4R is sufficient to permit the effect of RYGB on energy intake. Importantly, 
carriers of a MC4R variant known to increase basal MC4R activity show greater weight loss after 
RYGB compared to noncarriers of this variant (Mirshahi et al., 2011). In contrast to VSG (Stefater et 
al., 2010), RYGB surgery in rats increased mRNA levels of the orexigenic neuropeptides AgRP and NPY 
in the ARC, whereas no change was observed in anorexigenic POMC mRNA levels. This suggests that 
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RYGB surgery puts a brake on orexigenic hypothalamic output signals (Barkholt et al., 2016). 
Furthermore, MC4R-/- mice showed that MC4R function is critical for the sustained reductions in food 
intake and weight loss induced by RYGB (Hatoum et al., 2012). Intracerebroventricular administration 
of a specific MC4R antagonist in sham and RYGB rats led to a doubling of food intake and weight 
regain (Mumphrey et al., 2014). MC4R may also be directly involved in the regulation of PYY and GLP-
1 secretion, since the MC4R is expressed on enteroendocrine L-cells and intraperitoneal 
administration of melanocortin peptides in mice stimulate PYY and GLP-1 release (Panaro et al., 
2014). However, until know it is unclear if central affects play a causal role in the weight loss after 
bariatric surgery, or if they occur in response to other alterations in postsurgical physiological 
responses.  
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1.2 Chemosensory signaling pathways in the gut 
RYGB surgery is an invasive technique but mimicking the sustained and enhanced release of GLP-1 
and PYY and reducing postprandial ghrelin levels through combination therapy might be a valuable, 
non-invasive alternative for bariatric surgery. The magnitude of postprandial gut hormone release 
depends on the caloric content and macronutrient composition of the meal. Several taste receptors 
(sweet, umami, bitter, fatty acid) and the taste receptor coupled G-protein, α-gustducin, are not only 
present on taste buds of the tongue but also on enteroendocrine cells (EECs) and may tune gut 
hormone release in response to a meal. However, the physiological role of taste receptors on EECs 
has not yet been fully elucidated. In this PhD manuscript we mainly focused on the carbohydrate and 
SCFA sensing mechanisms of ghrelin secreting X/A cells and GLP-1 and PYY containing L-cells as 
targets for new anti-obesity treatment strategies. The next part therefore only focuses on the 
chemosensing pathways of carbohydrates and SCFAs in the gut.  
1.2.1 Chemosensing on the tongue 
Animals and humans can perceive five basic tastes; sweet, salty, bitter, sour and umami. Because fat 
can be recognized based on its texture, it is still a matter of debate whether it should be considered 
as a basic taste. The taste quality of molecules plays an important role in their perception as 
nutritional or harmful compounds. Sweet taste is present in energy-rich food and indicates a 
carbohydrate source of calories. Umami taste is an appetitive taste elicited by L-glutamate present in 
protein-rich food. Salty taste regulates the intake of minerals, required for electrolyte homeostasis 
and water balance. Bitter, present in many poisonous substances elicits an aversive reaction in 
humans. Ion channels play a role in the detection of sour taste, which signals the presence of 
ingested acids and aims to prevent the intake of unripe fruits or spoiled food (Chaudhari and Roper, 
2010). Besides dietary guidance, the thought, sight and smell of nutrients stimulate a cephalic phase 
response (Smeets et al., 2010).  
The taste (gustatory) system enables us to sense these tastants through taste receptors on taste 
buds. A taste receptor can be defined as a receptor protein that recognizes ligands belonging to one 
of the six taste modalities: salty, sweet, bitter, sour, umami and fat. The best characterized taste 
receptors are G protein-coupled receptors (GPCRs) and are divided into two classes; the taste 
receptor family type 1 (TAS1R) and the taste receptor family type 2 (TAS2R). TAS1R1 and TAS1R2 are 
the first receptors of the TAS1R family that have been identified via a large screening of taste 
receptor cells (Hoon et al., 1999). TAS1R3 was reported to be co-expressed with TAS1R1 and TAS1R2 
and TAS1R1-TAS1R3 and TAS1R2-TAS1R3 can function as an umami and sweet taste receptor, 
respectively (Nelson et al., 2001, Li et al., 2002, Nelson et al., 2002). Amino acids are not only sensed 
through TAS1R1-TAS1R3, but also by the calcium sensing receptor, G protein-coupled receptor class 
C group 6 member A and the metabotropic receptors. The lysophosphatidic acid receptor 5 is 
considered as a di-and tri-peptide receptor. The family of TAS2Rs has been discovered through 
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genome screening techniques. In humans, the TAS2R family consists of 25 functional bitter taste 
receptors (Adler et al., 2000, Chandrashekar et al., 2000, Matsunami et al., 2000). Furthermore, free 
fatty acid receptors (FFAR) have been identified that can be activated by long- (FFAR1, FFAR4), 
medium- (FFAR1, FFAR4) (Briscoe et al., 2003, Fredriksson et al., 2003) and SCFAs (FFAR2, FFAR3) (Le 
Poul et al., 2003, Brown et al., 2003). Sour and sodium are not detected through GPCRs but through 
ion channels (Huang et al., 2006). 
The sensory responses to sweet, umami and bitter are initiated by the binding of the tastant to these 
GPCRs. These GPCRs couple to downstream signaling effectors that include Gβγ activation of 
phospholipase Cβ2 (PLCβ2), 1,4,5-inositol trisphosphate (IP3) mediated Ca2+ release from intracellular 
stores and Ca2+-dependent activation of the monovalent selective cation channel, the transient 
receptor potential cation channel subfamily M member 5 (TRPM5) which leads to membrane 
depolarization and the release of ATP as a transmitter to activate gustatory afferents (Lindemann, 
2001, Margolskee, 2002). The function of the α-gustducin subunit in this cascade is not yet fully 
elucidated. It has been proposed that the basal activity of α-gustducin keeps the cAMP levels in the 
cell low by phosphodiesterase activation (Yan et al., 2001, McLaughlin et al., 1992, Ruiz-Avila et al., 
2001, Ruiz-Avila et al., 1995). These low cAMP levels inhibit protein kinase A activity, which otherwise 
seems to inhibit PLCβ2 and IP3-mediated Ca2+-responses to tastants. Mice that lack α-gustducin are 
deficient for sweet, umami and bitter (Wong et al., 1996, He et al., 2004), but are not completely 
insensitive to these stimuli, indicating that alternative signaling pathways may also play a role. For 
instance, some taste receptors couple to other G-protein subunits of the Gαi-subfamily, including α-
transducin (Ruiz-Avila et al., 1995, He et al., 2004, Ueda et al., 2003, Sainz et al., 2007, Ozeck et al., 
2004). 
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1.2.2 Chemosensing in the gut 
The gastrointestinal (GI) system has a surface membrane area of ~260-300m2 according to textbooks, 
although recent analyses using light and electron microscopy report the surface area to be about 
~32m2 of which about 2m2 refers to the large intestine 
(Helander and Fandriks, 2014). With this large surface 
area, the intestine continuously monitors the 
composition of the luminal content. The idea that the 
gastrointestinal system is a sensory organ was first 
suggested by Bayliss and Starling who discovered the gut 
hormone secretin, and showed that it was released by 
luminal acid (Bayliss and Starling, 1902). Later it has been 
shown that the intestine is endowed with a range of 
cells, such as enterocytes, and EECs that sense nutrients 
directly and send signals from the epithelium to the 
vagal sensory afferents in the lamina propria as depicted 
in Figure 1.4.  
Figure 1.4 Chemosensing in the gut. Ingested food is digested 
into its nutrient metabolites in the lumen of the small 
intestine. The intestinal epithelium is arranged in absorptive 
enterocytes and secretory EECs. Nutrients stimulate EECs in 
the gut and trigger the secretion of gut hormones, which 
partially trigger the body’s postprandial response. (Adapted 
from Psichas, J Clin Invest., 2015). 
1.2.2.1 Enteroendocrine cells 
EECs are specialized epithelial cells that constitute the largest endocrine organ of the body despite 
the fact that they occupy less than 1% of the epithelial cell population. At least 15 types of EECs have 
been described, capable of secreting over 20 peptide hormones that influence processes including 
gut motility, gastric acid secretion, and energy intake. It was previously thought that EECs could be 
separated into discrete classes of cells with specific secretory profiles; G-cells produce gastrin, P/D1 
or X/A-cells ghrelin, D-cells somatostatin, I-cells CCK, entero-chromaffin cells produce serotonin, K-
cells GIP and L-cells produce glucagon-like peptides and PYY. However, recent studies using 
fluorescence-activated cell sorting analysis and microarray expression profiling suggested that most 
EECs contain more than just one hormone (Egerod et al., 2012, Habib et al., 2012). The hormones 
released by EECs can act locally, on nerve endings, on other cells, or on organs at remote sites 
including pancreatic islets and the CNS.  
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Two groups of EECs can be distinguished according to their shape and localization (Solcia et al., 
2000). The first type are the ‘open type cells’ with microvilli extending into the intestinal lumen 
which enables them to sense the luminal content directly. After stimulation by the luminal content 
they can release gut hormones. In contrast to the ‘open type cells’, the ‘closed type cells’, do not 
reach the epithelial surface and can only indirectly be affected by the luminal content through neural 
and humoral pathways. 
Taste receptors of the types previously characterized in the oral cavity were first reported in the 
intestine in 2001 (Wu et al., 2002). Symonds et al. investigated the relative distribution of the 
transcripts of taste receptors throughout the mouse and human gut. Most taste receptors were 
expressed throughout the mouse GI tract from stomach to colon, with the exception of TAS1R2 
which was only detected in the small intestine. Furthermore, several amino acid receptors and the 
SCFA receptors were more highly expressed distally (Symonds et al., 2015). EECs can sense the 
luminal content via activation of these different taste receptors on their membrane. The presence of 
these nutrient receptors on EECs has been reviewed by Depoortere et al. (Depoortere, 2014) and is 
depicted in Figure 1.5.  
 
Figure 1.5 Nutrient sensing in the gut. Overview of the expression of taste receptors in different types of EECs 
along the gut that control the release of gut hormones in response to nutrients. (Adapted from Depoortere, 
Gut, 2014). Abbreviations: AA, amino acids; CaSR, calcium sensing receptor; FFAR1, free fatty acid receptor 1; 
FFAR2, free fatty acid receptor 2; FFAR3, fatty acid receptor 3; GPRC6A, G-protein coupled receptor family C 
group 6 member A; LCFA, long-chain fatty acids; LPAR5, Lysophosphatidic acid receptor 5; TAS1R1, taste 
receptor type 1 member 1; TAS1R2, taste receptor type 1 member 2; TAS1R3, taste receptor type 1 member 3; 
TAS2R, taste receptor type 2. 
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Not only the taste receptors, but also several signaling molecules that play an important role in the 
taste signaling pathway on the tongue are expressed by EECs. For instance, α-gustducin is expressed 
by the X/A and L-cells (McLaughlin et al., 1992, Jang et al., 2007, Janssen et al., 2011) (Rozengurt et 
al., 2006). Furthermore, glucose- and SCFA induced GLP1 release and bitter-induced ghrelin release is 
blunted in α-gustducin knockout (α-gust-/-) mice (Jang et al., 2007, Li et al., 2013, Janssen et al., 
2011). 
In contrast to α-gustducin, TRPM5 may not play a role in the direct sensing of tastants by EECs. A 
study in mice showed that TRPM5-positive cells in the mouse duodenum, jejunum and ileum do not 
contain secretory granules characterized by the presence of chromogranin A and/or B (Kokrashvili et 
al., 2009b). Moreover, they also did not express some of the hormones known to be present in 
intestinal enteroendocrine and enterochromaffin cells such as GLP-1, secretin, somatostatin, and 
serotonin. The TRPM5-positive cells however did co-express the opioid peptides beta-endorphin, 
Met-enkephalin and uroguanylin (Kokrashvili et al., 2009b) and were later identified as tuft cells that 
sense the luminal content and signal to neighboring EECs to tune gut hormone release to the luminal 
content (Kaske et al., 2007, Eberle et al., 2013).  
Nevertheless studies in STC-1 cells did show that the foodborne contaminant, vomitoxin, elicits Ca2+ 
dependent secretion of CCK and GLP-1 via activation of TRPM5, by using the TRPM5 channel inhibitor 
triphenylphosphine oxide (Zhou and Pestka, 2015). Furthermore, linoleic acid induced CCK secretion 
in STC-1 cells was greatly diminished after siRNA knockdown of TRPM5 (Shah et al., 2012). However, 
microarray analysis of primary mouse L-cells showed very low levels of TRPM5 but high expression 
levels of TRPA1, TRPC1, TRPC3 and TRPM7 (Emery et al., 2015). Furthermore, in primary intestinal 
cultures GLP-1 secretory responses to GW9508 (a FFAR1 agonist) were impaired by an inhibitor of 
the TRPC3 channel, Pyr3 (Gribble et al., 2016). These results suggest that TRPM5 plays a minor or no 
role in the direct sensing of EECs. 
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1.2.2.1.1 Gastric X/A cells 
Ghrelin cells or X/A cells are EECs that produce the orexigenic hormone ghrelin and are mostly 
located in the oxyntic gland of the stomach and to a lesser extent in the small and large intestine 
(Date et al., 2000). Ghrelin cells exist as open and closed type cells. The number of the open-type 
cells gradually increases in the direction from the stomach to the lower gastrointestinal tract (Sakata 
et al., 2002).  
Sweet sensing mechanism of the X/A cell 
Foster-Shubert et al. concluded that the postprandial decline in plasma ghrelin levels is dependent 
on the macronutrient composition of the meal: Ingestion of carbohydrates decreases plasma ghrelin 
levels more than the ingestion of proteins or lipids (Foster-Schubert et al., 2008). This suggests that 
the ghrelin cell contains the machinery to sense nutrients. Indeed, TAS1R3, a component of both the 
sweet and umami taste receptor, has been localized in ghrelin containing X/A cells and in brush cells 
in the stomach (Hass et al., 2010), although the TAS1R2 subunit was reported to have a very low 
(Koyama et al., 2016) or no (Iwatsuki et al., 2010) gastric expression. In healthy patients, artificial 
sweeteners that can bind the TAS1R2-TAS1R3 receptor did not elicit differences in plasma ghrelin 
levels (Steinert et al., 2011a, Brown et al., 2011). Therefore the TAS1R3 subunit may indicate the 
presence of the umami taste receptor instead. Indeed, amino acids have been shown to affect 
ghrelin release from a stomach-derived cell line and gastric segments (Vancleef et al., 2015).  
Previous studies also suggested that KATP channels are involved in the glucose-dependent ghrelin 
secretion in MGN3-1 cells (a gastric ghrelinoma cell line) (Oya et al., 2015). However, tolbutamide (a 
potassium channel blocker) and diazoxide (a potassium channel activator) neither enhanced nor 
inhibited glucose-induced ghrelin secretion in primary cultures of gastric mucosal cells (Sakata et al., 
2012). Therefore the sweet sensing mechanism of the ghrelin cell remains to be elucidated. 
SCFA sensing mechanism of the X/A cell 
While most digestible carbohydrates will be transported out of lumen in the proximal intestine, non-
digestible carbohydrates can reach the distal intestine where some will be fermented by the gut 
microbiota. The produced fermentation products will include the SCFAs. SCFAs are fatty acids with a 
carbon chain length of 6 carbons or less. The major SCFA products generated by the microbiome are 
acetate (C2), propionate (C3) and butyrate (C4). These microbial fermentation products can activate 
the SCFA receptors FFAR2 and FFAR3. FFAR2 is activated by all three SCFAs and most potently by 
propionate and acetate (Le Poul et al., 2003), while FFAR3 has a higher affinity for propionate and 
butyrate than for acetate (Brown et al., 2003). Besides their difference in ligand affinity FFAR2 and 
FFAR3 also differ in their signaling pathway. Both are GPCRs that are coupled to Gαi/o, the pertussis 
toxin-sensitive G protein. In addition, FFAR2 can also couple to the pertussis toxin-insensitive Gαq 
(Brown et al., 2003). The signaling pathway of FFAR2 and FFAR3 is depicted in Figure 1.6.  
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Figure 1.6 FFAR2/3 signaling pathways. Overview of the 
possible signaling pathways of the FFAR2 and FFAR3 receptos. 
(Based on Brown, J Biol Chem, 2003). Abbreviations: AC, 
adenylate cyclase; cAMP, cyclic AMP; DAG, diacylglycerol; FFAR, 
free fatty acid receptor; IP3, inositol triphosphate; IP3R, inositol 
triphosphate receptor; PLC, phospholipase C. 
The gastric X/A cells, harvested from ghrelin-hrGFP 
reporter mice, colocalize with both FFAR2 and FFAR3, 
indicating that SCFAs might be able to bind these 
receptors to regulate ghrelin secretion (Engelstoft et al., 
2013). The hypothesis that the decreased ghrelin 
secretion after SCFA supplementation is mostly FFAR2 mediated is strengthened by several 
observations; 1) propionate induced ghrelin release was markedly attenuated in ghrelin cells from 
FFAR2-/-, but not FFAR3-/-mice, 2) acetate and propionate decreased ghrelin secretion from primary 
gastric mucosal cells with similar efficacy, although acetate is a poor ligand for FFAR3, 3) selective 
agonists and antagonists for FFAR2 and FFAR3 showed a predominant role for FFAR2 and 4) the 
expression level and degree of enrichment after fluorescence-activated cell sorting (about 20-fold in 
ghrelin positive compared to ghrelin negative cells) of FFAR2 was much greater compared to FFAR3 
(Engelstoft et al., 2013). In contrast, Koyama et al. observed that neither acetate nor propionate 
affected ghrelin secretion from a mouse ghrelinoma cell line (Koyama et al., 2016).  
1.2.2.1.2 Intestinal L-cells 
Mature L-cells are commonly defined as EECs that express the preproglucagon gene. 
Posttranslational processing of preproglucagon is tissue-specific, and hence yields different bioactive 
proteins whether it is processed in the pancreas (glucagon, glicentin-related pancreatic polypeptide, 
major proglucagon fragment) or gut/brain (GLP-1, GLP-2, oxyntomodulin, glicentin) (Holst et al., 
1994, Larsen et al., 1997a). 
Spectrum of L-cells 
L-cells co-secrete distinct peptides depending on their location. L-cells in the upper small intestine 
demonstrate co-localization with GIP (Habib et al., 2012). L-cells that co-express GLP-1 and PYY are 
located along much of the length of the gastro-intestinal epithelium, starting at the proximal jejunum 
and increasing in density towards the colon (Eissele et al., 1992). The GLP-1 and PYY co-expressing L-
cells are typically considered to be involved in the regulation of energy homeostasis, in addition to 
other functions. 
GLP-1 and PYY exhibit a two-phase release profile after a meal. The initial rapid rise in GLP-1 may 
partially represent release from L-cells in the upper small intestine, although it is thought that most 
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of this first phase response for GLP-1 and that of PYY is mediated via a neural reflex or a circulating 
factor. The arrival of food in the large intestine is thought to drive the second phase of the release of 
GLP-1 and PYY into the circulation, by activation of specific nutrient receptors and other cellular 
machinery present on the L- cell. 
Sweet sensing mechanism of the L-cells 
Glucose is a robust stimulant of incretin release. Three possible glucose sensors are proposed by 
which the L-cell might couple glucose detection to GLP-1 secretion: the sweet taste receptor 
(TAS1R2-TAS1R3), the sodium coupled glucose transporter (SGLT1) and ATP-sensitive K+ (KATP) 
channels (Figure 1.7). The sweet taste receptor and glucose transporter are predominantly present in 
the small intestine (Steinert et al., 2011a), while KATP channels have been proposed to play a role in 
colonic glucose sensing (Reimann et al., 2008). Activation of the sweet taste receptor, coupled to the 
gustatory G-protein, increases calcium from intracellular stores, leading to gut hormone release. In 
contrast, SGLT1 and KATP channels both couple electrical current to gut hormone release.  
The hypothesis that TAS1R2-TAS1R3 coupled to α-gustducin may function as a glucose sensor of the 
L-cell has been supported by different lines of evidence. Firstly, TAS1R2, TAS1R3 and α-gustducin are 
present in rodent and human L-cells of the small intestine (Margolskee et al., 2007, Jang et al., 2007). 
Secondly, several sweet taste receptor agonists, such as the carbohydrates glucose, fructose and the 
artificial sweetener sucralose were able to elicit GLP-1 secretion from mouse (GLUTag) and human 
(NCI-H716) enteroendocrine lines and mouse jejunal and ileal explants (Jang et al., 2007). Thirdly, this 
glucose-induced GLP-1 secretion, was almost or completely impaired in knockout animals for α-
gustducin or TAS1R3 (Jang et al., 2007) or in the presence of a sweet taste receptor antagonist; 
lactisole in Hutu-80 cells (Ohtsu et al., 2014). Finally, human studies showed the involvement of the 
sweet taste receptor in glucose-induced GLP-1 and PYY secretion, using lactisole (Gerspach et al., 
2011, Steinert et al., 2011b). 
However, despite promising in vitro results most in vivo studies show no effect of artificial 
sweeteners on GLP-1 release in healthy volunteers (Ford et al., 2011, Wu et al., 2012, Ma et al., 
2009). These results question the physiological relevance of the sweet taste receptor complex in gut 
hormone secretion. 
A second proposed glucose sensor is Na+-dependent glucose uptake by the glucose transporter 
SGLT1 which is colocalized with intestinal L-cells (Reimann et al., 2008). The small transporter-
associated currents generated by SGLT1, can drive membrane depolarization, triggering electrical 
activity, resulting in voltage-gated calcium entry and peptide release (Gribble et al., 2003). This idea 
is supported by the fact that glucose-dependent GLP-1 and GIP secretion in vitro, are prevented in 
the presence of SGLT1 antagonists in GLUTag cells and primary cell cultures (Parker et al., 2012). 
Furthermore SGLT1-/- mice have impaired GIP and GLP-1 release after glucose gavage (Gorboulev et 
al., 2011). Reimann et al. further showed that the sweet taste receptor is not involved in these 
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effects since GLP-1 release was induced at glucose concentrations too low to activate the sweet taste 
receptor complex (Gorboulev et al., 2011, Reimann et al., 2008).  
SGLT1 and GLUT2 expression was upregulated in brush-border membrane vesicles from the intestine 
of wild type mice, but not of TAS1R3-/- and α-gustducin-/- mice, that were fed a high carbohydrate diet 
(70% sucrose) for 2 weeks. This suggests a relationship between the activation of the TAS1R2-TAS1R3 
in the L-cells and the expression of glucose transporters in enterocytes (Margolskee et al., 2007). 
A third possible glucose-sensor is the ATP-sensitive K+ channel. L-cells and K-cells express glucokinase 
and KATP channel subunits (Nielsen et al., 2007). This machinery can couple glucose metabolism, and 
subsequent ATP generation, to membrane depolarization resulting in voltage-gated calcium entry 
and peptide release (Reimann and Gribble, 2002). The reduced K+-efflux lowers the threshold for 
action potentials, opening voltage dependent Ca2+ channels which may result in higher GLP-1 release 
(Reimann and Gribble, 2002). The KATP channel blocker tolbutamide increased GLP-1 secretion from 
GLUTag cells and from isolated L-cells from upper small intestine and colon (Reimann and Gribble, 
2002, Reimann et al., 2008). However, KATP channel blockers did not affect glucose-induced GLP-1 
secretion in humans (Stephens et al., 2011). Therefore metabolism-
dependent pathways may not be responsible for glucose induced GLP-1 
concentrations (Kuhre et al., 2014). Overall, our current understanding 
of the importance of the sweet taste receptor, SGLT1 and KATP channels 
on EECs remains limited. 
Figure 1.7 The glucose sensing mechanisms of the L-cell. Several glucose 
sensors have been proposed to regulate glucose-induced GLP-1 release from L-
cells. A fist mechanism is sweet taste receptor (TAS1R2-TAS1R3) activation 
which induces Ca2+ release from intracellular stores. A second proposed 
glucose sensor is Na+-coupled glucose uptake by SGLT1, which generates small 
currents that trigger depolarization and voltage-gated Ca2+ entry. A third 
possible candidate is ATP-induced closure of ATP-sensitive (KATP) channels 
(induced by glucose metabolism) which trigger voltage gated Ca2+ entry. 
Abbreviations: α-gust, α-gustducin; SGLT1, sodium coupled glucose 
transporter 1; TASR, taste receptor; KATP channel, ATP-sensitive K+ channel. 
SCFA sensing mechanism of the L-cell 
FFAR2 and FFAR3 are both expressed in the ascending colon and are co-localized with the PYY and 
GLP-1 secreting endocrine L-cells (Sykaras et al., 2012, Nohr et al., 2013). In vitro studies using 
isolated primary colonic cultures showed that SCFAs stimulate GLP-1 and PYY secretion in a FFAR2 
and FFAR3 dependent manner (Tolhurst et al., 2012, Psichas et al., 2015, Karaki et al., 2006). FFAR2-/- 
mice show lower basal and glucose induced GLP-1 levels (Tolhurst et al., 2012) and reduced portal 
vein GLP-1 and PYY levels after propionate infusion, indicating that FFAR2 is important for GLP-1 
secretion (Psichas et al., 2015). The impaired glucose-induced GLP-1 secretion observed in FFAR2-/- 
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mice was less pronounced in FFAR3-/- mice (Tolhurst et al., 2012). Lin et al. confirmed that FFAR3 
plays a minor role in butyrate-induced stimulation of GLP-1, and is not required for butyrate- and 
propionate-dependent induction of GIP (Lin et al., 2012). In contrast, germ-free mice which have no 
colonic fermentation, display increased GLP-1 levels and delayed gastrointestinal transit (Wichmann 
et al., 2013). This has been suggested to serve as an adaptive mechanism to inadequate energy 
availability in the colon. The increased GLP-1 levels would delay transit and hence increase nutrient 
absorption. 
1.2.2.1.3 Opposite regulation of gastric X/A cells and intestinal L-cells by chemoreceptors 
Ghrelin and GLP-1 have opposite secretory pattern where ghrelin levels increase before the meal and 
decrease postprandially and GLP-1 levels increase after a meal. However, their secretory pattern is 
controlled by similar chemosensors as discussed in the previous paragraphs. Most taste receptors 
controlling ghrelin secretion are inhibitory while the activation of these taste receptors on L-cells 
induces stimulatory responses. This dichotomy in function of these taste receptors can be obtained 
through 1) a combination of the differential expression of several receptors on gastric X/A (no 
expression of Gαs-coupled receptors TGR5 and GPR119) and intestinal L-cells (weak expression of 
GαI-coupled lactate receptor GPR81), 2) the presence of different receptors for medium-and long 
chain fatty acids (Gαi-coupled FFAR4 on ghrelin cells and the Gαq-coupled FFAR1 on the GLP-1 cells) 
and 3) cell-dependent signaling bias by metabolite receptors that are able to signal through Gαi in the 
ghrelin cells and conceivably through Gαq in the GLP-1 cells (Engelstoft and Schwartz, 2016).  
1.2.2.2 Enterocyte 
Enterocytes are the major cell type lining the gut. They express several transporters regulating 
uptake of sugars, amino acids and fatty acids. On their apical side they contain microvilli to enlarge 
the luminal contact surface. Enterocytes regulate nutrient uptake and can therefore be seen as 
absorptive cells which do not possess secretory vesicles.  
1.2.2.2.1 Carbohydrate transport 
Enterocytes predominantly transport carbohydrates out of the lumen of the small intestine in the 
form of free glucose and fructose. Polysaccharides are first digested by amylases (present in saliva 
and pancreatic fluids) to disaccharides, which are digested to monosaccharides by the brush border 
enzymes; maltase, sucrase-isomaltase, lactase and trehalase. Furthermore, HCl present in the 
stomach can also catalyze the hydrolysis of sucrose to glucose and fructose. The model for glucose 
transport is depicted in Figure 1.8. Glucose is transported across the apical membrane via active 
transport through SGLT1 and can be metabolized intracellularly (Crane, 1965). In a state of low 
luminal glucose concentrations, the passive glucose transporter GLUT2 can transport glucose from 
the blood stream into the enterocyte to ensure glucose metabolism, while in a state of high luminal 
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glucose, GLUT2 will transport the excess of glucose across the basolateral epithelial membrane 
(Thorens et al., 1988). Strikingly GLUT2-/- animals only show a modest reduction (Roder et al., 2014), 
or no reduction at all (Stumpel et al., 2001) in peripheral blood glucose levels after a high luminal 
glucose bolus. These observations suggest the existence of an additional glucose transporter in the 
basolateral membrane. 
High luminal glucose concentrations increase the expression of SGLT1 (Lescale-Matys et al., 1993) 
which has been hypothesized to mediate the incorporation and upregulation of GLUT2 in the apical 
membrane (Kellett and Helliwell, 2000). The presence of apical GLUT2 was demonstrated after a 
glucose bolus in intestinal tissue rings (Gouyon et al., 2003) and isolated intestinal segments 
(Chaudhry et al., 2012). Furthermore apical GLUT2 has also been shown in ob/ob mice, mice on a 
low-carbohydrate/high-fat diet and in 76% of the biopsies of obese subjects (Ait-Omar et al., 2011). 
Despite these findings there is some controversy to whether or not GLUT2 can translocate to the 
apical membrane; 1) lean subjects did not show any apical GLUT2 insertion (Ait-Omar et al., 2011), 2) 
Röder et al. did not observe an increased SGLT1 expression, nor apical GLUT2 insertion after a high 
oral glucose bolus in mice (Roder et al., 2014), 3) SGLT1-/- mice develop glucose-galactose 
malabsorption syndrome pointing towards SGLT1 as the predominant transporter (Gorboulev et al., 
2011), 4) radiotracer studies of glucose absorption in SGLT1-/- and GLUT2-/- mice revealed a 
predominant role for SGLT1 in apical glucose transport (Roder et al., 2014) and 5) patients suffering 
from congenital GLUT2 deficiency (Fanconi-Bickel syndrome) did not display impaired luminal 
glucose absorption (Santer et al., 2003). 
However, Kellet responded to some of these arguments, suggesting that the mice used in the study 
of Gorboulev et al. (Gorboulev et al., 2011) were not optimally handled since the mice were first 
starved which reduces intestinal GLUT2 apical protein levels (Kellett, 2012). Other studies with 
GLUT2-/- mice have showed that GLUT2 makes no substantial contribution to the net glucose 
absorption (Stumpel et al., 2001). Furthermore, D-glucose accumulation in enterocytes is increased 
in GLUT2-/- mice (Roder et al., 2014). This increase can in part be ascribed to loss of GLUT2 mediated 
transport activity from the baso-lateral membranes. Therefore evidence on the importance of GLUT2 
mediated apical glucose transport remains limited and controversial but suggests that GLUT2 does 
not play an important role in apical glucose transport. 
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Figure 1.8 The model of intestinal glucose absorption 
before and after a meal. Before the meal glucose is 
transported across the apical membrane by SGLT1. The 
basolateral GLUT2 operates in the opposite direction to 
supply glucose from the blood and maintain the energy 
requirements of the cell. At high luminal glucose 
concentrations initial transport across the apical membrane 
occurs through SGLT1. This may result in apical insertion of 
GLUT2. Basolateral GLUT2 will transport the excess of 
intracellular glucose out of the cell. Abbreviations: GLUT2, 
glucose transporter 2; SGLT1, sodium coupled glucose 
transporter 1. 
Fructose is transported across the apical membrane 
via the glucose transporter GLUT5 (Burant et al., 
1992), but similarly to glucose it needs GLUT2 to be 
transported through the basolateral membrane into the blood stream (Thorens et al., 1988). 
1.2.2.2.2 SCFA transport 
Dietary fibers, like OFS, are carbohydrates which are not digested in the small intestine by human 
gastrointestinal enzymes. These molecules are fermented to SCFAs by the colonic gut microbiota. 
Approximately 500-600mmol SCFAs are produced in the human colon per day (Cummings, 1981), 
whereas fecal SCFA extracts range from 5-30mmol/day (den Besten et al., 2013). This implies that 
most of the SCFAs are absorbed by the colonocytes (McNeil et al., 1978). A schematic presentation of 
SCFA transport on the colonocytes is depicted in Figure 1.9. SCFAs can be absorbed by the 
colonocytes via three different mechanisms; 1) passive diffusion of the protonated SCFA (Hoverstad 
et al., 1982), 2) exchange with bicarbonate in a 1:1 ratio (Titus and Ahearn, 1988), or 3) active 
transport of the dissociated SCFAs via a monocarboxylate transporter (MCT). The electrogenic 
sodium-dependent monocarboxylate transporter 1 (SMCT-1) and the MCTs; MCT-1, MCT-2 and MCT-
4, are found in the apical membrane of enterocytes and transport SCFAs (Moschen et al., 2012, 
Ritzhaupt et al., 1998). Flux measurements of labeled compounds in Xenopus laevis oocytes 
expressing the isoforms MCT-1, MCT-2 and MCT-4 showed that all these transporters mediate 
acetate uptake with MCT4 being the weakest acetate transporter (Moschen et al., 2012). MCT-1 can 
also mediate propionate and butyrate transport, but the bulk of propionate and butyrate transport 
will be mediated through non-ionic diffusions (Moschen et al., 2012). Furthermore, butyrate uptake 
by the colonocytes mainly involved MCT-1 and SMCT-1 in rat small intestinal epithelial cells (IEC-6) 
but not in fetal human colonic epithelial (FHC) cells (Goncalves et al., 2011). 
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The absorbed SCFAs are not completely metabolized by the colonocytes, but can exit the colonocytes 
across the basolateral membrane into the blood stream. This basolateral transport into the 
circulation can be mediated via MCT-4, MCT-5 or transport via the SCFA/HCO3- exchanger (Gill et al., 
2005). This uptake results in concentrations of SCFAs in the portal blood ranging from 260µM for 
acetate to 30µM for propionate and butyrate (Bloemen et al., 
2009). 
Figure 1.9 The model of intestinal SCFA absorption. SCFAs are absorbed 
by the enterocytes across the apical membrane via passive diffusion of 
the protonated SCFA, the SCFA/HCO3- exchanger, or active transport of 
the dissociated SCFAs via SMCT-1, MCT-1, MCT-2 and MCT-4. In the 
enterocytes, the SCFAs can enter the citric acid circle (TCA) to generate 
ATP, or they can be transported across the basolateral membrane via 
MCT-4, MCT-5 or transport via the SCFA/HCO3- exchanger. 
Abbreviations: MCT, monocarboxylate transporter; SMCT, sodium-
dependent monocarboxylate transporter; SCFA, short-chain fatty acid; 
TCA, citric acid circle. 
1.2.2.2.3 Brush cells 
Brush cells are a specific type of enterocytes with a pear shape and long apical microvilli which 
overreach those of the enterocytes. They only represent a small portion of the cells in the 
gastrointestinal tract. Brush cells express gustatory signaling elements, like α-gustducin, transducin 
and TRPM5, but do not contain secretory granules. Therefore it has been hypothesized that these 
cells may sense the luminal content and signal the information to nearby EECs (Hass et al., 2007). 
Furthermore, three recent publications show that infection with parasitic worms such as helminths 
or protozoa are sensed via brush cells in the gut epithelium. They orchestrate the type 2 cell-
mediated immunity by producing IL-25 in mice. Brush cells and goblet cells accumulate during 
infection in a TRPM5 and gustducin-dependent manner. Up till now it is unclear which infection-
induced molecules are sensed by the gustducin coupled taste receptors on brush cells to initiate this 
signaling cascade (von Moltke et al., 2016, Gerbe et al., 2016, Howitt et al., 2016). 
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1.2.3 Chemosensing in a setting of obesity  
Obesity has been associated with altered meal-induced gut hormone release. Obese and overweight 
patients reported attenuated postprandial GLP-1 (Adam and Westerterp-Plantenga, 2005, Verdich et 
al., 2001) and PYY levels (Brownley et al., 2010, Cahill et al., 2011, le Roux et al., 2006), while fasting 
and postprandial plasma ghrelin levels were reported to be lower in obese compared to normal-
weight individuals (Tschop et al., 2001).  
Furthermore, changes in circulating peptides during obesity are linked to a change in their receptor 
expression levels in vagal afferent neurons (Kentish et al., 2013). A HFD increased the expression of 
the ghrelin and the CCK receptor (GHSR and CCK1R) compared to rats on a normal chow diet (Paulino 
et al., 2009). Furthermore, the presence of ghrelin in cultured nodose ganglia from lean mice 
increased CCK1R expression and decreased GHSR expression, while the effect of ghrelin on the 
expression of these receptors on nodose ganglia from HFD-fed mice was reversed (Kentish et al., 
2013). Therefore, obesity does not only alter circulating gut hormone levels and their vagal receptor 
expression but also disrupts the inter-regulation of appetite regulatory receptors in vagal afferents 
(Kentish et al., 2013). 
The altered gut hormone levels in a setting of obesity coincide with altered expression levels of 
chemosensory elements on the tongue and in the GI tract. On the tongue diet-induced obesity 
decreased the detection of some taste stimuli through decreased taste receptor signaling (Maliphol 
et al., 2013). In gastric tissue, qPCR analyses revealed differences in mRNA expression levels for 
GPR120, α-gustducin, PLCβ2, TRPM5 and TAS1R3 in obese patients (Widmayer et al., 2012). EECs in 
the colon of overweight and obese patients showed an upregulation of the bitter taste receptor 
TAS2R38 (Latorre et al., 2016). 
Furthermore, a human genetics study revealed an association between the genetic risk of metabolic 
syndrome and polymorphisms coding for α-gustducin (Farook et al., 2012). These initial findings led 
to the hypothesis that the alteration in gut hormone levels and chemosensory elements may be 
linked and may mediate functional responses occurring during an altered energy balance. 
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2 RESEARCH OBJECTIVES 
Before the ingestion of a meal, food is sensed by taste receptors on the taste buds of the tongue 
which transmit signals via sensory afferents to inform the brain about the macronutrient 
composition of the meal. Sweet and umami are detected by heterodimers of 3 subtypes from the 
taste receptor family type 1 (TAS1R), bitter by 25 subtypes of the taste receptor family type 2 
(TAS2R) and short, medium and long chain fatty acids by 4 subtypes of the free fatty acid receptors 
(FFAR). The brain will respond accordingly to the transmitted taste signals with learned anticipatory 
responses.  
After the ingestion of a meal, taste receptors in the gut sense nutrients to elicit motor and secretory 
responses to assimilate the ingested macronutrients. As such, taste receptors on EECs coordinate the 
release of gut hormones (ghrelin, GLP-1, PYY) involved in appetite regulation.  
Evidence suggests that extra-oral taste receptors on EECs play an important role in detecting changes 
in the intraluminal content associated with a HFD and contribute to the dysregulated gut hormone 
levels and disturbed appetite signaling in obese patients. For example, a human genetics study 
revealed an association between the genetic risk of metabolic syndrome and polymorphisms coding 
for α-gustducin, a gustatory G-protein coupled to several taste receptors (sweet, fatty acid, umami, 
bitter) (Farook et al., 2012). Furthermore, in obese patients the mRNA expression levels of several 
chemosensory elements are altered in the stomach and bitter taste receptor expression is 
upregulated in EECs of the colon (Widmayer et al., 2012, Latorre et al., 2016). These initial findings 
further strengthen the hypothesis that chemosensory elements may mediate functional responses 
occurring during an altered energy balance. 
We investigated whether current treatment strategies for obesity such as the usage of functional 
foods (sucralose, oligofructose) or gastric bypass surgery interfere with the molecular events 
associated with intraluminal chemosensing. Since α-gustducin is coupled to several taste receptors 
(Jang et al., 2007, Janssen et al., 2011, Li et al., 2013), α-gustducin-/- mice were used in all our studies 
to elucidate the role of gut chemosensing in the applied treatments.  
In the first aim of this study, we investigated whether targeting the α-gustducin-mediated sweet 
taste receptor signaling pathway has an acute effect on the release of the hunger hormone ghrelin, 
using carbohydrates, artificial sweeteners or prebiotic carbohydrates 
In the second aim we studied whether long-term targeting of taste receptors with sweeteners in 
diet-induced obese mice has beneficial effects on gut hormone release and hence on glucose –and 
energy homeostasis but also on other events such as the “leaky gut” associated with obesity.  
In the last aim we investigated whether the nutrient overexposure or underexposure that occurs in 
some regions of the gut after Roux-en-Y gastric bypass surgery affects the nutrient sensing 
mechanisms and hence contributes to the restoration of the gut hormone balance and body weight 
regulation after bariatric surgery.  
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The general hypothesis and research objectives of this PhD manuscript is depicted in Figure 2.1. 
 
Figure 2.1 Research objectives of the thesis manuscript. Abbreviations: RYGB, Roux-en-Y gastric bypass 
surgery; TASR, taste receptor. 
 
Aim 1. Unraveling the sweetener sensing mechanisms of the ghrelin cell 
Sweet taste receptors (TAS1R2+TAS1R3), coupled to the gustatory G protein, α-gustducin, among 
others, are involved in the glucose-dependent secretion of the gut satiety peptide, GLP-1 from the L-
cells (Jang et al., 2007, Gerspach et al., 2011, Steinert et al., 2011b). Recent studies, including from 
our lab, showed that the ghrelin cell also expresses TAS1R3 and gustatory G-proteins (Hass et al., 
2010, Janssen et al., 2011), but their physiological role has not yet been elucidated. 
We investigated whether the α-gustducin-mediated sweet taste receptor signaling pathway is 
involved in the effect of carbohydrates and sweeteners on ghrelin release in three different models; 
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1) a ghrelinoma cell line, 2) ex vivo preparations from gastric and jejunal segments from wild type 
(WT) and α-gustducin (α-gust-/-) mice and 3) in vivo after acute administration of carbohydrates or 
sweeteners in WT and α-gust-/- mice. 
Aim 2. Exploring the role of gustducin-mediated gut hormone release in the effect 
of sweeteners (oligofructose and sucralose) on high-fat diet induced body weight 
gain 
Artificial sweeteners, such as sucralose, are non-caloric but might not be metabolically inert. 
Furthermore, the prebiotic sweetener oligofructose (OFS), has been proposed as a functional food 
ingredient that beneficially affects gut microbiota composition, gut permeability and modulates the 
secretion of gut hormones to prevent obesity and diet-induced T2DM in rodents (Cani et al., 2004b, 
Cluny et al., 2015, Cani et al., 2009). Both OFS and sucralose can activate the sweet taste receptor. In 
addition, colonic fermentation of OFS by the gut microbiota will increase the production of short-
chain fatty acids (SCFAs) which can activate FFAR2 and FFAR3 on EECs. 
We investigated whether long-term gavage of equisweet concentrations of a prebiotic (oligofructose) 
or an artificial (sucralose) sweetener could prevent the induction of diet-induced obesity and T2DM 
by altering gut hormone release through interaction with extra-oral taste receptors coupled to α-
gustducin. The underlying pathways were investigated with a specific focus on the effect of the 
sweeteners on sweet-and fatty acid taste receptor expression along the gut, the release of gut 
hormones and possible intestinal adaptations such as changes in gut morphology and gut 
permeability. 
Aim 3. Exploring the role of nutrient sensing in the metabolic changes after Roux-
en-Y gastric bypass (RYGB) surgery 
After RYGB surgery food passes directly from a small stomach pouch into the distal part of the small 
intestine. Due to this rerouting, gastric acid production is decreased while bile acids and pancreatic 
enzymes are secreted in the excluded duodenum and reach the undigested food in the distal part of 
the jejunum. To adapt to the new digestive route we hypothesized that RYGB surgery has a major 
impact on the extra-oral taste receptors on EECs that control the pattern of gut hormone secretion 
both in the foregut and distal gut.  
We investigated the role of extra-oral gustducin-mediated taste receptor signaling in the altered gut 
hormone secretion, favoring sustained improvement of glucose -and energy homeostasis after RYGB 
surgery in obese WT and α-gust-/- mice. In addition, we performed an in-depth study on the origin of 
the altered gut hormone levels and the physiological adaptations along the gut (e.g. gut morphology 
and gut permeability). 
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3 UNRAVELING THE SWEETENER SENSING MECHANISMS OF THE GHRELIN 
CELL  
3.1 Abstract 
Carbohydrate administration decreases plasma levels of the ‘hunger hormone’ ghrelin. The ghrelin 
cell is co-localized with the sweet taste receptor subunit, TAS1R3, and the gustatory G-protein, 
gustducin, both involved in the sensing of sweeteners by EECs. This study investigated the role of 
gustducin mediated sweet taste receptor signaling on ghrelin secretion in a gastric ghrelinoma cell 
line, tissue segments and mice. The monosaccharide D-glucose and low-intensity sweetener 
oligofructose decreased (P<0.001) ghrelin secretion while the high-intensity sweetener sucralose 
increased (P<0.001) ghrelin secretion in vitro. These effects were not mediated via the sweet taste 
receptor or glucose transporters (SGLT1 and GLUT2). The effect of these compounds was mimicked 
ex vivo in gastric and jejunal segments from both wild type (WT) and -gustducin knockout (-gust-/-) 
mice. In vivo, the sensing of D-glucose was polarized since intragastric but not intravenous 
administration of D-glucose decreased (P<0.05) ghrelin levels in a -gustducin-independent manner 
which involved inhibition of duodenal ghrelin release. In contrast, neither oligofructose nor sucralose 
affected ghrelin secretion in vivo. In conclusion, α-gustducin mediated sweet taste receptor signaling 
does not play a functional role in the sensing of carbohydrates, low- or high-intensity sweeteners by 
the ghrelin cell.  
3.2 Graphical abstract 
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3.3 Introduction 
Over the past four decades, we have transitioned from a world in which underweight prevalence was 
more than double that of obesity, to one in which more people are obese than underweight (NCD et 
al., 2016). This increase in obesity prevalence has been linked to an excessive sugar intake (Medina-
RemOn et al., 2016, Bray and Popkin, 2014). Therefore guidelines in healthcare arose, recommending 
reductions in added sugar intake (WHO, 2015). Sugar replacers, such as HIS (e.g. sucralose), can help 
reduce the sugar content of meals without affecting its taste. These sweeteners are non-caloric but 
might not be metabolically inert, since contradictory results have been reported on their impact on 
energy homeostasis (Roberts, 2015). 
Next to these HIS, prebiotic sweeteners such as oligofructose (OFS) have been proposed as functional 
food ingredients. OFS has a low caloric content (1.7kcal/g) which is derived from its microbial 
fermentation products, the short-chain fatty acids (SCFAs), which can be used as an energy substrate 
by the colonocytes. It has a sweetening power of 35% of that of sucrose (table sugar) (Niness, 1999). 
Furthermore, OFS decreases food intake, fat mass development, and hepatic steatosis in normal and 
obese rodents (Delzenne et al., 2011b, Woting et al., 2015, Cluny et al., 2015, Anastasovska et al., 
2012, Delmee et al., 2006, Cani et al., 2006, Cani et al., 2005b). In humans, contradictory results have 
been reported with inulin-type fructans on body weight reduction (Liber and Szajewska, 2013). 
The hunger hormone ghrelin can stimulate food intake, prevent fatty acid utilization, increase body 
weight, inhibit glucose-induced insulin release and stimulate gastrointestinal motility (Kojima et al., 
1999, Muller et al., 2015, Avau et al., 2013, Verhulst and Depoortere, 2012). Ghrelin needs a 
posttranslational modification, catalyzed by the enzyme ghrelin-O-acyltransferase (GOAT) to exert its 
biological activity (Kojima et al., 1999, Gutierrez et al., 2008, Yang et al., 2008). Both GOAT and 
ghrelin are present in X/A like cells of the gastric oxyntic mucosa.  
Plasma ghrelin levels increase before a meal and decrease thereafter to determine the frequency of 
the meals. Whereas the preprandial rise involves activation of the autonomic nervous system (Zhao 
et al., 2010), the magnitude of the postprandial decline is dependent on the macronutrient 
composition of the meal (Foster-Schubert et al., 2008). Whether the latter is mediated via pre- or 
postabsorptive effects or involves chemosensation by the ghrelin cell is still not clear. However, 
recent evidence suggests that the ghrelin cell is equipped not only with receptors for neuropeptides 
but also with receptors for dietary and endogenous metabolites such as amino acids and free fatty 
acids that can directly regulate ghrelin release (Vancleef et al., 2015, Janssen et al., 2012). 
Immunohistochemical studies also provided evidence for the presence of gustatory G-proteins 
(gustducin, transducin) (Janssen et al., 2011) and a subunit of the sweet taste receptor (TAS1R2-
TAS1R3) (Hass et al., 2010) on the ghrelin cell but their functional role remains to be elucidated. The 
sweet taste receptor is broadly tuned to detect glucose and other simple sugars, and is activated by 
artificial sweeteners (DuBois, 2016). The sweet taste receptor, coupled to gustducin, and the sodium-
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dependent glucose cotransporter (SGLT1) act as glucose-sensors of the L-cells in the small intestine 
(Jang et al., 2007, Gorboulev et al., 2011).  
This study aimed to investigate whether α-gustducin mediated sweet taste receptor signaling is 
involved in the effect of carbohydrates and sweeteners on ghrelin release. A ghrelinoma cell line was 
used to investigate the in vitro effect and the mechanism of action of carbohydrates and sweeteners 
(sucralose and OFS) on ghrelin release. Ex vivo gastric and jejunal segments from wild type (WT) and 
α-gustducin (α-gust-/-) mice were used to determine whether the sweet sensing mechanisms of the 
ghrelin cell are tissue dependent and involve a sweet taste receptor coupled to the gustatory G-
protein, α-gustducin. Finally, the effect of glucose and sweeteners on ghrelin release was 
investigated in vivo in WT and α-gust-/- mice to investigate the role of α-gustducin mediated sweet 
taste receptor activation and signaling. 
3.4 Materials and Methods  
3.4.1 Materials 
D-glucose was obtained from Merck (Merck, Germany), sucralose, phloridzin and phloretin were 
purchased from Sigma-Aldrich (Sigma-Aldrich, USA). Oligofructose (OFS) was kindly provided by 
Beneo-Orafti (Beneo-Orafti, Germany) and gurmarin by Prof. L. Briand (Center for Taste and Feeding 
Behaviour, Dijon, France). The stock solutions of phloretin and phloridzin were made in DMSO and 
further diluted in Krebs-Ringer buffer with 11mM D-glucose resulting in a final concentration of 
0.001% DMSO for 10µM phloretin/phloridzin and 0.002% DMSO for 20µM phloretin,. The ghrelinoma 
cell line, MGN3-1, was kindly provided by Prof. H. Iwakura (Kyoto University Hospital, Kyoto, Japan). 
3.4.2 Mice 
Male C57BL/6 WT mice and α-gust-/- mice (kindly provided by Prof. R. Margolskee, Monell Chemical 
Senses Center, Philadelphia, United States) were kept in the animal facility. All mice were housed 
(20–22 °C) under a 14-h:10-h light-dark cycle and had ad libitum access to food and drinking water. 
All experimental procedures were approved by the Ethical committee for Animal Experiments of the 
KU Leuven (P100/2013). 
3.4.3 Experimental design 
Overnight-fasted mice were either gavaged (150µL) with D-glucose (4g/kg body weight), OFS (5.6g/kg 
body weight), sucralose (8.95mg/kg body weight) or 0.9% NaCl, or injected intravenously (IV) (150µL) 
into the tail vene with 1g/kg body weight D-glucose or 0.9% NaCl. In humans sucralose is in general 
320-1000 times sweeter than sucrose and sucrose is 1.25-1.43 times more sweet than glucose 
(Friedman, 1998, Wildman, 2011). This indicates that sucralose is about 1000 times sweeter 
compared to glucose, resulting in a dose of 8.95 mg/kg for sucralose compared to 4g/kg for glucose. 
Furthermore, oligofructose is 2 to 3.3 times less sweet than sucrose (Niness, 1999), resulting in a 
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dose of about 5.6g/kg for OFS. These doses were chosen to be “equisweet” in order to study the 
effect of the sweeteners after a similar degree of sweet taste receptor activation. However, the 
“equisweet” doses were based on human studies, although the dose used in human studies does not 
necessarily apply to mice.  
Forty minutes after IV injection or gavage, mice were humanely killed. Blood was collected by cardiac 
puncture and supplemented with 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (4mM) 
and ethylenediaminetetraacetic acid (1mg/ml). Plasma was acidified (0.1N HCl) and stored at -80°C. 
The stomach and duodenum were removed and stored for protein extraction. 
3.4.4 Ghrelin tissue extraction 
Tissue from stomach and duodenum was boiled for 10 minutes followed by homogenization in 3 
volumes of water with protease inhibitors (MP Biomedicals, CA) and 9 volumes of 6% acetic acid. 
After 10 minutes of boiling, the homogenate was centrifuged to collect the supernatant which was 
diluted and subjected to radioimmunoassay (RIA). Protein levels were determined using the Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific Inc., MA). 
3.4.5 Ghrelin release from intestinal segments 
Overnight fasted WT and α-gust-/- mice were refed for 2 hours prior to being sacrificed. Segments of 
the intact corpus of the stomach (0.3x0.3 cm) and jejunum (0.4x1 cm) were dissected and incubated 
at 37°C in Krebs-Ringer buffer (11mM D-glucose) with the test solutions (D-glucose (200mM), OFS 
(10%), sucralose (200mM)) for 2 hours. The culture medium was collected, acidified (0.1N HCl) and 
stored at -80°C. Tissue segments were dried to correct ghrelin release for dry tissue weight of the 
segment. 
3.4.6 Ghrelin release from ghrelinoma cells 
MGN3-1 cells were cultured in Dulbecco’s modified eagle medium (DMEM, Sigma Aldrich) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. Cells were 
incubated with D-glucose (11.1-200mM), D-fructose (20-200mM), OFS (0.1-10%) or sucralose (1-
200mM) in Krebs-Ringer buffer with 11mM D-glucose for 3 hours. Osmolality was corrected to 
physiological levels by adapting the concentration of NaCl. The effect of the sweet taste receptor 
antagonist (30µg/ml gurmarin) (Margolskee et al., 2007), or glucose transporter inhibitors (SGLT1 
antagonist; 10µM phloridzin (Parker et al., 2012), GLUT-family antagonist; 10-20µM phloretin (Zou et 
al., 2014)) was investigated by preincubation of the cells during 30 minutes with the respective 
inhibitors after which the culture medium was removed and replaced by a combination of the 
antagonist and the indicated carbohydrate or sweetener for 3 hours. The dose of gurmarin was high 
enough to block both TAS1R2-TAS1R3 (Margolskee et al., 2007) and the TAS1R3 homodimer since 
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this dose blocked the umami taste receptor (TAS1R1-TAS1R3) and thus the common subunit of the 
sweet and umami taste receptor, namely TAS1R3 (Vancleef et al., 2015, Daly et al., 2013). Following 
the incubation, the supernatant was collected, acidified (0.1N HCl) and stored at -80°C. 
3.4.7 Radioimmunoassay (RIA) 
Plasma samples and cell/tissue culture supernatants were extracted on a SEP-Pak C18 cartridge 
(Waters Corporation), vacuum-dried and subjected to ghrelin RIA as previously described (Janssen et 
al., 2011). For determination of octanoyl ghrelin a rabbit anti-human ghrelin [1-8] antibody was used 
which does not recognize desoctanoyl ghrelin. Total ghrelin levels were determined using a rabbit 
anti-human ghrelin [14-28] antibody, which recognizes both octanoyl and desoctanoyl ghrelin.  
3.4.8 Quantitative real-time PCR 
Total RNA was isolated from MGN3-1 cells and tissue segments from the mouse gastro-intestinal (GI) 
tract using the RNeasy kit (Qiagen), treated with Turbo DNAfree kit (Ambion) and reverse transcribed 
to cDNA using Superscript II Reverse Transcriptase (Invitrogen). The qRT-PCR reaction was performed 
as described previously, using the Lightcycler 480 (Roche Diagnostics) with the Lightcycler 480 Sybr 
Green I Master mix (Roche Diagnostics) (Verhulst et al., 2008), and analyzed using the LightCycler® 
480 SW 1.5.1 software (Roche Diagnostics). Results were expressed relative to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). The following primers were used: GAPDH: forward 
CCCCAATgTgTCCgTCgTg, reverse gCCTgCTTCACCACCTTCT; SGLT1: forward CggAAgAAggCATCTgAgAA, 
reverse AATCAgCACgAggATgAACA; GLUT2: forward TCTTCACggCTgTCTCTgTg, reverse 
AATCATCCCggTTAggAACA; TAS1R2: forward gCACCAAgCAAATCgTCTATCC, reverse 
ATTgCTAATgTAggTCAgCCTCgTC; TAS1R3: forward CAggCAgTTgTgACTCTgTTg, reverse 
TgCgATgCAgATACCTCgTg. 
3.4.9 Statistical analysis 
Results are presented as mean ± SEM. The data representing the effect of the test compounds on 
ghrelin release from intestinal segments and on plasma ghrelin levels and tissue ghrelin content were 
assessed for normality of distribution. As the data were distributed in a non-normal and/or non-
homogeneous manner, log-transformed data were used to examine the main effects of the 
compounds using a multivariate analysis of variance (MANOVA). An interaction effect between 
compounds and genotypes was included in the model as well. Post-hoc t-tests with Holm-Sidak 
correction for multiple testing were applied (SAS Studio University Edition 9.4). Dose-response curves 
of the test compounds in the MGN3-1 cell line were analyzed using a repeated measures analysis 
(factors; compound and dose), followed by planned comparisons post-hoc testing and Bonferroni 
correction (Statistica 12, Statsoft). The effect of the different antagonists on the effect of the test 
compounds on ghrelin release was analyzed with a two-way ANOVA, followed by planned 
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comparisons post-hoc testing and Bonferroni correction (factors; compound and antagonists) 
(Statistica 12, Statsoft). Significance was accepted at the 5% level. 
3.5 Results 
3.5.1 In vitro studies in the MGN3-1 ghrelinoma cell line 
The gastric MGN3-1 cell line shows a strong expression of the TAS1R3 subunit of the sweet taste 
receptor and the glucose transporters (SGLT1 and GLUT2). The sweet taste receptor subunit TAS1R2 
is not detectable in the cell line (Figure 1a).  
MGN3-1 cells were incubated with increasing concentrations of D-glucose, oligofructose (OFS) or 
sucralose and the effect on octanoyl ghrelin release was determined. 
D-glucose (200mM) and OFS (10%) induced a significant (P<0.001) decrease in octanoyl ghrelin levels 
while sucralose (200mM) stimulated (P<0.001) octanoyl ghrelin release. Lower concentrations had no 
effect (Figure 1b).  
 
Figure 1. D-glucose and the low-intensity sweetener oligofructose decrease octanoyl ghrelin release while a 
high-intensity sweetener sucralose increases octanoyl ghrelin secretion from a ghrelinoma cell line. (a) 
Relative mRNA expression levels of the two subunits of the sweet taste receptor (TAS1R2-TAS1R3), and the 
glucose (SGLT1, GLUT2) transporters in the ghrelinoma cell line, MGN3-1 (n=3/sensor). (b) Concentration-
dependent effect of a 3 h stimulation with D-glucose, oligofructose (OFS) and sucralose on octanoyl ghrelin 
release (n=9-12). Results (mean ± SEM) are expressed relative to the control stimulation (Krebs buffer 
containing 11.1mM D-glucose). *** P<0.001 vs. control. AU: arbitrary units 
The inhibitory effect of 200mM D-glucose or 10% OFS and the stimulatory effect of 200mM sucralose 
on octanoyl ghrelin release was not blocked by the sweet taste receptor antagonist gurmarin 
(30µg/ml), the SGLT1 inhibitor phloridzin (10µM) or the GLUT family inhibitor phloretin (10-20µM) 
(Figure 2a-e). Phloretin (20µM), but not phloretin (10µM), phloridzin (10µM) or gurmarin (30µg/ml), 
increased basal ghrelin release with about 60% (P<0.05) (Figure 2e). 
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Figure 2. The effect of carbohydrates and sweeteners on octanoyl ghrelin release in the ghrelinoma cell line 
are not mediated via the sweet taste receptor or the glucose transporters. Effect of preincubation (30 min) of 
MGN3-1 cells with a (a-c) TAS1R2-TAS1R3 antagonist (gurmarin, 30µg/ml) (n=9), (d) SGLT1 inhibitor (phloridzin, 
10µM) (n=9) or (e) GLUT family antagonist (phloretin, 10-20µM) (n=9) or their respective vehicle (Krebs with or 
without DMSO) on the effect of (a, d, e) 200mM D-glucose, (b) 10% oligofructose (OFS), and (c) 200mM 
sucralose compared to Krebs buffer on octanoyl ghrelin release in MGN3-1 cells. Results (mean ± SEM) are 
expressed relative to the control stimulation (Krebs buffer containing 11.1mM D-glucose). * P<0.05, ** P<0.01, 
*** P<0.001 vs. vehicle, $ P<0.05 vs. vehicle stimulated control. 
3.5.2 Ex vivo studies in intestinal segments 
The mRNA expression levels of the different glucose sensors were determined in several regions of 
the GI tract of mice. The TAS1R3 subunit and α-gustducin were expressed throughout the GI tact 
with a high expression in the stomach and distal GI tract (Figure 3a, c). In contrast, the highest 
expression levels of the TAS1R2 subunit and the glucose transporters (SGLT1 and GLUT2) were 
observed in the small intestine (Figure 3b, d, e). 
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Figure 3. TAS1R3 and α-gustducin are expressed throughout the GI tract while TAS1R2 and the glucose 
transporters are expressed in the small intestine. Relative mRNA expression levels of (a, b) the two subunits of 
the sweet taste receptor (TAS1R2-TAS1R3), (c) α-gustducin and (d, e) the glucose (SGLT1, GLUT2) transporters 
throughout the mouse GI tract (n=5). Results are presented as mean ± SEM. AU: arbitrary units. 
The differential expression of the TAS1R3 subunit (corpus and jejunum) and the TAS1R2 subunit (only 
jejunum) allowed us to investigate, in the respective ex vivo segments, whether the effect of glucose 
and the high- and low-intensity sweeteners on ghrelin release is region-dependent and thus involves 
the TAS1R2-TAS1R3 receptor heterodimer. Furthermore, the effect of the compounds was tested in 
segments from WT and α-gust-/- mice to elicit the role of the G-protein, α-gustducin, coupled to the 
sweet taste receptor complex. 
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3.5.2.1 D-glucose decreased ghrelin release from gastric and jejunal segments in an α-gustducin-
independent manner 
D-glucose (200mM) tended to or decreased octanoyl ghrelin release (WT: P=0.076; α-gust-/-: P<0.01) 
from segments of the corpus of WT and α-gust-/- mice (Figure 4a). A similar effect was observed in 
jejunal segments from both WT and α-gust-/- mice (Figure 4b). Accordingly D-glucose decreased total 
ghrelin release from segments of the corpus (WT; P<0.01, α-gust-/-; P<0.001) and jejunum (WT; 
P<0.05, α-gust-/-; P<0.05) (Figure 4c, d). No interaction effects (genotype*treatment) were observed. 
3.5.2.2 Oligofructose decreased ghrelin release from gastric and jejunal segments in an α-
gustducin-independent manner 
OFS (10%) tended to or decreased (WT: P=0.076; α-gust-/-: P<0.05) octanoyl ghrelin release from 
segments of the corpus in both genotypes (Figure 4e). A significant (P<0.05) OFS-induced reduction in 
octanoyl ghrelin release was also observed in jejunal segments (Figure 4f). Accordingly, OFS 
significantly decreased total ghrelin release from segments of the corpus and jejunum from both 
genotypes (Figure 4g, h). No interaction effects (genotype*treatment) were observed. 
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Figure 4. The effect of D-glucose and oligofructose on ghrelin release from segments of the corpus and 
jejunum is α-gustducin-independent. Effect of a 2h stimulation with Krebs buffer or 200mM D-glucose (upper 
panel) or 10% oligofructose (lower panel) on octanoyl (left panels) and total ghrelin release (right panels) from 
tissue segments of the corpus of the stomach (n=6) or the jejunum (n=6) from WT and α-gust-/- mice. Results 
are presented as mean ± SEM. * P<0.05, ** P<0.01, *** P<0.001 vs. Krebs treated segments 
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3.5.2.3 Sucralose increased octanoyl ghrelin, but not total ghrelin release from gastric and jejunal 
segments in an α-gustducin-independent manner 
Sucralose (200mM) significantly increased octanoyl ghrelin release from segments of the corpus and 
jejunum of both genotypes (Figure 5a, b). However, sucralose did not affect total ghrelin release 
from segments of either the corpus or jejunum in both genotypes (Figure 5c, d). No interaction 
effects were observed. 
 
Figure 5. Sucralose increased octanoyl ghrelin, but not total ghrelin release from gastric and jejunal segments 
in an α-gustducin-independent manner. Effect of a 2h stimulation with 200mM sucralose or Krebs buffer on (a, 
b) octanoyl and (c, d) total ghrelin release from tissue segments of the corpus of the stomach (n=6) or the 
jejunum (n=6) from WT and α-gust-/- mice. Results are presented as mean ± SEM. * P<0.05, *** P<0.001 vs. 
Krebs treated segments. 
3.5.3 In vivo studies in mice 
The effect of the caloric and non-caloric sweeteners was tested in vivo in WT and α-gust-/- mice to 
investigate the physiological role of sweet taste receptor activation.  
Sweetener sensing mechanisms of the ghrelin cell
 
54 
 
3.5.3.1 The sensing of D-glucose by the ghrelin cell is polarized and occurs via the lumen 
Basal fasted octanoyl ghrelin levels were 41% lower (P<0.05) in α-gust-/- control mice, compared to 
WT control mice. Intragastric administration of D-glucose (4g/kg) in fasted mice significantly 
decreased plasma octanoyl (WT: -41±11%; α-gust-/-: -48±5%) and total ghrelin levels (WT: -38±8%; α-
gust-/- -48±4%) in both genotypes compared to vehicle-treated mice (Figure 6a, b). This was 
accompanied by an increase in duodenal tissue octanoyl ghrelin content in both WT (P<0.01) and α-
gust-/- mice (P<0.05) but not in gastric tissue octanoyl ghrelin content (Figure 6c, d). 
 
Figure 6. The inhibition of plasma ghrelin levels after an intragastric administration of D-glucose originates 
mainly from duodenal ghrelin cells. WT and α-gust-/- mice were gavaged with D-glucose (4g/kg) (n=8) or saline 
(n=13). Ghrelin levels were determined in (a, b) plasma, (c) stomach and (d) duodenum, 40 min after 
administration. Results (mean ± SEM) are expressed relative to the control stimulation (saline treated WT 
mice). * P<0.05, ** P<0.01 and *** P<0.001 vs. saline, $ P<0.05 vs. saline treated WT mice. 
To determine whether D-glucose is sensed via the lumen or the bloodstream after glucose uptake, 
the effect of intragastric (4g/kg) versus intravenous administration of D-glucose (1g/kg) on ghrelin 
release was compared. A pilot experiment showed that 1g/kg D-glucose induced comparable peak 
blood glucose levels (330±15 mg/dl) compared to the intragastric administration of 4g/kg D-glucose 
(317±31 mg/dl). Intravenous administration of D-glucose neither affected plasma octanoyl or total 
ghrelin levels nor gastric or duodenal tissue octanoyl ghrelin content (Figure 7a-d).  
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Figure 7. The sensing of D-glucose is polarized and occurs at the luminal side. Mice were intravenously 
injected with D-glucose (1g/kg) (n=10) or saline (n=11). Ghrelin levels were determined in (a, b) plasma, and in 
protein extracts from the (c) stomach and (d) duodenum, 40 min after administration. Results (mean ± SEM) 
are expressed relative to the control stimulation (saline treated WT mice). 
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3.5.3.2 Intragastric administration of neither a low- nor a high-potency sweetener affected 
plasma ghrelin levels 
In contrast to D-glucose, intragastric administration of oligofructose (OFS) (5.6g/kg) or sucralose 
(9.0mg/kg) did not affect plasma octanoyl or total ghrelin levels in either genotype (Figure 8a-d). 
 
Figure 8. Intragastric administration of sweeteners does not affect ghrelin release. WT and α-gust-/- mice 
were gavaged (a, b) oligofructose (5.63 g/kg) (n=8), (c, d) sucralose (8.95mg/kg) (n=9) or saline (n=9-13). 
Plasma octanoyl and total ghrelin levels were determined 40 min after administration. Results (mean ± SEM) 
are expressed relative to the control stimulation (saline treated WT mice). $ P<0.05 vs. vehicle treated WT 
mice. 
3.6 Discussion 
The in vitro results in the ghrelinoma cell line and ex vivo results obtained in tissue segments showed 
that D-glucose and oligofructose (OFS) reduced ghrelin release at concentrations physiological to the 
postprandial luminal fluid. In contrast, the artificial sweetener sucralose increased ghrelin release at 
the supraphysiological concentration of 200mM. Furthermore, neither α-gustducin mediated sweet 
taste receptor signaling nor glucose transport (SGLT1, GLUT family) played a role in the effect of D-
glucose, OFS or sucralose on ghrelin release. 
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Our in vivo findings indicate that the sensing of D-glucose by the X/A cells is polarized and occurred 
at the luminal side. The glucose-induced reduction in plasma ghrelin levels is α-gustducin-
independent and originates from a reduced ghrelin release from duodenal, but not gastric cells. In 
contrast, the low-and high-intensity sweeteners (OFS and sucralose) did not elicit any changes in 
plasma ghrelin levels.  
Previous studies showed that concentrations of D-glucose physiological to the postprandial 
basolateral concentrations were able to elicit changes in ghrelin secretion.  
For instance, Sakata et al. showed that, compared to a low glycemic state (1mM), normoglycemic 
(5mM) and high (10mM) concentrations of D-glucose decreased octanoyl ghrelin secretion from 
primary cultures of gastric mucosal cells, respectively (Sakata et al., 2012). Oya et al. showed that low 
(1mM), normoglycemic (5mM) and high (10mM) concentrations of D-glucose increased ghrelin 
secretion compared to 25mM D-glucose in MGN3-1 cells (Oya et al., 2015).  
We could not confirm these findings and only observed an inhibition of ghrelin secretion at 200mM 
D-glucose both in vitro and ex vivo. This dose mimics luminal glucose concentrations which range 
between 50-500mM (Ferraris et al., 1990). A similar observation was made for oligofructose which is 
usually supplemented at a dose of 8-21g/day in the diet or in a drink, and results in 5-10% OFS in the 
luminal fluid (Liber and Szajewska, 2013). These findings suggest that the sensing of D-glucose and 
OFS may occur at the luminal side of the intestinal epithelium. This was confirmed by our in vivo 
studies which showed that intravenous administration of D-glucose did not affect plasma ghrelin 
levels. Immunohistochemistry studies previously showed that in contrast to “closed-type “ghrelin 
cells, which are not in contact with the lumen, “open-type” ghrelin cells show the presence of the 
TAS1R3-subunit in their apical cell pole contacting the lumen (Hass et al., 2010). Since sweet taste 
receptors on the tongue are typically activated by 30–1000mM glucose (Damak et al., 2003, Reimann 
et al., 2008), the apical localization of the TAS1R3 subunit could explain the luminal sensing of D-
glucose. Nevertheless, many open-type duodenal ghrelin cells also showed TAS1R3 staining in their 
basolateral domain. We have previously shown that in contrast to glucose, the sensing of amino 
acids is not polarized (Vancleef et al., 2015). Since TAS1R3 is also involved in amino acid sensing, it is 
likely that the TAS1R3 staining in the basolateral domain is selectively involved in amino acid sensing.  
The amount of sucralose in sweetened soft drinks represents about 0.4mM and sucralose typically 
activates the sweet taste receptor at low millimolar concentrations (Damak et al., 2003). Our findings 
therefore indicate that sucralose only stimulated ghrelin release at supraphysiological concentrations 
(200mM).  
The effect of sucralose on ghrelin release in the ghrelinoma cell line and ex vivo segments was 
opposite to those of D-glucose and OFS. Functional studies of the sweet taste receptor have revealed 
at least four binding sites for sweet-tasting compounds (Sanematsu et al., 2014). It is likely that low-
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intensity sweeteners (glucose and OFS) and high-intensity sweeteners such as sucralose will bind to a 
different binding site, possibly activating a different signaling cascade. Sugars are thought to increase 
cAMP levels while artificial sweeteners may act by increasing levels of IP3 (Bernhardt et al., 1996). 
Still, both the cAMP and IP3 cascades eventually result in increased Ca2+ levels in the cell (Bernhardt 
et al., 1996) and cannot explain why glucose and OFS decrease ghrelin release and sucralose 
stimulates ghrelin release.  
Sucralose (> 0.62mM) has a bitter taste quality in rats (Torregrossa et al., 2015), but not in humans 
(Schiffman et al., 1995). However, it cannot be excluded that at high concentrations (200mM) 
surcralose might also taste bitter in mice and humans. Activation of bitter taste receptors has been 
shown to stimulate ghrelin secretion in vivo in mice, partially via α-gustducin (Janssen et al., 2011). 
Since sucralose stimulated ghrelin secretion in segments from both WT and α-gust-/- mice, it unlikely 
that the effect of sucralose is mediated via bitter taste receptors. Sucralose specifically increased 
octanoyl, but not total and thus desoctanoyl ghrelin release, therefore it might exert its activity 
through modulation of the activity of ghrelin-O-acyl transferase (GOAT). No evidence in literature so 
far supports the hypothesis of a link between sucralose and GOAT activity.  
We could not assign an important role of the TAS1R2-TAS1R3 heterodimer in the effect of glucose 
and sweeteners on gastric ghrelin release. Indeed, the mRNA expression of the TAS1R2 subunit was 
absent in segments from the corpus and in the ghrelinoma cell line, which is of gastric origin. Other 
studies using the TAS1R2-lacZ knock-in mouse did not observe TAS1R2 expression in the stomach 
(Iwatsuki et al., 2010). In contrast, Koyama et al. showed a very low expression of TAS1R2 in the 
MGN3-1 cell line and primary gastric ghrelin cells using RNA sequencing (Koyama et al., 2016). 
However, TAS1R3 may also function as a homodimer, as previously shown on the tongue (Zhao et al., 
2003), in adipocytes (Masubuchi et al., 2013) and in pancreatic β-cells (Nakagawa et al., 2014). Zhao 
et al. showed that the TAS1R3 homodimer was not able to detect sweeteners and carbohydrates at 
low concentrations (<300mM) (Zhao et al., 2003). This may explain why only high concentrations of 
glucose (200mM), sucralose (200mM) and oligofructose (10%) affected ghrelin secretion in the 
MGN3-1 cells. 
However, the lack of effect of the sweet taste receptor antagonist, gurmarin, which has been shown 
to block the TAS1R3 subunit (Vancleef et al., 2015, Daly et al., 2013), on glucose and sweetener 
induced ghrelin release suggests that neither TAS1R2-TAS1R3 nor the TAS1R3 homodimer is 
important. Furthermore, the effect of D-glucose and the sweeteners did not differ between 
segments from WT and α-gust-/- mice, indicating that gustducin mediated signaling does not play an 
important role. However, it cannot be excluded that the sweet taste receptor heterodimer or the 
TAS1R3 homodimer can couple to other G-proteins than α-gustducin. Indeed, α-gust-/- mice are not 
completely unresponsive to sweet compounds (Danilova et al., 2006) and the TAS1R3 homodimer 
has been shown to couple to Gs in adipocytes (Masubuchi et al., 2013). Furthermore, indirect effects, 
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mediated via glucose-induced GLP-1 release, seem unlikely since the effect should be blunted in 
segments from α-gust-/- mice (Jang et al., 2007). 
In L-cells, both α–gustducin mediated sweet taste receptor signaling and the glucose transporter, 
SGLT1, mediate glucose-induced GLP-1 secretion (Jang et al., 2007, Gorboulev et al., 2011). However, 
inhibitors for SGLT1 and the GLUT family could not confirm an involvement of these proposed 
glucose-sensors in the effect of D-glucose on octanoyl ghrelin secretion. Previous studies also 
suggested that KATP channels are involved in the effect of 25mM D-glucose on ghrelin secretion in 
MGN3-1 cells (Oya et al., 2015). However, tolbutamide (a potassium channel blocker) and diazoxide 
(a potassium channel activator) neither enhanced nor inhibited 1, 5 or 10mM glucose-induced 
ghrelin secretion in primary cultures of gastric mucosal cells (Sakata et al., 2012). 
Our in vivo studies showed that the glucose-induced ghrelin inhibition was due to a tissue-specific 
inhibition of octanoyl ghrelin release from the duodenum. Williams et al. showed that intragastric 
infusion of glucose or water inhibited ghrelin release when gastric emptying was permitted but not 
when emptying was prevented, indicating that gastric chemosensation is not a sufficient trigger for 
the ghrelin response (Williams et al., 2003). Thus although our in vitro and ex vivo studies indicate 
that glucose can inhibit ghrelin secretion in the stomach, in vivo this glucose sensing may be 
ineffective.  
Parker et al. showed that an intraduodenal glucose infusion proved to be just as effective in 
suppressing ghrelin levels as an intragastric infusion in healthy older men and women (Parker et al., 
2005). The magnitude of the glucose-induced decrease in plasma ghrelin levels was even dependent 
on the length of the small intestine exposed (Little et al., 2006). Tamboli et al. showed that jejunal 
glucose administration suppressed ghrelin levels to a greater degree compared with an intagrastric 
glucose administration in obese subjects. This was independent of circulation glucose levels, 
indicating that a nutrient-initiated signal in the jejunum may have regulated ghrelin secretion in this 
study (Tamboli et al., 2016). These results indicate that although the primary source of ghrelin is the 
gastric mucosa, small intestinal nutrient exposure is sufficient to decrease postprandial ghrelin levels. 
The sweeteners OFS and sucralose were not able to affect plasma ghrelin levels or gastric or 
duodenal ghrelin content in vivo. These findings, together with the observation that the effect of D-
glucose on ghrelin levels is not dependent on signaling through α-gustducin, would argue against a 
role for α-gustducin mediated sweet taste receptor signaling as glucose sensor of the X/A cell. Also in 
a dose-escalation study from 0 to 55 g daily of OFS, no significant effects were observed on plasma 
ghrelin levels (Pedersen et al., 2013). Artificial sweeteners did also not elicit differences in plasma 
ghrelin levels in healthy subjects in previous studies (Steinert et al., 2011a, Brown et al., 2011). 
Furthermore, results comparing equicaloric doses of glucose and fructose observed that the decrease 
in ghrelin levels after fructose administration, which is sweeter than glucose, was less pronounced 
Sweetener sensing mechanisms of the ghrelin cell
 
60 
 
(Prodam et al., 2006) or equal (Bowen et al., 2006) to the effect of glucose. These results suggest that 
the effect of glucose and fructose is not determined by their sweetness. 
In fact, a similar discrepancy has been found for the effect of sucralose on GLP-1 release in in vitro 
and in vivo studies. In enteroendocrine cell lines sucralose stimulates GLP-1 release via the sweet 
taste receptor (Jang et al., 2007, Ohtsu et al., 2014) whereas in vivo studies in humans and rodents 
fail to demonstrate an effect of sucralose on GLP-1 release (Steinert et al., 2011a, Wu et al., 2012). 
The regulatory interface of the GI tract is more complex than the physiological processes mimicked in 
in vitro experiments and is modulated by multiple homeostatic and non-homeostatic factors. This 
complexity may explain the discrepancy between in vitro and in vivo findings. 
3.7 Conclusions 
In conclusion, sensing of D-glucose by the ghrelin cell is polarized, occurs at the luminal side of the 
duodenum and may overrule gastric glucose sensing. Furthermore, α-gustducin-mediated sweet 
taste receptor signaling does not play a physiological role in the sensing of carbohydrates and 
sweeteners by the ghrelin cell since; 1) the effects of D-glucose and sweeteners in the ghrelinoma 
cell line are not blocked by the sweet taste receptor antagonist gurmarin, 2) D-glucose and the 
sweeteners affect ghrelin release in gastric segments which do not express one of the subytpes 
(TAS1R2) of the sweet taste receptor, 3) the effects are not reduced in α-gust-/- mice and 4) the 
sweeteners oligofructose and sucralose were not able to elicit the same responses on ghrelin 
secretion as D-glucose in vivo. 
We were unable to show a role for SGLT1 or GLUT2 as glucose sensor of the ghrelin cell and prior 
data on the involvement of the KATP channel are inconclusive. Therefore, the role of different G-
proteins and the functional role of a TAS1R3 homodimer or KATP channels as glucose sensors of the 
ghrelin cell warrant further investigation.  
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Chapter 4 
EXPLORING THE ROLE OF GUSTDUCIN-MEDIATED GUT 
HORMONE RELEASE IN THE EFFECT OF SWEETENERS 
(OLIGOFRUCTOSE AND SUCRALOSE) ON HIGH-FAT 
DIET INDUCED BODY WEIGHT GAIN
 
 
The data represented in the following chapter are published in Molecular Nutrition & Food 
Research: 
Supplementation of oligofructose, but not sucralose, decreases high-fat diet induced body 
weight gain in mice independent of gustducin-mediated gut hormone release 
Steensels S., Cools L., Avau B., Vancleef L., Farré R., Verbeke K., Depoortere I. 
Mol Nutr Food Res. 2016; doi: 10.1002/mnfr.201600716. 
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4 EXPLORING THE ROLE OF GUSTDUCIN-MEDIATED GUT HORMONE 
RELEASE IN THE EFFECT OF SWEETENERS (OLIGOFRUCTOSE AND 
SUCRALOSE) ON HIGH-FAT DIET INDUCED BODY WEIGHT GAIN 
4.1 Abstract 
Scope: Enteroendocrine cells (EECs) sense nutrients through taste receptors similar to those 
on the tongue. Sweet -and fatty acid taste (FFAR) receptors coupled to the gustatory G-
protein, gustducin, on EECs play a role in gut hormone release. We studied if supplementation 
of artificial (sucralose) or prebiotic (oligofructose; OFS) sweeteners target gustducin-mediated 
signaling pathways to alter gut hormone release and reduce obesity-associated disorders. 
Methods and results: Wild type (WT) and α-gustducin knockout (α-gust-/-) mice were fed a 
high-fat diet and gavaged once daily (8 weeks) with water or equisweet concentrations of 
sweeteners. OFS but not sucralose decreased body weight gain (-19±3%, P<0.01), fat pad mass 
(-55±6%, P<0.001) and insulin resistance (-39±5%, P<0.001) independent of α-gustducin. 
Neither sweetener improved glucose intolerance, while solely OFS improved the disturbed 
colonic permeability. OFS decreased (-65±8%, P<0.001) plasma GLP-1 but not ghrelin and PYY 
levels in WT mice. Caecal acetate and butyrate levels were reduced by OFS in both genotypes 
suggesting enhanced uptake of short-chain fatty acids which may target FFAR2 (upregulated 
expression) in adipose tissue. 
Conclusion: OFS, but not sucralose, reduced body weight gain and decreased intestinal 
permeability, but not glucose intolerance. Effects were not mediated by altered gut hormone 
levels or gustducin-mediated signaling. 
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4.2 Graphical abstract 
 
Artificial sweeteners do not affect gut hormone levels and are metabolically inert in mice on a 
high fat diet. In contrast, prebiotic oligosaccharides (OFS) prevent body weight gain but not 
glucose intolerance. Alterations in sweet and short-chain fatty acid receptors (FFAR) (studied 
in WT and α-gust-/- mice) which regulate gut hormone levels are not mandatory for the positive 
effects of OFS. Enhanced uptake of SCFAs may favor interaction with FFAR2/3 on adipose 
tissue to induce weight loss. 
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4.3 Introduction 
Obesity is posing a major healthcare problem to our modern society. Excessive sugar 
consumption is a major contributor to the obesity epidemic. Therefore guidelines from the 
WHO recommend a reduction in sugar intake (Organization, 2015). Sugar replacers, such as 
the artificial sweetener sucralose, can help reduce the sugar content of meals without 
affecting its taste. Artificial sweeteners are non-caloric but may not be metabolically inert. 
Epidemiological studies found a positive correlation (Fowler, 2016) or no correlation (Duran 
Aguero et al., 2014) between sweetener intake and weight gain. Two large randomized 
controlled trials showed that replacing sugar-containing beverages with noncaloric sweetened 
beverages reduced weight gain in children and adults (de Ruyter et al., 2012, Tate et al., 2012). 
Next to these artificial sweeteners, prebiotic sweeteners such as oligofructose (OFS), have 
been proposed as functional food ingredients that modulate the secretion of gut hormones to 
prevent obesity and obesity-related diseases in rodents (Cani et al., 2004a, Cluny et al., 2015, 
Cani et al., 2009). In humans, the link between OFS and body weight loss is less straightforward 
with studies reporting no effect (Pedersen et al., 2013, Liber and Szajewska, 2014) or a modest 
positive effect (Parnell and Reimer, 2009) on body weight loss after OFS supplementation.  
EECs in the gut sense nutrients through taste receptors (TASR) and chemosensory signaling 
pathways similar to those present on the tongue (Depoortere, 2014, Janssen and Depoortere, 
2013). Both OFS and sucralose can activate the sweet TASR (consisting of the TAS1R2-TAS1R3 
heterodimer) which is present on X/A cells secreting the hunger hormone ghrelin and L-cells 
secreting the satiety hormones, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), and the 
trophic hormone glucagon-like peptide-2 (GLP-2) to affect gut hormone release (Hass et al., 
2010, Jang et al., 2007). 
In addition, colonic fermentation of OFS by the gut microbiota will increase the production of 
short-chain fatty acids (SCFAs). SCFAs may induce satiety by stimulating the release of GLP-1 
and PYY (Canfora et al., 2015) via activation of the SCFA receptors FFAR2 and FFAR3 on the L-
cells. Indeed, in vitro and in vivo studies using FFAR2-/- and FFAR3-/- mice showed reduced 
SCFA-induced GLP-1 secretion together with a parallel impairment of glucose tolerance 
(Tolhurst et al., 2012). Furthermore, circulating SCFAs mainly inhibit the secretion of the 
orexigenic hormone ghrelin through FFAR2 receptor activation (Engelstoft et al., 2013). α-
gustducin, the α-subunit of the G-protein coupled to TASRs, plays an important role in taste 
transduction (McLaughlin et al., 1992) and is colocalized with TAS1R2-TAS1R3, FFAR2 and 
FFAR3 on L-cells (Jang et al., 2007, Li et al., 2013). Accordingly, glucose and SCFA-induced GLP-
1 release is blunted in α-gustducin knockout (α-gust-/-) mice (Jang et al., 2007, Li et al., 2013). 
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In addition to the increased incretin production, oligofructose may improve inflammation and 
metabolic disorders associated with obesity by lowering intestinal permeability through a 
mechanism involving GLP-2 release from intestinal L-cells (Cani et al., 2009). Since GLP-2 is co-
secreted with GLP-1, we hypothesized that the GLP-2 induced improvement in intestinal 
permeability would be decreased in α-gustducin knockout mice. Furthermore, the trophic 
effects of GLP-2 and the SCFAs produced during fermentation of oligofructose may increase 
mucosal thickness (Kripke et al., 1989). This may affect both the number of EECs and hence 
plasma levels of gut hormones, and the intestinal barrier function by increasing paracellular 
transport.  
This study aimed to investigate whether daily intragastric administration of artificial 
(sucralose) or natural (OFS) sweeteners can prevent high-fat diet induced body weight gain, 
glucose intolerance and impairment of gut permeability by interacting with extra-oral taste 
receptors specifically coupled to α-gustducin. In addition, we performed an in-depth study on 
the origin of the altered gut hormone levels which may involve changes in enteroendocrine 
plasticity induced by an increased mucosal thickness. By using equisweet concentrations we 
aimed to get the same degree of sweet taste receptor activation allowing us to discriminate 
between the role of sweet taste receptor-induced (activated by both sweeteners) and short 
chain fatty acid taste receptor-induced (only activated by the fermentation products of OFS) 
effects. 
4.4 Materials and Methods 
4.4.1 Animals 
Male C57BL/6 wild type (WT) mice and α-gust-/-mice (Dr. R. Margolskee, Monell Chemical 
Senses Center, Philadelphia, United States) were kept in the animal facility (20–22 °C) under a 
14-h:10-h light-dark cycle and had ad libitum access to food and water. All experimental 
procedures were approved by the Ethical committee for Animal Experiments of the KU Leuven 
(P100-2013). 
4.4.2 Experimental design 
6 week-old WT and α-gust-/-mice were fed a high-fat diet (HFD; 60% kcal fat, D12492, Research 
Diets) and gavaged once daily (1 hour before the dark phase) with water or equisweet 
solutions of 300mg OFS (oligofructose, Beneo orafti) or 0.52mg sucralose (Sigma-Aldrich) for 8 
weeks (n=9/group). A daily dose of 300mg OFS was used, since previous studies showed 
metabolic improvements in rodents fed a HFD supplemented with 10% OFS which corresponds 
to a daily intake of ±300mg OFS (Everard et al., 2011). 
The effect of sweeteners on energy-and glucose homeostasis
 
67 
 
4.4.3 In vivo analyses 
Body weight and food intake were monitored during 8 weeks. An oral glucose tolerance test 
(OGTT) was performed after 6 weeks of treatment and blood glucose and serum insulin levels 
were measured. After 8 weeks, fasted (6h) mice were gavaged with 2g D-glucose/kg, 10 min 
before sacrifice.  
4.4.4 Biochemical analyses 
Blood was taken by cardiac puncture and supplemented with 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride (4mM) and ethylenediaminetetraacetic acid (1mg/ml). Plasma was 
supplemented with dipeptidyl peptidase-4 inhibitor (10µl/ml) (for GLP-1 and PYY) or acidified 
(10% with 1N hydrochloride) (for ghrelin). The stomach, small intestine, colon and fat deposits 
were collected and divided in predefined parts which were used for immunohistochemistry 
(fixed in 4% paraformaldehyde), or RT-PCR (overnight incubation in RNALater (Qiagen)) and 
stored at -80°C for further analysis. Plasma ghrelin, GLP-1, PYY and leptin levels were 
measured by radioimmunoassay (RIA) and ELISA respectively. Caecal content was used for 
SCFA analyses, and a part of the distal colon was immediately used for permeability 
experiments. See expanded Materials and Methods for a detailed description. 
4.4.5 Statistical analyses 
All values are represented as mean±SEM. Data was assessed for normality and homogeneity of 
distribution using histograms and Q-Q plots; as the data were non-normally distributed, log-
transformation was applied. Changes in body weight, food intake, glucose tolerance and 
plasma insulin levels were analyzed on log transformed data using a repeated measures mixed 
models analysis (SAS Studio University Edition). TEER and fluorescein levels over time between 
different genotypes and treatments were analyzed using a repeated measures mixed models 
analysis. Other data were analyzed with a two-way ANOVA, followed by planned comparisons 
post-hoc testing and Bonferroni correction (Statistica 12, Statsoft). Prism (GraphPad Software) 
was used to calculate the area under the curve (AUC) for the OGTT and plasma insulin levels 
over time. Significance was accepted at the 5% level. 
4.5 Results 
4.5.1 OFS, but not sucralose prevents body weight gain from a HFD 
Daily gavage of OFS, but not sucralose, for 8 weeks decreased body weight gain in WT (-
19±3%, treatment*time P<0.01) mice and tended to decrease body weight gain in α-gust-/-
mice (-14±2%, treatment*time P=0.055) (Figure 1A, B). The effect was significant from week 4 
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on in WT mice (P<0.05), and at week 8 in α-gust-/-mice (P<0.01). This correlates with plasma 
leptin levels which were decreased from week 6 on in WT (P<0.01) but not in α-gust-/-mice 
(treatment*genotype P<0.05) (Figure 1E, F). 
OFS but not sucralose administration reduced (P<0.001) total fat pad mass (WT:-55±6%; α-
gust-/-;-41±7%) (Figure 1C, D) and plasma leptin levels (P<0.001) at sacrifice (8 weeks), in both 
genotypes to a similar extent (Figure 1F, G). 
 
Figure 1: Natural, but not artificial sweeteners prevent HFD-induced body weight gain. Effect of daily 
gavage (8 weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on (A, B) time-
dependent changes in body weight (n=9/group), (C, D) fat mass (n=9/group) and (E-H) plasma leptin 
levels after 6 or 8 weeks (n=7-9/group) of treatment. Results are presented as mean±SEM. *P<0.05, 
**P<0.01 ***P<0.001 vs. control. Genotype*treatment effect: £ P<0.05. 
Neither OFS nor sucralose administration affected cumulative food intake in either genotype 
(Figure S1A, B). 
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4.5.2 OFS, but not sucralose reduces HFD-induced insulin resistance in an α-
gustducin-independent manner 
6 weeks HFD impaired glucose tolerance to a similar extent in WT and α-gust-/-mice (Figure 2A, 
B). OFS treatment did not affect blood glucose during the OGTT in either genotype, but 
decreased serum insulin profiles (P<0.05) and the AUC (P<0.01) during an OGTT in WT mice 
but not in α-gust-/-mice (Figure 2A-D). The insulin resistance index (HOMA-IR) was lower in 
both genotypes (Figure 2E). 
Sucralose treatment did not improve blood glucose during the OGTT in either genotype, but 
tended (P=0.057) to increase serum insulin profiles and significantly (P<0.01) increased insulin 
AUC values in a genotype-dependent manner in WT mice (treatment*genotype; P<0.05) 
(Figure 2A-D). The HOMA-IR was not affected in either genotype (Figure 2F). 
 
Figure 2: Intragastric administration of natural sweeteners prevent HFD-induced insulin resistance. An 
OGTT was performed in WT and α-gust-/-mice (n=9) 6 weeks after daily gavage with OFS (300 mg), 
sucralose (0.52mg) or water. (A, B) Plasma glucose and (C, D) serum insulin profiles during an OGTT and 
the calculated AUC (n=7-9/group) and (E, F) calculated insulin resistance index (HOMA-IR). Results are 
presented as mean±SEM. **P<0.01, ***P<0.001 vs. control. 
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4.5.3 OFS, but not sucralose affects gut hormone secretion in an α-gustducin-
independent manner 
4.5.3.1 Ghrelin 
OFS, but not sucralose, significantly increased plasma octanoyl ghrelin levels in α-gust-/-mice 
(P<0.05), but not in WT mice (Figure 3A, B). A representative immunofluorescence staining for 
octanoyl ghrelin in gastric sections of all groups is shown in Figure 3C. OFS did not affect 
gastric ghrelin immunoreactive cell density but decreased (P<0.01) gastric ghrelin IR cell 
intensity in α-gust-/-mice (Figure 3D, E). Neither sweetener affected gastric nor duodenal 
ghrelin mRNA expression levels (Figure 3F, G). 
4.5.3.2 GLP-1 
OFS decreased glucose-induced plasma GLP-1 (GLP-1(7-36)amide and GLP-1(7-37)) levels in 
WT mice (P<0.001), but not in α-gust-/-mice. Notably, water-treated α-gust-/-mice tended to 
have lower plasma GLP-1 levels (P=0.056) than water-treated WT mice (Figure 4A, B). 
The origin of the plasma changes was determined by measuring the number of L-cells and the 
mRNA expression levels of proglucagon in the duodenum and colon. Despite the increase 
(P<0.001) in duodenal mucosal height in both genotypes after OFS administration (Figure S2A), 
the number or density of duodenal GLP-1 IR L-cells was not affected. Only duodenal GLP-1 IR L-
cell intensity, which is a reflection of the amount of GLP-1 released, tended to be decreased 
(P=0.054) in WT but not in α-gust-/-mice (Figure 4C-E). Moreover, duodenal proglucagon mRNA 
expression levels were decreased (P<0.05) in α-gust-/-mice (Figure 4I). In the colon, mucosal 
height was specifically increased in WT (P<0.001) but not in α-gust-/-mice 
(treatment*genotype; P<0.05) after OFS administration (Figure S2B). This did not result in 
changes in colonic GLP-1 IR L-cell number, density or intensity. Colonic proglucagon mRNA 
levels were not affected in either genotype (Figure 4F-I). 
Sucralose tended (P=0.054) to increase glucose-induced plasma GLP-1 (GLP-1 (7-36)amide and 
GLP-1 (7-37)) levels in α-gust-/-mice but not in WT mice (Figure 4B). Sucralose also did not alter 
duodenal or colonic mucosal height in either genotype (Figure S2C, D) and did not affect 
duodenal or colonic GLP-1 IR L-cell number, density, intensity (data not shown) or proglucagon 
mRNA expression levels (Figure 4J). 
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Figure 3: Natural sweeteners increase plasma ghrelin levels in mice on a HFD. Effect of daily gavage (8 
weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on (A, B) glucose-induced 
plasma octanoyl ghrelin levels (n=7-9/group), (C) Representative immunofluorescence staining for 
octanoyl ghrelin in stomach sections of WT and α-gust-/-mice. (D, E) density and mean intensity of gastric 
octanoyl ghrelin IR cells (n=5/group) and (F, G) relative gastric and duodenal ghrelin mRNA levels (n=7-
8/group). The dotted line indicates the mean relative ghrelin mRNA levels in controls. Results are 
presented as mean±SEM. *P<0.05, **P<0.01 vs. control. 
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Figure 4: Natural sweeteners decrease plasma GLP-1 levels in mice on a HFD. Effect of daily 
gavage (8 weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on (A, 
B) glucose-induced plasma levels of GLP-1(7-36)amide and GLP-1(7-37) (C, F) number, (D, G) 
density and (E, H) mean intensity of duodenal and colonic GLP-1 IR cells (n=4-5/group) and (I, 
J) relative duodenal and colonic proglucagon mRNA levels (n=8-9/group). The dotted line 
indicates the mean relative proglucagon mRNA levels in controls. Results are presented as 
mean±SEM. * P<0.05, *** P<0.001 vs. control. $ P<0.05 vs. the water-treated WT group. 
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4.5.3.3 PYY 
OFS administration did not affect glucose-induced plasma PYY (PYY(1-36) and PYY(3-36)) levels 
in either genotype (Figure 5A, B). However, sucralose administration tended (P=0.056) to 
increase PYY levels in WT mice. Neither of the sweeteners changed the number or intensity of 
the colonic PYY IR L-cells (Figure 5C, D). The increased colonic mucosal height after OFS 
administration resulted in a decreased PYY IR L-cell density in WT (P<0.01), but not in α-gust-/-
mice (treatment*genotype; P<0.01)(Figure 5E). Colonic PYY mRNA levels were not affected 
(Figure 5F, G). 
In water-treated WT mice, 48% of the L-cells selectively stained for GLP-1 and 59% for PYY. 
Treatment with the sweeteners did not induce a shift in the L-cell subpopulations (OFS: 63% 
GLP-1, 46% PYY; sucralose: 46% GLP-1, 42% PYY). 
Figure 5: Natural nor artificial sweeteners affect plasma PYY levels in mice on a HFD. Effect of daily 
gavage (8 weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on (A, B) glucose-
induced plasma levels of PYY(1-36) and PYY(3-36) (n=7-8/group), (C) number, (D) density and (E) mean 
intensity of colonic PYY IR cells (n=5/group) and (F, G) relative colonic PYY mRNA levels (n=7-8/group). 
The dotted line indicates the mean relative PYY mRNA levels in controls. Results are presented as 
mean±SEM. ** P<0.01 vs. control. $ P<0.05, $$ P<0.01 vs. the water-treated WT group. 
Genotype*treatment effect: ££ P<0.01. 
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4.5.4 OFS, but not sucralose affects the expression of nutrient sensors at local and 
remote sites 
4.5.4.1 Effect on the expression of glucose sensors in the proximal gut  
Neither sweetener changed relative gastric TAS1R3 mRNA levels, a subunit of the sweet TASR 
heterodimer (Figure 6A, B). The gastric mRNA expression of the other sweet TASR subunit, 
TAS1R2, and the glucose transporters SGLT1 and GLUT2 was undetectable. Furthermore, 
neither sweetener altered duodenal TAS1R2 or TAS1R3 mRNA levels. However, OFS but not 
sucralose administration significantly decreased duodenal mRNA expression of SGLT1 and 
GLUT2 in both genotypes (Figure 6C, D). 
 
Figure 6: Natural, but not artificial sweeteners affect the glucose transporters in the proximal 
gastrointestinal tract in mice on a HFD. Effect of daily gavage (8 weeks) of OFS (300mg), sucralose 
(0.52mg) or water in WT and α-gust-/-mice on relative (A, B) gastric and (C, D) duodenal mRNA levels of 
the sweet TASR subunits (TAS1R2 and TAS1R3) and the monosaccharide transporters (SGLT1, GLUT2) 
(n=7-9/group). The dotted line indicates the mean relative mRNA levels in controls. Results are 
presented as mean±SEM. ** P<0.01, *** P<0.001 vs. control. 
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4.5.4.2 Effect on the SCFA production and signaling in the distal gut 
The wet caecal weight was higher in OFS-treated mice compared to controls (WT:203%; α-gust-
/-:353%) but not after sucralose treatment (WT:93%; α-gust-/-:124%).  
Furthermore, OFS administration decreased caecal levels of the microbial fermentation 
products; acetate and butyrate but not propionate in both genotypes (Figure 7A-C). These 
decreased levels may result from an increased caecal uptake by the SCFA transporter 
monocarboxylate transporter-1 (MCT1). OFS treatment significantly downregulated MCT1 
mRNA expression in α-gust-/-mice, but not in WT mice (P=0.08) (Figure 7G).  
In contrast, sucralose did not affect acetate or butyrate levels, but increased (P<0.05) 
propionate levels in WT but not in α-gust-/-mice (Figure 7D-F). Caecal MCT1 mRNA expression 
was not affected in either genotype (Figure 7H). 
SCFAs directly interact with FFAR2/3 in the colon to affect GLP-1 and PYY secretion (Nohr et al., 
2013). OFS decreased colonic FFAR3 (P<0.001), but not FFAR2 mRNA levels in both genotypes 
(Figure 7G). Sucralose did not affect FFAR2 mRNA levels, but surprisingly decreased (P<0.001) 
FFAR3 mRNA levels in α-gust-/-mice, but not in WT mice (Figure 7H). 
4.5.4.3 Effect on the expression of SCFA receptors in the proximal gut 
After uptake, SCFAs enter the blood stream and interact with FFAR2/3 expressed in remote 
tissues. OFS, but not sucralose administration decreased duodenal FFAR2 expression in α-gust-
/-mice (P<0.05), but not in WT mice, and tended to decrease FFAR3 mRNA levels in both 
genotypes (Figure 7I, J). In contrast, neither sweetener affected gastric FFAR2/3 expression 
(Figure 7I, J). 
4.5.4.4 Effect on the expression of SCFA receptors in adipose tissue 
SCFAs affect adipocyte differentiation via FFAR2-dependent and independent pathways 
(PPAR. Neither OFS nor sucralose affected PPARmRNA expression 
levels (Figure 7K, L). In contrast OFS, but not sucralose, increased (P<0.05) FFAR2 expression in 
subcutaneous fat in WT, but not in α-gust-/-mice (Figure 7K, L). Subcutaneous fat FFAR3 mRNA 
levels were not detectable. 
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Figure 7: Natural and artificial sweeteners affect SCFA production and FFAR2/3 expression in the 
proximal and distal gastrointestinal tract in mice on a HFD. Effect of daily gavage (8 weeks) of OFS 
(300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on caecal (A, D) acetate, (B, E) butyrate 
and (C, F) propionate levels (n=7-9/group), relative mRNA levels of (G, H) caecal MCT1 and colonic 
FFAR2 and FFAR3, (I, J) gastric and duodenal FFAR2 and FFAR3 and (K, L) PPARɣ and FFAR2 in 
subcutaneous fat (n=7-9/group). The dotted line indicates the mean relative mRNA levels in controls. 
Results are presented as mean±SEM. * P<0.05, *** P<0.001 vs. control. 
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4.5.4.5 OFS, but not sucralose improves gut permeability in an α-gustducin-independent 
manner 
Sucralose did not affect gut permeability, but OFS increased TEER (P<0.001) and decreased 
fluorescein passage (P<0.001) in both genotypes (Figure 8A-D). 
After correcting for the α-gustducin-dependent colonic hypertrophy, the increase in TEER 
(Figure 8C, D) and decrease in fluorescein passage (data not shown) were more pronounced in 
both genotypes. Furthermore the corrected TEER, but not the corrected fluorescein passage, 
became α-gustducin-dependent and more pronounced in WT mice (treatment*genotype; 
P<0.05) (Fig 8C). OFS but not sucralose decreased (WT: P<0.05; α-gust-/-: P<0.01) the 
expression of claudin 5, a tight junction protein, independent of the genotype (Figure 8E, F). 
Figure 8: Natural, but not artificial sweeteners improve gut permeability in mice on a HFD. Effect of 
daily gavage (8 weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on (A, B) 
colonic fluorescein passage (n=6-9/group), (C, D) transepithelial electrical resistance (TEER) and TEER 
corrected for mucosal height (n=7-8/group) and (E, F) relative colonic claudin 5 mRNA expression levels 
(n=7-9/group). The dotted line indicates the mean relative claudin 5 mRNA levels in controls. Results are 
presented as mean±SEM. *P<0.015, **P<0.01, ***P<0.001 vs. control. Genotype*treatment effect: £££ 
P<0.001. 
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4.6 Discussion 
Low caloric sweeteners could be used as food additives to favor body weight loss. These 
sweeteners may not be metabolically inert since they can affect the release of gut hormones 
involved in the control of energy –and glucose homeostasis through modulation of the 
nutrient sensing pathway. To investigate this hypothesis we determined whether daily 
intragastric administration of equisweet amounts of low caloric non-fermentable (sucralose) or 
fermentable (OFS) sweeteners can prevent obesity-associated disorders by interacting with 
extra-oral taste receptors specifically coupled to α-gustducin to alter gut hormone release. 
Our data show that long-term in vivo supplementation with sucralose did not modulate 
nutrient sensor expression, gut hormone release, intestinal permeability, glucose homeostasis 
or body weight, indicating that sweet taste receptor activation does not play an important 
regulatory role in these parameters. In contrast, intragastric administration of OFS decreased 
body weight gain and fat pad mass in mice. This was not mediated via gustducin or the result 
of an altered energy intake or gut hormone release since GLP-1 levels were decreased. Rather 
enhanced uptake of OFS fermentation products (acetate, butyrate) favored interaction with 
FFAR2 in peripheral adipose tissue to reduce adipogenesis. Furthermore OFS did not improve 
glucose intolerance but reduced the development of insulin resistance and improved the 
increased gut permeability induced by a HFD.  
OFS but not sucralose reduced body weight gain. This effect was delayed in α-gust-/-mice, and 
was reflected in a retarded reduction in plasma leptin levels. This suggests that α-gustducin 
plays a role in the delayed formation of fat deposits after OFS supplementation. α-gustducin 
has previously been shown to play a role in brown adipose tissue thermogenic activity (Avau et 
al., 2015). The decreased body weight gain was not reflected in differences in energy intake 
which confirms previous observations in mice fed a HFD supplemented with OFS (Dewulf et al., 
2011). 
Intragastric OFS administration did not improve glucose intolerance. A systematic review also 
showed no significant effect of inulin-type fructans on glucose levels in humans (Bonsu et al., 
2011). Our findings and previous mice studies suggest that the route of administration 
determines the outcome of OFS-supplementation. Indeed, 1) a HFD supplemented with 10% 
OFS (=±300mg/day) improved glucose homeostasis and body weight (Cani et al., 2006), 2) 
supplementation of the drinking water with 300mg OFS/day improved glucose homeostasis 
but not body weight (Everard et al., 2011), and 3) intragastric administration of 300mg 
OFS/day, in our study, improved body weight but not glucose homeostasis. The intragastric 
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administration allowed us to administer a fixed amount at a well determined time point to 
mimic the pharmacological profile patients would get after a single supplement before a meal. 
Furthermore, it allowed us to bypass potential participation of the cognitive behavioral axis 
since sweet taste receptors are also present on the tongue and play a role in hedonic signals. 
Sucralose neither affected glucose tolerance nor insulin resistance although it increased serum 
insulin levels during an OGTT in an α-gustducin-dependent manner. Sucralose has also been 
shown to increase glucose-induced insulin levels associated with an increase in peak plasma 
glucose concentrations in obese subjects after an acute administration (Pepino et al., 2013). 
Previous studies showed that sucralose induced insulin release from the pancreatic beta cell 
line, MIN6. In contrast to our findings, knockdown of gustducin in this model did not lead to an 
attenuated insulin release in the presence of three sweeteners (Nakagawa et al., 2013). These 
results contradict the hypothesis of a direct involvement of gustducin on pancreatic beta cells. 
Nevertheless, the sweet taste receptors and short chain fatty acid receptors are present on 
pancreatic beta cells, suggesting a role for nutrient sensing in insulin release (Nakagawa et al., 
2009, Regard et al., 2007). 
Neither OFS nor sucralose affected plasma levels of the orexigenic and adipogenic hormone 
ghrelin in WT mice. It is therefore unlikely that the reduced body weight after OFS 
supplementation is mediated by ghrelin. Previous rodent studies also showed no effect on 
plasma ghrelin levels after supplementation of a western style diet with 10% OFS for 6-7 weeks 
(Cluny et al., 2015). Although others reported decreased plasma ghrelin levels after 3 weeks of 
a standard diet enriched with 100g/day OFS (Cani et al., 2004a). Surprisingly OFS 
administration increased glucose-induced plasma ghrelin levels in α-gust-/-mice but the 
physiological relevance is unclear.  
One of the limitations of our study is that we could only measure gut hormone levels at a 
single time point. Although plasma GLP-1 levels peak 10 min after glucose administration, this 
time-point is too early to observe a postprandial decline in plasma ghrelin levels. Therefore the 
measured levels rather represent fasted plasma ghrelin levels. Tarini et al. observed a delayed 
(5h) effect of inulin administration on ghrelin levels, indicating that the decrease in plasma 
ghrelin levels parallels the start of the colonic fermentation (Tarini and Wolever, 2010). 
The decreased plasma levels of the satiety hormone GLP-1 in WT mice after OFS 
administration can also not explain the reduced body weight, but could explain why OFS 
decreased glucose-induced insulin levels in WT mice (decreased incretin effect) and was 
unable to improve glucose intolerance in our study. Indeed, previous studies in GLP-1R-/- mice 
or administration of the GLP-1 receptor antagonist exendin 9-39 totally prevented the 
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beneficial effects of OFS on glucose intolerance and body weight gain (Delzenne et al., 2007, 
Cani et al., 2006). In healthy volunteers and in overweight and obese subjects, 5-6 weeks of 
OFS supplementation did not alter plasma GLP-1 levels (Pedersen et al., 2013, Daud et al., 
2014). 
The decrease in plasma GLP-1 levels probably originated from changes in the duodenum. 
Indeed, proglucagon expression and GLP-1 IR L-cell intensity were decreased in the duodenum 
together with SGLT1 and GLUT2 mRNA expression in WT mice. These glucose transporters 
have been shown to function as glucose sensors for the L-cells and could contribute to the 
reduced duodenal proglucagon expression and hence GLP-1 release (Gorboulev et al., 2011, 
Reimann et al., 2008). Furthermore, the decreased expression of SGLT1 and GLUT2 could 
result in a decreased glucose transport from the lumen into the blood stream. However, no 
differences in peak glucose levels were observed between the different treatment and the 
different groups. Sucralose administration did not affect glucose-induced GLP-1 release. 
Artificial sweeteners have been shown to elicit GLP-1 release in vitro (Jang et al., 2007, 
Reimann et al., 2008) These findings were not confirmed in vivo in humans and rodents and 
thereby question the importance of the sweet taste receptor complex in L-cells (Fujita et al., 
2009, Steinert et al., 2011a) However, the ‘equisweet’ nature of the administered doses are 
based on human studies and the relative sweetness may differ in mice. Nevertheless we would 
like to point out that the expression pattern of sweet taste receptors and FFARs is quite similar 
between mice and man (Symonds et al., 2015). 
Sucralose, but not OFS administration tended to increase plasma PYY levels in WT animals. In 
contrast, studies in rodents and humans observed an increased plasma PYY levels after OFS 
supplementation (Pedersen et al., 2013, Daud et al., 2014), while a single dose of artificial 
sweeteners did not affect plasma PYY levels in a double blinded cross-over study (Steinert et 
al., 2011a). 
OFS is fermented by the gut microbiome to SCFAs that interact with FFAR2 or FFAR3 on EECs. 
The decrease in caecal acetate and butyrate levels could be due to an increased SCFA uptake 
by the MCT1 transporter on the colonocytes which displayed a compensatory downregulation. 
Sucralose increased caecal propionate levels. This is in agreement with a recent study of Suez 
et al., who showed that artificial sweeteners consumption functionally altered the microbiota 
leading to elevated stool SCFA levels (Suez et al., 2014). 
SCFAs can affect body weight and adiposity. In humans, targeted colonic delivery of an inulin-
propionate ester was more effective in decreasing body weight than inulin alone, without 
affecting plasma GLP-1 and PYY levels (Chambers et al., 2015). Clearly, the increased 
propionate after sucralose administration was not high enough to elicit these effects in our 
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study. SCFAs can stimulate GLP-1 and PYY secretion from L-cells in vitro and in vivo in a FFAR2, 
and FFAR3 dependent manner (Tolhurst et al., 2012). Although both sweeteners decreased 
colonic FFAR3 mRNA levels, neither sweetener affected the colonic PYY or GLP-1 containing L-
cell number or intensity, nor the PYY or proglucagon mRNA levels. Therefore a direct effect of 
SCFAs via FFARs on EECs of the distal colon was not shown. Although plasma SCFA levels could 
not be quantified due to our study design, we assume that SCFA levels increased in the blood 
stream after MCT1-mediated transport and can interact with FFAR2/3 receptors in other 
peripheral tissues. FFAR2/3 transcripts are found on both the apical and basolateral side of L-
cells in the proximal intestine (Nohr et al., 2013) and FFAR2 is found in adipocytes (Dewulf et 
al., 2011). 
Since duodenal FFAR2 mRNA levels were decreased after OFS, we speculate that circulating 
SCFAs might be involved in the decreased plasma GLP-1 levels. Surprisingly these effects 
occurred in a genotype-independent manner although Li. et al. showed that the SCFAs affect 
GLP-1 release in a α-gustducin-dependent manner, at least in the colon (Li et al., 2013). 
After entering the bloodstream the SCFAs can also directly affect the adipose tissue via FFAR2-
dependent or FFAR2-independent pathways involving PPARγ (Dewulf et al., 2011). However, 
neither of the sweeteners affected PPARγ mRNA expression. In contrast, OFS supplementation 
increased FFAR2 mRNA levels in the adipose tissue, which could point towards an FFAR2-
dependent pathway. The genotype-independent nature of the decreased fat mass would 
suggest that FFAR2 is coupled to another G-protein in the adipose tissue. Indeed, FFAR2 may 
activate the Gi, Gq, and G12 families of G proteins (Brown et al., 2003). 
OFS, but not sucralose supplementation, decreased the colonic permeability for ions and 
larger molecules via an α-gustducin-independent mechanism. This improvement in colonic 
permeability was not mediated by changes in mucosal height. It has previously been 
demonstrated that OFS supplementation alters tight junction expression and thereby 
decreases gut permeability (Cani et al., 2009). Claudin 5 is a tight junction protein which 
influences the paracellular leak passage of small molecules of approximately 800 Da (Gunzel 
and Yu, 2013). OFS decreased claudin 5 mRNA expression independent of α-gustducin which 
could explain the decreased gut permeability if the downregulation is a reflection of increased 
protein expression (Weber, 2012). Strangely the improved permeability did not result in lower 
glucose profiles, although the link between intestinal permeability and glucose homeostasis 
has been shown previously (Cani et al., 2009). 
In conclusion, despite the controversy in the field our study shows that the artificial 
sweetener, sucralose, is metabolically inert. Nevertheless, oligofructose, an oligosaccharide 
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with prebiotic properties has beneficial effects on body weight gain. The dose used in these 
mice is relatively high and unlikely to be used in humans because of flatulence, bloating, 
cramps and abdominal pain due the increase gas production associated with fermentation. 
However, agonists targeting FFAR2/3 might be an alternative but the route and time point of 
administration may be important.  
Alterations in gut hormone profiles are not mandatory for the beneficial effect of oligofructose 
on body weight. Our data rather suggest that targeting of FFAR2 receptors on adipose tissue 
might be the way forward to combat obesity. However, these results should first be verified in 
human intervention studies. Furthermore, our results highlight that gustducin-mediated 
nutrient signaling does not play an important role in the effects of oligofructose on energy 
homeostasis although FFAR2/3 signaling through a different G protein might contribute to 
these effects and needs to be addressed in additional studies 
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4.7 Expanded Materials and Methods 
4.7.1 Oral glucose tolerance test 
An OGTT was performed 6 weeks after the start of the experiment. Mice were fasted for 6 hours and 
gavaged with 2g/kg D-glucose. Blood glucose levels were measured from the tail vein at 0, 15, 30, 60 
and 120 minutes after glucose administration with a glucometer (Glucomen LX®, A. Menarini 
Diagnostics) and serum was collected and subsequently snap frozen in liquid nitrogen for insulin and 
leptin measurements. Insulin resistance was calculated using the Homeostasis Model of Insulin 
Resistance (HOMA-IR) index: (fasting insulin (ng/mL) × fasting glucose (mg/dL))/405. 
4.7.2 Plasma ghrelin measurement 
Plasma samples were extracted on a SEP-Pak C18 cartridge (Waters Corporation), vacuum-dried and 
subjected to ghrelin RIA as previously described (Janssen et al., 2011). For determination of octanoyl 
ghrelin a rabbit anti-human ghrelin [1-8] antibody was used which does not recognize desoctanoyl 
ghrelin. Total ghrelin levels were determined using a rabbit anti-human ghrelin [14-28] antibody, 
which recognizes both octanoyl and desoctanoyl ghrelin.  
4.7.3 Plasma Glucagon-Like Peptide-1, Peptide YY, Insulin and Leptin measurement 
Samples were analysed for plasma GLP-1 (GLP-1(7-36)amide and GLP-1(7-37)) using the active GLP-1 
(ver. 2) Kit (Mesoscale Discovery) and plasma leptin and serum insulin levels were determined using 
the Mouse metabolic Kit (Mesoscale Discovery). Plasma PYY levels (PYY(1-36) and PYY(3-36)) were 
determined using a PYY ELISA (Phoenix pharmaceuticals). 
4.7.4 Histology and Immunohistochemistry 
Duodenal and colonic segments (8 µm), were stained with hematoxylin and eosin. The mucosal villus 
height was determined by counting five representative high-power fields (20x) per slice (3 
slices/animal). Gastric, duodenal or colonic tissue samples were immediately fixed with 
paraformaldehyde (4%) for 2h (4°C) followed by cryoprotection in 30% sucrose at 4°C overnight. 
Cryostat sections (8 µm) were incubated for 2 h in 0.1M PBS containing 10% donkey serum and 0.3% 
Triton X-100 and incubated with one of the following primary antibodies: rabbit anti-octanoyl ghrelin 
(1/1000, Ab5004, in-house developed), goat anti-GLP-1 (1/150, SC-7782, Santa Cruz Biotechnology) 
or rabbit anti-PYY (1/1000, Ab22663, Abcam). Substitution of the primary antibody with phosphate-
buffered saline was used as a negative control. After washing, tissues were incubated with secondary 
antibody for 2 hours: donkey anti-rabbit Alexa488 (1/1500, A21206, Thermofisher), anti-goat 
Alexa594 (1/1000, A11058, Thermofisher) or donkey anti-rabbit AMCA (1/250, 711-225-152, Jackson 
Immuno Labs). For the double-immunofluorescence staining, after being incubated with the 
secondary antibody and washed three times, sections were incubated for 24 hours at room 
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temperature with the second primary antibody. Subsequently, tissues were incubated with the 
appropriate second secondary antibody for 2 hours. Sections were mounted in Citifluor and 
visualized under a fluorescence microscope (Olympus BX41). Of each tissue segment three sections 
were analyzed using Cell^F Imaging Software (Olympus Soft Imaging Solutions GmbH). Octanoyl 
ghrelin-, GLP-1- or PYY-positive cells, were counted in 5 randomly chosen fields (20x) for the 
stomach, or in the whole section (20x) for the segments from the duodenum and distal colon. 
4.7.5 RT-PCR 
Total RNA was isolated from tissue segments using the RNeasy kit (Qiagen),treated with Turbo 
DNAfree kit (Ambion) and reverse transcribed to cDNA using Superscript II Reverse Transcriptase 
(Invitrogen). The qRT-PCR reaction was performed as described previously, using the Lightcycler 480 
(Roche Diagnostics) with the Lightcycler 480 Sybr Green I Master mix (Roche Diagnostics) (Verhulst et 
al., 2008), and analyzed according to the method of Vandesompele et al. (Vandesompele et al., 
2002). Results were expressed relative to the geometric mean of the normalized expression of the 
three most stable housekeeping genes tested; hypoxanthine phosphoribosyltransferase 1 (Hprt1), 
ribosomal protein L13a (RPL13a) and β-actin.  
The following primers were used: 
Gene Forward primer Reverse primer 
RPL13a CACTCTggAggAgAAACggAAgg gCAggCATgAggCAAACAgTC 
β-Actin gATCTggCACCACACCTTCTAC TggATggCTACgTACATggCTg 
Hprt1 TCAgTCAACgggggACATAAA ggggCTgTACTgCTTAACCAg 
ghrelin CCAgAggACAgAggACAAgC ACATCgAAgggAgCATTgAA 
GOAT ATTTgTgAAgggAAggTggAg CAggAgAgCAgggAAAAAgAg 
proglucagon gAggAgAACCCCAgATCATTCC gTggCgTTTgTCTTCATTCATC 
PYY CAgTggTgAAgACTCCCCCAAg TgAACACACACAgCCCTCCAg 
SGLT1 CggAAgAAggCATCTgAgAA AATCAgCACgAggATgAACA 
GLUT2 TCTTCACggCTgTCTCTgTg AATCATCCCggTTAggAACA 
TAS1R2 gCACCAAgCAAATCgTCTATCC ATTgCTAATgTAggTCAgCCTCgTC 
TAS1R3 CAggCAgTTgTgACTCTgTTg TgCgATgCAgATACCTCgTg 
FFAR2 CCCTgTgCACATCCTCCTgC gCgTTCCATgCTgATgCCCg 
FFAR3 TgTCCAATACTCTgCATCTgT AggTCCgAAATggTCAggTT 
Claudin 5 gCATCCTgCTggggCTgATCg ggCTTgggATAAggCCgTggTg 
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4.7.6 SCFA analysis 
SCFAs were extracted from fecal samples using an ether extraction. 50 mg of fecal sample was 
suspended in 1 ml saturated NaCl (36%). Ether (3 ml), Na2SO4 (50 mg), H2SO4 (150 µl) and internal 
standard (50 µl) (2-ethylbutyric acid (Merck)) was added to each sample. The ether layer was 
collected and analyzed on a GC-MS quadrupole (Finnigan Trace GC, Thermoquest) as previously 
described (De Preter et al., 2009). Samples were absolutely quantified using an calibration curve. 
4.7.7 Gut Permeability Assays 
The distal colon was dissected in carbogenated Krebs-Ringer buffer (11mM D-glucose). Intestinal 
segments of approximately 0.5 cm2 (n=3/mouse) were mounted in Ussing chambers (Mussler 
Scientific Instruments) with an area of 0.017cm2. Potential difference (PD) was continuously recorded 
and transepithelial electrical resistance (TEER) (Ωxcm2) was calculated from the voltage deflections 
induced by bipolar constant-current pulses of 16 mA every 60 s with duration of 200 ms and was 
recorded over 2h. Meanwhile, paracellular permeability was measured after a equilibration period of 
30 minutes, by adding fluorescein (354 Da, Sigma Aldrich) to the mucosal side. The fluorescence level 
at the serosal side (ng/ml*cm2) was measured using a fluorescence reader (FLUOstar Omega; BMG 
Labtech).  
4.8 Supplementary Figures 
Figure 
S1: Natural and artificial sweeteners do not affect food intake in mice on a HFD. Effect of daily oral gavage (8 
weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-gust-/-mice on (A, B) time-dependent changes 
in cumulative food intake (n=9/group). Results are presented as mean±SEM. 
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Figure S2: Natural sweeteners induce morphological changes in the proximal and distal gastrointestinal tract 
in mice on a HFD. Effect of daily gavage (8 weeks) of OFS (300mg), sucralose (0.52mg) or water in WT and α-
gust-/-mice on mucosal height of (A, B) duodenal and (E, F) colonic sections (8 μm) (n=5/group). Results are 
presented as mean±SEM. ***P<0.001 vs. control. Genotype*treatment effect: £ P<0.05.
  
 
 
 
 
 
Chapter 5 
EXPLORING THE ROLE OF NUTRIENT SENSING IN THE 
METABOLIC CHANGES AFTER ROUX-EN-Y GASTRIC 
BYPASS (RYGB) SURGERY
 
 
The data represented in the following chapter are published in Journal of Endocrinology: 
The role of nutrient sensing in the metabolic changes after gastric bypass surgery 
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5 EXPLORING THE ROLE OF NUTRIENT SENSING IN THE METABOLIC 
CHANGES AFTER ROUX-EN-Y GASTRIC BYPASS (RYGB) SURGERY 
5.1 Abstract 
Taste receptors coupled to the gustatory G-protein, gustducin, on enteroendocrine cells sense 
nutrients to regulate gut hormone release. During Roux-en-Y gastric bypass (RYGB) surgery, 
the altered nutrient flow to more distal regions can affect gustducin-mediated gut hormone 
release and hence energy –and glucose homeostasis. 
We studied the role of gustducin-mediated signaling in the metabolic improvements and 
intestinal adaptations along the gut after RYGB surgery in wild type (WT) and α-gustducin-/- (α-
gust-/-) mice. 
RYGB surgery decreased body weight in WT and α-gust-/-mice, while food intake was only 
decreased in WT mice. Pair-feeding to the RYGB group improved glucose homeostasis to a 
similar extent in WT mice. GLP-1 levels were increased in both genotypes, PYY levels in α-gust-
/-mice and octanoyl ghrelin levels were not affected after RYGB surgery. In WT mice, nutrients 
act via α-gustducin to increase L-cell differentiation (foregut) and L-cell number (foregut and 
hindgut) in a region-dependent manner. In α-gust-/-mice, the effect on gut hormone levels is 
probably tuned via increased peptide sensor and glucose transporter expression in the Roux 
limb and increased caecal butyrate and propionate levels in the hindgut that activate FFARs. 
Finally, signaling via α-gustducin plays a role in the increased ion transport of the foregut but 
not in the improvement in colonic barrier function. 
In conclusion, RYGB surgery decreased body weight in both WT and α-gust-/-mice. Elevated 
plasma GLP-1 and PYY levels might mediate this effect, although α-gustducin differentially 
affects several regulatory systems in the foregut and hindgut, tuning gut hormone release. 
5.2 Introduction  
The obesity epidemic is posing a major healthcare problem worldwide. Roux-en-Y gastric 
bypass (RYGB) surgery induces sustained weight loss and remission of comorbidities (Schauer 
et al., 2012). Altered gut hormone release is considered as one of the possible mechanisms for 
the post-surgical metabolic improvements (Svane et al., 2015). RYGB surgery enhances the 
secretion of the anorexigenic hormones glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), 
and although more controversial, inhibits secretion of the orexigenic hormone ghrelin 
(Sweeney and Morton, 2014). The mechanisms involved are incompletely understood.  
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After RYGB surgery, the contact of nutrients with much of the stomach and duodenum is 
bypassed, resulting in a rapid delivery of undigested nutrients to the jejunum. This rerouting 
could affect the nutrient sensing mechanisms controlling gut hormone release.  
EECs in the gut sense nutrients through taste receptors (TASRs) and chemosensory pathways 
similar to those on the tongue to regulate meal-induced gut hormone secretion (Depoortere, 
2014). The sweet TASR (TAS1R2-TAS1R3) and sodium-dependent glucose co-transporter 1 
(SGLT1) function as glucose-sensors of the L-cell (Jang et al., 2007, Gorboulev et al., 2011). 
Amino acid sensing is tuned by the umami TASR (TAS1R1-TAS1R3), the metabotropic 
glutamate receptors, the calcium sensing receptor, G protein-coupled receptor class C group 6 
member A and lysophosphatidic acid receptor 5 (LPAR5) (Wellendorph and Brauner-Osborne, 
2009). Subtypes of FFAR sense short-chain fatty acids (SCFAs) (FFAR2, FFAR3) and medium- 
and long chain fatty acids (FFAR1, FFAR4) on EECs (Hara et al., 2014). 
α-gustducin, the α-subunit of the G-protein coupled to TASRs, plays an important role in taste 
transduction and is colocalized with several, but not all, TASRs on EECs (McLaughlin et al., 
1992, Janssen et al., 2011, Jang et al., 2007). For example, glucose- and SCFA induced GLP-1 
release and bitter-induced ghrelin release is blunted in α-gustducin knockout (α-gust-/-) mice 
(Jang et al., 2007, Li et al., 2013, Janssen et al., 2011). 
Additionally, nutrient rerouting after RYGB surgery modifies the gut microbiome (Furet et al., 
2010) resulting in altered microbial fermentation products such as SCFAs (acetate, butyrate, 
propionate) which may regulate energy -and glucose homeostasis via FFAR2 and FFAR3 
signaling on EECs (Canfora et al., 2015). 
Butyrate can also enhance the impaired intestinal barrier function, associated with obesity, by 
facilitating tight junction assembly (Moreno-Navarrete et al., 2012, Peng et al., 2009). 
The present study investigated the role of the nutrient sensing pathway in the metabolic 
reprogramming associated with RYGB surgery. We hypothesized that the new digestive route 
after RYGB surgery affects the gustducin-mediated taste receptor signaling pathway that 
partially controls gut hormone secretion to regulate body weight and glucose homeostasis. 
Furthermore we elucidated whether gustducin-mediated signaling plays a role in the 
morphological changes in the mucosa, the enteroplasticity of EECs and the restoration of the 
‘leaky gut’ after RYGB surgery. To test these hypotheses, we compared body weight, glucose 
tolerance, mucosal thickness, nutrient sensor expression, SCFA production, gut hormone 
release/expression and gut permeability/transepithelial resistance in diet-induced obese wild 
type (WT) and α-gust-/-mice, 7 weeks after RYGB surgery. 
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5.3 Material and methods 
5.3.1 Animals 
Male C57BL/6 WT and α-gust-/-mice (Dr. R. Margolskee, Monell Chemical Senses Center, 
Philadelphia, USA) were kept in the animal facility (20–22°C) under a 14-h:10-h light-dark cycle 
and had ad libitum access to food and drinking water. All experimental procedures were 
approved by the Ethical committee for Animal Experiments of the KU Leuven (P100-2013). 
5.3.2 Experimental design 
6 week-old WT and α-gust-/-mice were fed a western style diet (TD.08811, 45% kcal fat 41% 
kcal carbohydrate, Harlan Laboratories Inc.) for 12 weeks. Mice were randomized in three 
groups: a sham-group fed ad libitum (ALF), a sham-group, pair-fed to the RYGB group of its 
respective genotype (PF), and a RYGB group fed ad libitum (RYGB) (see Supplementary 
material). All mice received the western style diet for 7 weeks till sacrifice (Fig. S1). 
5.3.3 Post-operative analyses 
Post-surgical body weight and food intake were monitored. All pair-fed mice received the 
same amount of food per day as their respective RYGB group ate on that postsurgical day. 
Seven weeks post-surgery, fasted (6h) mice were gavaged with Nutridrink® (Nutricia) 15 
minutes before sacrifice. Blood was collected by cardiac puncture and supplemented with 
AEBSF (4mM) and EDTA (1mg/ml). Plasma was supplemented with dipeptidyl peptidase 4 
inhibitor (10µl/ml) (for GLP-1 and PYY) or acidified (for ghrelin). Tissue segments were sampled 
as illustrated (Fig. 3A) and stored in paraformaldehyde (4%) or RNA later at -80°C for further 
analysis. The distal colon and common limb, or corresponding segment, were used for 
permeability experiments. See Supplementary material for a detailed description of the post-
operative analyses. 
5.3.4 Statistical analyses 
All values are expressed as mean ± SEM. Changes in body weight, food intake, glucose 
tolerance, plasma insulin levels, TEER and fluorescein levels over time between different 
genotypes and operations were analyzed using a repeated measures mixed models analysis 
(SAS software package 9). Other data were analyzed with a two-way ANOVA, followed by 
planned comparisons post-hoc testing, corrected for multiple testing with Bonferroni-Holm 
correction (Statistica 12, Statsoft). Significance was accepted at the 5% level. 
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5.4 Results 
5.4.1 RYGB induced body weight loss in WT and α-gust-/-mice  
Postsurgical body weight, food intake, fat mass and plasma leptin levels were measured in WT 
and α-gust-/-mice.  
Body weight did not differ between the different genotypes and groups before surgery or at 
the time of surgery (Fig. 1A, B, S2A). Body weight decreased in the first week after surgery in 
all groups to a similar extent (Fig. 1A, B). Body weight completely recovered in WT ALF mice 
but not in α-gust-/- ALF mice (-15%, P<0.05) (Fig. 1A, B). The latter group also showed lower 
plasma leptin levels (-46%, P<0.05) (Fig. 1D) at sacrifice. 
Pair-feeding (to determine the effects due to caloric restriction) and RYGB surgery decreased 
body weight in a more pronounced manner in WT mice (operationALF-PF*genotype*time; 
P<0.001) (operationALF-RYGB*genotype*time; P<0.05) compared to α-gust-/-mice (Fig. 1A, B). This 
interaction effect may be partially due to the genotype-dependent effect of sham surgery on 
body weight (operationALF*genotype*time; P<0.05). Therefore we cannot draw any important 
conclusions about the role of α-gustducin in the effect of pair-feeding or RYGB surgery on body 
weight loss. Postoperative cumulative food intake was decreased (P<0.05) in WT RYGB but not 
in α-gust-/- RYGB mice compared to ALF mice (Fig. 1C). 
However, PF mice weighed more than RYGB mice in week 1-7 (operationPF-RYGB*time; WT: 
P<0.001, α-gust-/-: P<0.01) in both genotypes, indicating that diminished food intake is only 
partially responsible for the body weight loss after RYGB surgery (Fig. 1A, B). Total fat pad mass 
(P<0.001) and plasma leptin levels (WT: P<0.001, α-gust-/-: P<0.01) were reduced after RYGB 
surgery in both genotypes (Fig. 1D, E). 
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Figure 1: RYGB surgery induced weight loss in WT and α-gust-/-mice. (A, B) Time-dependent changes in 
body weight in ALF, PF and RYGB groups in WT and α-gust-/-mice (n= 7-9). (C) Cumulative food intake (7 
weeks) in ALF and RYGB groups in WT and α-gust-/-mice (n= 5-9). (D) Plasma leptin levels in ALF, PF and 
RYGB WT and α-gust-/-mice (n= 5-9). (E) Total fat mass of ALF, PF and RYGB WT and α-gust-/-mice (n= 6-
9). *: P<0.05, **: P<0.01, ***: P<0.001 vs. ALF groups. #: P<0.05, ###: P<0.001 vs. PF groups. $ P<0.05 vs. 
WT ALF mice. £ P<0.05, £££ P<0.001 genotype*operation effect. 
5.4.2 RYGB improves glucose homeostasis in WT mice while α-gust-/-mice are 
protected from the diabetogenic effect of a western diet 
An oral glucose tolerance test was performed and serum insulin levels were determined to 
elucidate the effect of RYGB surgery on glucose homeostasis. Fasting blood glucose and serum 
insulin levels were used to measure the insulin resistance by calculating the insulin resistance 
index.  
Two weeks before surgery and five weeks after sham-surgery α-gust-/-mice were less glucose 
intolerant than WT mice (P<0.05) (Fig. 2A, B, S2B). Their serum insulin profiles did not 
statistically differ (Fig. 2C, D). Accordingly, insulin resistance was lower (P<0.05) in α-gust-/- ALF 
mice compared to WT ALF mice (Fig. 2E). 
RYGB surgery and pair-feeding improved glucose tolerance (P<0.05) in WT but not in α-gust-/-
mice (Fig. 2A, B). However, RYGB surgery resulted in a fast glucose response after an oral 
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glucose challenge, while pair-feeding was associated with lower blood glucose levels at all time 
points (Fig. 2A). 
WT PF (P<0.01) and WT RYGB mice (P<0.05) showed lower plasma insulin levels during the oral 
glucose tolerance test (Fig. 2C), suggesting that the improvement in glucose tolerance was due 
to changes in insulin resistance. Indeed, the insulin resistance decreased in WT PF and WT 
RYGB mice (P<0.001) to a similar extent (Fig. 2E). 
 
Figure 2: RYGB improves glucose homeostasis and insulin resistance in WT mice. (A, B) plasma glucose 
and (C, D) serum insulin levels during an oral glucose tolerance test (OGTT) (2g/kg) in ALF, PF and RYGB 
WT and α-gust-/-mice (n=5-8). (E) Insulin resistance index (HOMA-IR) of ALF, PF and RYGB WT and α-gust-
/-mice (n= 5-8). * P<0.05, ** P<0.01, *** P<0.001 vs. ALF groups. $ P<0.05 vs. WT ALF mice. ££ P<0.01 
genotype*operation effect. 
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5.4.3 α-gustducin plays a role in the morphological changes induced by nutrient 
rerouting  
Bariatric surgery can lead to structural changes in gut morphology, especially in regions 
overexposed to nutrients (le Roux et al., 2010, Taqi et al., 2010). This raises the possibility that 
nutrient sensing mechanisms may directly regulate these effects. 
Fig. 3A represents a schematic illustration of the postoperative anatomy after RYGB surgery 
and the sampled corresponding segments in the sham-groups. A representative hematoxylin 
and eosin stained section of the Roux limb (RL) (RYGB group) and corresponding jejunum 
(sham-group) of both genotypes is illustrated in Fig. 3B. RYGB decreased (P<0.05) the mucosal 
height of the biliopancreatic limb (BPL) of WT, but not of α-gust-/-mice, compared to the 
duodenum of ALF mice (Fig. 3C, D). The mucosal height of the RL was increased in a genotype-
dependent manner compared to the jejunal segment of ALF mice (operationALF-RYGB*genotype; 
P<0.05) (Fig. 3C, D). No changes were observed in the common limb (CL). These morphological 
changes did not occur after pair-feeding (data not shown). GLP-2 receptor mRNA levels in the 
RL were increased (P<0.05) in both genotypes, despite the absence of mucosal hypertrophy in 
α-gust-/-mice (Fig. 3E, F). 
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Figure 3: RYGB induces changes in gut morphology in an α-gustducin-dependent manner. (A) 
Schematic illustration of the postoperative anatomy after RYGB surgery and the sampled corresponding 
segments in the sham-operated groups. (B) Representative Hematoxylin & Eosin (H&E) staining of the 
RL (RYGB group) and the jejunum (ALF group) of both genotypes. (C, D) mucosal height from sections 
from the limbs (BPL, RL, CL) or corresponding segments of sham-groups (duodenum, jejunum) of WT 
and α-gust-/-mice (n= 5). (E, F) Relative GPL2R mRNA expression in the RL (RYGB) or jejunum (ALF, PF) in 
WT and α-gust-/-mice (n= 6-9). The dotted line indicates the mean mRNA levels in ALF mice. * P<0.05, 
*** P<0.001 vs. ALF groups. 
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5.4.4 The effect of nutrient rerouting on nutrient sensor expression differs between 
WT and α-gust-/-mice 
We hypothesize that the absence of nutrients in the BPL or the exposure to undigested 
nutrients in the RL after RYGB surgery may alter nutrient sensor expression and signaling on 
EECs resulting in altered gut hormone release. 
The mRNA expression of the following nutrient sensors was determined in the RL and BPL: a) 
the sweet taste receptors (TAS1R2-TAS1R3) and consequently one of the subunits of the 
umami taste receptor (TAS1R3), b) the glucose transporters SGLT1 and glucose transporter 2 
(GLUT2), c) the di-tri peptide sensor LPAR5 and d) the medium/long chain fatty acid sensor 
FFAR4. 
Pair-feeding did not affect mRNA levels of nutrient sensors. In WT mice, RYGB surgery 
increased (P<0.001) LPAR5 mRNA levels in the BPL but did not affect nutrient sensor 
expression in the RL (Fig. 4A). 
In α-gust-/-mice, RYGB surgery decreased (P<0.01) TAS1R3 mRNA levels compared to the PF 
group in the BPL, while it increased GLUT2 (operationALF-RYGB*genotype; P<0.05) and LPAR5 
(P<0.05) mRNA levels in the RL (Fig. 4B). 
5.4.5 SCFA production and the nutrient sensing mechanisms in the distal gut differ 
between WT and α-gust-/-mice 
The nutrient rerouting after RYGB surgery will also affect bacterial fermentation in the distal 
gut. RYGB surgery increased wet caecal weight (WT; +63±23g, α-gust-/-; +46±18g) compared to 
ALF groups. Furthermore, caecal butyrate and propionate levels were increased (P<0.001) in α-
gust-/-mice, but not in WT mice (operationALF-RYGB*genotype; P<0.001) (Fig. 4C-E). These 
alterations were not the result of an altered caloric intake (PF group). 
The increased SCFA production in α-gust-/-mice, was accompanied by decreased colonic FFAR2 
mRNA levels (P<0.01). Furthermore, RYGB surgery decreased colonic FFAR3 mRNA levels in 
both genotypes (P<0.001) (Fig. 4A, B). 
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Figure 4: Effect of RYGB on different elements of the nutrient sensing machinery. (A, B) Relative mRNA 
levels of the monosaccharide transporters (SGLT1, GLUT2), the sweet-and umami taste receptor subunit 
(TAS1R3), the peptide sensor (LPAR5), the fatty acid sensor (FFAR4) and the SCFA receptors (FFAR2, 
FFAR3) in the BPL, RL or colon (RYGB) and jejunum, duodenum or colon (ALF, PF) in WT and α-gust-/-
mice (n= 7-9). (C-E) Caecal SCFA levels 15 min after nutridrink gavage in ALF, PF and RYGB WT and α-
gust-/-mice (n = 6-9). Results are presented as mean ± SEM. AU: arbitrary units. * P<0.05, ** P<0.01, *** 
P<0.001, vs. ALF groups. # P<0.05, ## P<0.01, ### P<0.001, vs. PF groups. £££ P<0.001 
genotype*operation effect. 
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5.4.6 α-gustducin plays a role in the increased postsurgical plasma PYY levels, but 
not in the increased GLP-1 levels 
The altered gut morphology and nutrient sensor mRNA expression may affect the release of 
gut hormones, key regulators of the energy -and glucose homeostasis. Plasma ghrelin, GLP-1 
and PYY levels were determined. Immunohistochemical studies and real-time PCR was 
performed in the different limbs to determine the origin of these hormonal changes. 
5.4.6.1 Ghrelin levels 
RYGB surgery did not alter meal-induced (15 min) plasma octanoyl ghrelin levels but increased 
(P<0.01) total (octanoyl+desoctanoyl) ghrelin levels in α-gust-/-mice, but not in WT mice (Fig. 
5A, B). Pair-feeding did not affect plasma ghrelin levels. 
The number of octanoyl or total ghrelin immunoreactive cells in the bypassed stomach, RL or 
BPL was not affected in either genotype (Fig. S3A-F). A representative immunofluorescence co-
staining between gastric octanoyl and total ghrelin immunoreactive cells is shown in Fig. 5C. 
The increased plasma total ghrelin levels in α-gust-/-mice were accompanied with decreased 
ghrelin mRNA levels in the BPL (P<0.01) and RL (P<0.05), but not in the bypassed stomach, the 
main production site of ghrelin. Ghrelin mRNA levels were decreased in WT mice in the BPL 
after pair-feeding (P<0.01) and RYGB surgery (P<0.001), but this did not result in altered 
plasma ghrelin profiles (Fig. 5D, E). The mRNA levels of ghrelin-O-acyl transferase, the enzyme 
catalyzing the octanoylation of ghrelin, were not altered in the bypassed stomach or different 
limbs of either genotype (Fig. S3J, K). 
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Figure 5: RYGB increased plasma total ghrelin levels in α-gust-/-mice. (A, B) Meal-induced (15 min) 
plasma octanoyl and total ghrelin levels in ALF, PF and RYGB WT and α-gust-/-mice (n= 5-9). (C) Double-
immunofluorescence staining for octanoyl and total ghrelin in stomach sections of ALF and RYGB mice. 
(D, E) Relative ghrelin mRNA expression in the bypassed stomach, BPL or RL (RYGB) or corresponding 
small intestine (ALF, PF) in WT and α-gust-/-mice (n= 5-8). The dotted line indicates the mean mRNA 
levels in ALF mice. *: P<0.05, ***: P<0.001 vs. ALF groups. #: P<0.05, vs. PF groups. £ P<0.05, ££ P<0.01. 
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5.4.6.2 GLP-1 levels 
RYGB surgery, but not pair-feeding, increased (P<0.001) meal-induced plasma GLP-1 secretion 
in both genotypes (Fig. 6A). 
GLP-1 levels may originate from L-cells in the proximal or distal gut. In the BPL, no changes in 
the number of GLP-1 immunoreactive cells were observed in either genotype (Fig. 6B). In the 
RL, the genotype-dependent increase in mucosal thickness was accompanied by an increase 
(P<0.001) in the number of GLP-1 immunoreactive L-cells in WT mice (Fig. 6C), but not in α-
gust-/-mice (operationALF-RYGB*genotype; P<0.01). Furthermore L-cell density, obtained after 
normalization for the section area, was increased with 89% in WT but not in α-gust-/-mice 
(operationALF-RYGB*genotype; P<0.01) and was accompanied by a downregulation (P<0.05) of 
the entero-endocrine differentiation marker neurogenin 3 (Ngn3) (Fig. S4B-D) (Gradwohl et al. 
2000). Proglucagon mRNA levels in the RL and BPL were not affected (Fig. 6E, F). 
Additionally, RYGB surgery induced a genotype-dependent increase in the number of colonic 
GLP-1 immunoreactive cells of WT but not of α-gust-/-mice (Fig. 6D). This was probably due to a 
thicker mucosa of the distal colon which tended (P=0.09) to increase after RYGB surgery (Fig. 
S4A), resulting in an unchanged L-cell density (Fig. S4E). Accordingly colonic Ngn3 mRNA levels 
were not altered by RYGB surgery or pair-feeding in both genotypes (Fig. S4F, G). RYGB surgery 
decreased (P<0.001) colonic proglucagon mRNA transcripts of α-gust-/-mice, but not of WT 
mice (Fig. 6E, F). 
The effect of RYGB on energy-and glucose homeostasis
 
102 
 
 
Figure 6: RYGB increased plasma GLP-1 levels in an α-gustducin-independent manner. (A) Meal-
induced (15 min) plasma levels of GLP-1 (7-36)amide and GLP-1 (7-37) in ALF, PF and RYGB WT and α-
gust-/-mice (n= 6-9). Number of GLP-1 immunoreactive cells in sections of the BPL (B), RL (C) and distal 
colon (D) in RYGB groups or corresponding segment (ALF, PF) in WT and α-gust-/-mice (n = 5). (E, F) 
Relative proglucagon mRNA expression in the BPL, RL, DC (RYGB) or corresponding segment (duodenum, 
jejunum, distal colon (ALF-PF) in WT and α-gust-/-mice (n= 5-8). The dotted line indicates the mean 
mRNA levels in ALF mice. *: P<0.05, ***: P<0.001 vs. ALF groups. #: P<0.05, ##: P<0.01 vs. PF groups. £ 
P<0.05, ££ P<0.01 genotype*operation effect: £ P<0.05, ££ P<0.01. 
5.4.6.3 PYY levels 
RYGB surgery, but not pair-feeding, significantly increased postprandial plasma PYY levels in α-
gust-/-mice, and tended (P=0.07) to increase plasma PYY levels in WT mice resulting in an 
interaction effect (operationALF-RYGB*genotype; P<0.001) (Fig. 7A). 
RYGB surgery increased the number (P<0.05), but not the density, of colonic PYY 
immunoreactive L-cells in WT but not in α-gust-/-mice (operationALF-RYGB*genotype; P<0.05) (Fig. 
7B). A representative immunostaining showing colocalization between GLP-1 and PYY 
The effect of RYGB on energy-and glucose homeostasis
 
103 
 
containing L-cells in the colon is shown in Fig. 7E. Under ALF conditions 27% and 20% of the L-
cells only stained for GLP-1 or PYY respectively. After RYGB surgery, no shift in any 
subpopulation was observed (30% GLP-1, 16% PYY). Furthermore RYGB surgery increased 
(P<0.001) colonic PYY mRNA levels in both genotypes (Fig. 7C, D). 
 
Figure 7: RYGB increased plasma PYY levels in an α-gustducin-dependent manner. (A) Meal-induced 
(15 min) plasma levels of PYY(1-36) and PYY(3-36) in ALF, PF and RYGB WT and α-gust-/-mice (n= 6-9). (B) 
Number of PYY immunoreactive cells in the distal colon in ALF, PF and RYGB WT and α-gust-/-mice (n = 
5). (C, D) Relative PYY mRNA expression in the distal colon in PF and RYGB WT and α-gust-/-mice (n= 5-8). 
The dotted line indicates the mean mRNA levels in ALF mice. (E) Double-immunofluorescence staining 
for GLP-1 and PYY in sections from the distal colon of ALF and RYGB WT and α-gust-/-mice. *: P<0.05, 
***: P<0.001 vs. ALF groups, #: P<0.05, ###: P<0.001 vs. PF groups. £ P<0.05, £££ P<0.001 
genotype*operation effect: £ P<0.05, £££ P<0.001. 
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5.4.7 The RYGB-induced alterations in ion secretion in the foregut are α-gustducin-
dependent, while the altered gut permeability is α-gustducin-independent 
Via alterations in intestinal permeability, intestinal barrier function becomes compromised 
during obesity whereby access of dietary antigens to mucosal immune elements is facilitated. 
We investigated whether RYGB can restore the ‘leaky gut’ associated with obesity. 
Epithelial integrity of tissue segments was evaluated in Ussing chambers by measuring trans-
epithelial electrical resistance (TEER) and fluorescein passage (permeability). Ion transport was 
calculated (short circuit current; Isc). 
RYGB surgery, but not pair-feeding, increased the Isc of the CL in WT mice (P<0.001) but not in 
α-gust-/-mice, compared to the corresponding segment in the sham-operated group 
(operationALF-RYGB*genotype; P<0.01). Colonic Isc was unaffected (Fig. S5A-F). 
RYGB surgery and pair-feeding did not affect TEER in the CL (data not shown) or colon (Fig. 
S6A, B) in both genotypes. However, RYGB mice showed a genotype-independent decrease 
(WT; P<0.05, α-gust-/-; P<0.01) in colonic fluorescein passage compared to ALF mice (Fig. S6C, 
D), while fluorescein passage of the CL was unaffected (data not shown). Colonic mRNA levels 
of the tight junction protein occludin (Fig. S6E, F), which is important in the leak pathway 
regulation, were decreased in both genotypes after RYGB surgery (Buschmann et al., 2013). 
5.5 Discussion 
Bariatric surgery is not just an effective treatment option for obesity, but a platform that can 
yield new insights into the etiology of metabolic diseases. 
The idea behind the ‘restrictive’ RYGB surgery was that creation of a small pouch would reduce 
the amount of calories that would be consumed. In agreement with other studies, our results 
indicate that a decreased post-surgical food intake cannot fully explain the reduction in body 
weight since pair-feeding resulted in a less pronounced weight loss compared to RYGB surgery 
(Mokadem et al., 2014, Reddy et al., 2014). Increased EE as reported in mice and rats after 
RYGB surgery, is likely to contribute to the additional body weight loss (Nestoridi et al., 2012, 
Bueter et al., 2010). 
In the current study, α-gust-/-mice responded differently to the sham operation, resulting in a 
lower body weight at sacrifice. This genotype-dependent effect may play a role in the effect of 
RYGB surgery on the body weight loss in these mice. Therefore we could not clearly assess the 
role of α-gustducin in the RYGB-induced body weight loss. A previous study also reported 
comparable RYGB-induced body weight loss between WT and α-gust-/-mice (Mokadem et al., 
2014). 
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Solely a reduction in food intake seems to be sufficient to improve glucose homeostasis after 
gastric bypass since the WT pair-fed group also showed an improved glucose tolerance and 
insulin resistance. 
This observation has been made previously after an intra-peritoneal glucose tolerance test in 
mice that underwent RYGB, vertical sleeve gastrectomy (VSG) or pair-feeding (Chambers et al., 
2011). In contrast, an oral glucose tolerance test in obese insulin-resistant Zucker rats showed 
that RYGB, but not pair-feeding improved glucose homeostasis (Meirelles et al., 2009). Results 
in humans also suggest that caloric restriction underlies the short-term metabolic benefits of 
RYGB since a very low caloric diet and RYGB showed similar effects on glucose homeostasis 
(Lips et al., 2014). 
The role of α-gustducin in the RYGB-induced improvement of glucose homeostasis could not 
be clearly assessed since sham-operated α-gust-/-mice displayed better glucose profiles and 
tended to display lower insulin levels compared to sham-operated WT mice. These results 
indicate that α-gust-/-mice were partially protected from the diabetogenic properties of a 
western style diet. Avau et al. showed that high-fat diet-induced obese α-gust-/-mice have an 
increased heat production compared to WT mice, as a result of an increased brown adipose 
tissue thermogenic activity (Avau et al., 2015), this could explain why sham operated α-gust-/-
mice did not completely regain weight after surgery and were less glucose intolerant. 
The increased exposure of the gut to undigested nutrients after RYGB surgery can result in 
structural changes in gut morphology (Seeley et al., 2015). Our study provides novel 
mechanistic insights demonstrating that α-gust-/-mice do not ‘sense’ the need for 
morphological adaptations when deprived (BPL) or overexposed (RL) to undigested nutrients 
after RYGB. Increased plasma GLP-2 levels (trophic hormone) in rats and humans have been 
shown to correlate with increased crypth cell proliferation after RYGB surgery (le Roux et al., 
2010, Seeley et al., 2015). In our study, GLP-2 receptor mRNA levels increased in the RL of both 
WT and α-gust-/-mice, in contrast to the increased mucosal thickness which was genotype-
dependent. These findings suggest that the increased mucosal thickness is not GLP-2 receptor 
mediated or that α-gustducin plays a role in the GLP-2 receptor transduction cascade. 
Previous studies showed that alterations in gut morphology increased the number of L-cells in 
the RL (Mumphrey, 2013). We additionally highlighted similar changes in the distal gut and 
showed that L-cell number and/or density was affected in WT but not in α-gust-/-mice. Obesity 
per se is not the trigger for these changes in WT mice. Indeed, obese ob/ob mice did not show 
altered L-cell density while mice on a high fat diet did, highlighting the role of nutrient sensing 
and a nutrient rich environment in the changes in L-cell count (Aranias et al., 2015). 
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The increased L-cell density in the RL suggests that the increased L-cell number is not solely 
due to the morphological changes. Additionally, the α-gustducin-dependent compensatory 
decrease of the differentiation marker Ngn3 may indicate that sensing the luminal content 
through gustducin triggers the differentiation of progenitor cells towards EECs instead of 
enterocytes (Gradwohl et al., 2000). 
If the nutrient sensing cascade is disrupted (α-gust-/-mice), the gut may compensate by 
upregulating nutrient sensors on EECs to regulate gut hormone secretion. Indeed, α-gust-/-
mice, but not WT mice, showed increased LPAR5 and GLUT2 mRNA levels in the RL. Similarly, 
in a RYGB rat model mRNA expression levels of TAS1R2, SGLT1 and GLUT2 remained unaltered 
in the RL of WT mice (Bhutta et al., 2014). Nevertheless, a human study reported an 
upregulation of SGLT1 and GLUT2 but no change in sweet TASR expression in the RL after RYGB 
surgery (Nguyen et al., 2014). The sweet TASR has been shown to regulate the expression of 
SGLT1 and GLUT2 via a sweet taste receptor or α-gustducin-dependent signaling process 
(Margolskee et al., 2007, Mace et al., 2009). Therefore the lack of α-gustducin-mediated 
signaling could lead to a compensatory upregulation of GLUT2. 
One of the limitations of this study is that the protein levels of the different nutrient receptors 
were not investigated. 
The nutrient rerouting after RYGB surgery can also modify the gut microbiome (Furet et al., 
2010) resulting in an altered bacterial fermentation. The SCFAs acetate, butyrate and 
propionate are important microbial fermentation products. Literature concerning the effect of 
bariatric surgery on SCFA production is limited (Liou et al., 2013, Tremaroli et al., 2015). Caecal 
butyrate and propionate but not acetate levels were increased in α-gust-/-mice but not in WT 
mice, suggesting that α-gustducin mediated sensing mechanisms may be linked to bacterial 
fermentation. A previous rodent study showed increased ceacal propionate levels but 
decreased acetate levels after RYGB surgery (Liou et al., 2013). This discrepancy may be 
related to differences in the diet (high-fat vs western style) and period of fasting (2h vs 6h) 
(Liou et al., 2013). In humans, RYGB surgery tended to decrease fecal SCFA levels 10 years after 
RYGB surgery (Tremaroli et al., 2015). 
The increased SCFA levels in α-gust-/-mice may trigger gut hormone release. In vitro and in vivo 
studies showed that SCFAs stimulate the secretion of GLP-1 and PYY from L-cells in a FFAR2, 
and FFAR3 dependent manner (Tolhurst et al., 2012). However, the selective increase of 
propionate and butyrate in α-gust-/-mice did not correlate with the genotype-independent 
downregulation of FFAR3, but it did correlate with the FFAR2 mRNA transcripts, which were 
The effect of RYGB on energy-and glucose homeostasis
 
107 
 
selectively decreased in α-gust-/-mice. These mRNA levels might reflect a compensatory 
downregulation due to increased SCFA exposure. 
Diet-induced obese FFAR2-/-mice have a higher EE, higher core body temperature and 
decreased adiposity (Bjursell et al., 2011) suggesting that SCFAs can regulate EE via FFAR2 
signaling. Therefore the increase in SCFA production in α-gust-/-mice might lower EE through 
FFAR2 signaling, explaining the decrease in body weight after RYGB surgery. 
Butyrate can also improve intestinal permeability by decreasing paracellular passage through 
the facilitation of tight junction assembly (Peng et al., 2009, Cani et al., 2008). However, the 
genotype-dependent increase in butyrate levels cannot explain the genotype-independent 
nature of the decreased colonic paracellular passage of large molecules. Consequently, the 
altered expression of the tight junction protein occludin in both genotypes may explain the 
improvement in colonic leak passage but will not be due to altered butyrate levels. 
Furthermore, RYGB did not affect mucosal integrity in the proximal intestine, in contrast to a 
previous report which showed improvement in human proximal small intestine permeability 
six to eight months after RYGB surgery (Casselbrant et al., 2015). 
The morphological changes in the proximal gut in combination with the changes in nutrient 
sensor expression and altered bacterial fermentation in the distal gut after RYGB surgery may 
alter gut hormone profiles (Seeley et al., 2015, Umeda et al., 2011). 
In our study plasma octanoyl ghrelin levels were not significantly altered, although total 
ghrelin levels were selectively increased in α-gust-/-mice. Since the octanoylated form of 
ghrelin is biologically active, it is unlikely that plasma ghrelin levels contribute to the weight 
loss after RYGB. This is consistent with published data where vertical sleeve gastrectomy 
induced comparable effects on food intake and body weight in wild type and ghrelin-deficient 
mice (Chambers et al., 2013). Nevertheless, the decreased ghrelin mRNA levels in the BPL and 
RL indicate that nutrient rerouting enables the limbs, in addition to the stomach, to play a role 
in the regulation of plasma ghrelin secretion. The importance of nutrient sensing via TASRs in 
peptone-induced ghrelin secretion was already shown in a ghrelinoma cell line and in jejunal 
segments (Vancleef et al., 2015). 
The increase of postprandial GLP-1 levels after RYGB surgery has consistently been reported in 
rodents and humans (Miras and le Roux, 2013). Changes in the foregut and distal gut resulted 
in a genotype-independent elevation of plasma GLP-1 levels after RYGB surgery and might 
contribute to the weight loss after RYGB. However, the role of GLP-1 in body weight loss after 
RYGB surgery has been questioned. Both a pharmacological and a genetic loss-of-function 
approach provided no support for a role of GLP-1 or PYY in the RYGB-induced body weight loss 
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(Ye et al., 2014). In contrast, a human study showed that combined blockage of GLP-1 and PYY 
actions increased food intake after RYGB (Svane et al., 2016). 
The α-gustducin-independent nature of the increased plasma GLP-1 levels is in contrast with a 
previous study in α-gust-/-mice which reported an attenuated RYGB-enhanced GLP-1 secretion 
(Mokadem et al., 2014). However, Mokkadem et al. measured GLP-1 levels after an oral 
glucose load, while we studied GLP-1 levels after a liquid meal (Nutridrink®) (Mokadem et al., 
2014). 
In agreement with previous studies, RYGB surgery increased meal-induced PYY levels (Sweeney 
and Morton, 2014). The effect was more pronounced in α-gust-/-mice. Nevertheless, only WT 
mice displayed an increased colonic L-cell number, while PYY mRNA levels were genotype-
independently increased. Since the increase in L-cell number is not in line with the observed 
plasma levels, an altered secretion pattern may be responsible for the elevated plasma PYY 
levels. For instance, the selective increase in SCFA levels in α-gust-/-mice may trigger PYY 
release, explaining the genotype-dependent increase in PYY levels. 
Endogenous PYY release is known to suppress electrolyte secretion.(Panaro et al., 2014). The 
higher PYY levels in α-gust-/- mice were indeed accompanied by a less pronounced increase in 
ion transport in the common limb. These results indicate that α-gustducin-mediated signaling 
also plays a role in the increase in ion transport of the foregut. 
To summarize, our results argue against a major contribution of gustducin-mediated signaling 
in the metabolic effects of RYGB. Nevertheless, RYGB activated several regulatory systems in 
which the gustducin mediated signaling pathway plays a role. This study highlights that 
nutrients cannot only serve as fuel but may regulate a number of physiological processes after 
RYGB surgery such as tuning of gut hormone release which is the result of multifaceted 
intestinal adaptations along the gut. Gustducin-mediated sensing mechanisms regulate L-cell 
enteroplasticity in a region-dependent manner by increasing L-cell number in both the foregut 
and distal gut and selectively inducing L-cell differentiation in the foregut. Loss of these 
mechanisms as observed in α-gust-/-mice is accompanied with an altered expression of 
nutrient sensors along the gut and may favor SCFA-induced gut hormone release in the distal 
gut. 
Importantly, these gut hormones could contribute to the observed metabolic improvements 
after RYGB surgery. 
Selective targeting of nutrient sensors along the gut may contribute to our further 
understanding of the role of these chemosensory mechanisms. 
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5.6 Supplementary material 
5.6.1 Supplementary material and methods 
5.6.1.1 Roux-en-Y gastric bypass 
RYGB surgery was performed as previously described (Seyfried et al., 2012). In brief, surgical 
anaesthesia was induced and maintained throughout the procedure with isoflurane (2–3 % with O2). 
Mice were placed on a heating pad to avoid hypothermia and the abdomen was shaved and 
disinfected before a 4-cm midline laparotomy was performed. The esophagogastric junction was 
exposed and the esophagus mobilized. The left gastric vessels and the vagal nerve branches were 
dissected away from the esophagus to avoid respectively consecutive ischemia of the remaining 
stomach and damage to the vagal nerve. The small vessels on the cardia were cauterized. The 
stomach was transected at the gastro-esophageal junction. The native stomach was closed with non-
resorbable sutures. At 4 cm distal from the pylorus the jejunum was incised for 2 mm on the 
antimesenterial side and anastomosed in an end-to-side fashion to the esophagus with two 
continous, non resorbable sutures. The first 5 cm of the jejunum was used to create a Roux limb. 
Here, an end-to-side jejunojejunostomy between the biliopancreatic (4 cm) and Roux limb was 
performed to create the common limb. Hereafter the jejunum was double ligated and transected just 
proximal of the esophagojejunostomy to create the BPL. The abdominal wall and skin were closed. In 
the sham groups, the small bowel and the gastro-esophageal junction were mobilized and a 
gastrostomy (5 mm) on the anterior wall of the stomach was performed. The gastrostomy was closed 
subsequently. To prevent postoperative pain, all mice received carprofen (3mg/kg) and 
buprenorphine (0.1mg/kg) twice daily the first 2 days after surgery. A western style diet was 
continued in all groups for 7 weeks till sacrifice. The first three postoperative days, manually crushed 
chow together with 20ml of Nutridrink® was provided at the bottom of the cage in order to facilitate 
food intake. 
5.6.1.2 Plasma ghrelin Measurement 
Plasma samples were extracted on a SEP-Pak C18 cartridge (Waters Corporation, Milford, MA), 
vacuum-dried and subjected to ghrelin radioimmunoassay (RIA) as previously described (Janssen et 
al., 2011). For determination of octanoyl ghrelin a rabbit anti-human ghrelin [1-8] antibody was used 
which does not recognize desoctanoyl ghrelin. Total ghrelin levels were determined using a rabbit 
anti-human ghrelin [14-28] antibody, which recognizes both octanoyl and desoctanoyl ghrelin. 
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5.6.1.3 Plasma Glucagon-Like Peptide-1, Peptide YY, insulin and leptin measurement 
Samples were analysed for plasma GLP-1 (GLP-1(7-36)amide and GLP-1 (7-37)) using the Active GLP-1 
(ver. 2) Kit (Mesoscale Discovery) and plasma leptin and serum insulin levels were determined using 
the Mouse metabolic Kit (Mesoscale Discovery), according to the manufacturer’s instructions. Plasma 
PYY levels (PYY(1-36) and PYY(3-36)) were determined using a PYY ELISA (Phoenix pharmaceuticals), 
according to the manufacturer’s instructions. 
5.6.1.4 Oral Glucose Tolerance Test 
An Oral glucose tolerance test (OGTT) was performed 2 weeks before and 5 weeks after surgery. 
Mice were fasted for 6 hours and gavaged with 2g/kg D-glucose. Tail vein glucose levels were 
measured at 0, 15, 30, 60 and 120 minutes after glucose administration with a glucometer 
(Glucomen LX®, A. Menarini Diagnostics) and serum was collected after centrifugation for 7 min at 
2000 rpm (4°C) and subsequently snap frozen in liquid nitrogen for insulin measurements. The 
homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using the equation 
[(G0 × I0)/405)], where G0 and I0 refer to 6-h fasting plasma glucose and insulin values. 
5.6.1.5 Reverse transcription and quantitative real-time polymerase chain reaction 
Total RNA was isolated from mouse tissue segments using the RNeasy kit (Qiagen). Isolated RNA was 
treated with Turbo DNAfree kit (Ambion) and was reversed transcribed to cDNA using Superscript II 
Reverse Transcriptase (Invitrogen). The real-time PCR reaction was performed as described 
previously, using the Lightcycler 480 (Roche Diagnostics) with the Lightcycler 480 Sybr Green I Master 
mix (Roche Diagnostics). Results were expressed relative to the geometric mean of the normalized 
expression of the three most stable housekeeping genes tested; hypoxanthine 
phosphoribosyltransferase 1 (Hprt1), ribosomal protein L13a (RPL13a) and β-actin. The following 
primers were used 
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Gene Forward primer Reverse primer 
RPL13a CACTCTggAggAgAAACggAAgg gCAggCATgAggCAAACAgTC 
β-Actin gATCTggCACCACACCTTCTAC TggATggCTACgTACATggCTg 
Hprt1 TCAgTCAACgggggACATAAA ggggCTgTACTgCTTAACCAg 
ghrelin CCAgAggACAgAggACAAgC ACATCgAAgggAgCATTgAA 
GOAT ATTTgTgAAgggAAggTggAg CAggAgAgCAgggAAAAAgAg 
proglucagon gAggAgAACCCCAgATCATTCC gTggCgTTTgTCTTCATTCATC 
PYY CAgTggTgAAgACTCCCCCAAg TgAACACACACAgCCCTCCAg 
SGLT1 CggAAgAAggCATCTgAgAA AATCAgCACgAggATgAACA 
GLUT2 TCTTCACggCTgTCTCTgTg AATCATCCCggTTAggAACA 
TAS1R3 CAggCAgTTgTgACTCTgTTg TgCgATgCAgATACCTCgTg 
LPAR5 gCTgTCgTCTATTCgTCTggC CgAAgCACAgCAggAAgATg 
FFAR2 CCCTgTgCACATCCTCCTgC gCgTTCCATgCTgATgCCCg 
FFAR3 TgTCCAATACTCTgCATCTgT AggTCCgAAATggTCAggTT 
FFAR4 gTCCCATCATCATCACCATCC gATggCCAgATgACCAggTC 
Occludin gACTgggTCAgggAATATCCACC AgCAgCAgCCATgTACTCTTCAC 
 
5.6.1.6 Histology and Immunohistochemistry 
Gastric or colonic tissues and segments from the RL and BPL, or corresponding segments were 
sampled as illustrated (Fig. 3a). Samples (5 mice/group) were immediately fixed with 
paraformaldehyde (4%) for 2h (4°C) followed by cryoprotection in 30% sucrose at 4°C overnight. 
Cryostat sections (8 µm) were incubated for 2 h in 0.1 M phosphate-buffered saline (PBS) containing 
10% donkey serum and 0.3% Triton X-100 and incubated with one of the following primary 
antibodies: rabbit anti-octanoyl ghrelin (1/500 for limbs and 1/1000 for gastric tissue, Ab5004, in-
house developed), goat anti-ghrelin (1/1000, sc-10368, Santa Cruz), goat anti-GLP-1 (1/150, SC-7782, 
Santa Cruz Biotechnology) or rabbit anti-PYY (1/1000, Ab22663, Abcam). Substitution of the primary 
antibody with PBS was used as a negative control. Subsequently, tissues were incubated with 
secondary antibody for 2 hours, after washing: donkey anti-rabbit Alexa488 (1/1500, A21206, 
Thermofisher), anti-goat Alexa594 (1/1000, A11058, Thermofisher) or donkey anti-rabbit AMCA 
(1/250, 711-225-152, Jackson Immuno Labs). For the double-immunofluorescence staining, after 
being incubated with the secondary antibody and washed three times, sections were incubated for 
24 hours at room temperature with the second primary antibody. Subsequently, tissues were 
incubated with the second secondary antibody for 2 hours. Sections were mounted in Citifluor and 
visualized under a fluorescence microscope (Olympus BX41). Of each tissue segment three sections 
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were analyzed using Cell^F Imaging Software (Olympus Soft Imaging Solutions GmbH). Octanoyl 
ghrelin-, ghrelin-, GLP-1- or PYY-positive cells, were counted in 5 randomly chosen fields (20x) for the 
stomach and expressed per mm2, or in the whole section (20x) for the segments from colon, RL, BPL 
or corresponding segments. 
Morphological measurements were performed on hematoxylin and eosin (H&E) sections. Mucosal 
thickness was measured at 15 randomly chosen representative fields (4x). 
5.6.1.7 SCFA Analysis 
SCFAs were extracted from the fecal samples using an ether extraction. 50 mg of fecal sample was 
suspended in 1 ml saturated NaCl (36%). Ether (3 ml), Na2SO4 (50 mg), H2SO4 (150 µl) and internal 
standard (50 µl) (2-ethylbutyric acid (Merck)) was added to each sample. The ether layer was 
collected and the SCFA were analyzed on a gas chromatography–mass spectrometry quadrupole 
(Finnigan Trace GC, Thermoquest) as previously described.(De Preter et al., 2009) Samples were 
absolutely quantified using an appropriate calibration curve. 
5.6.1.8 Gut Permeability Assays 
The distal colon or tissue from the CL or corresponding segment, was dissected in carbogenated 
Krebs-Ringer buffer (11mM D-glucose). Intestinal segments of approximately 0.5 cm2 (n=3/mouse) 
were cut and mounted in modified Ussing chamber (Mussler Scientific Instruments) with an area of 
0.017cm2 for colonic segments, and 0.096cm2 for segments from CL or the corresponding tissue. 
Potential difference (PD) was continuously recorded and transepithelial electrical resistance (TEER) 
(Ωxcm2) was calculated from the voltage deflections induced by bipolar constant-current pulses of 16 
mA every 60 s with duration of 200 ms and was recorded over 2h. 
Meanwhile, permeability was measured, by adding fluorescein (376 Da, Sigma Aldrich) to the 
mucosal side after a calibration period of 30 min. Regular (every 30 min) sampling from the serosal 
side allowed to detect the degree of mucosal permeability. The fluorescence level (ng/ml*cm2) was 
measured using a fluorescence reader (FLUOstar Omega; BMG Labtech). 
Short circuit current was calculated using the measured TEER and recorded potential difference 
(voltage) using following formula; Isc = V/R where V and R refer to the measured Voltage (V) in micro 
Ampère and Resistance (R) in Ohm. 
5.6.1.9 Blinding 
Genotype paradigms were blinded during the sample collecting and genotype and treatment 
paradigms were blinded during the analysis. 
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5.6.2 Supplementary figures 
 
Figure S1. Experimental design. Scheme of the experimental design of the study. WT and α-gust-/-mice (6 
weeks old) were fed a western diet for 12 weeks. Mice were randomized in three groups: a sham-group fed ad 
libitum (ALF), a sham-group, pair-fed to the RYGB group (PF), and a RYGB group fed ad libitum fed (RYGB). All 
mice received the western diet for 7 weeks after surgery till sacrifice. An oral glucose tolerance test was 
performed 2 weeks before surgery and 2 weeks before sacrifice. Seven weeks post-surgery, (6h) fasted mice 
(between 7.30-9 a.m. – 1.30-3 p.m. to minimize circadian fluctuations) were gavaged with 200µL Nutridrink®, 
15 minutes before sacrifice. 
 
Figure S2. Pre-surgical weight gain and glucose tolerance. (A) Pre-surgical time-dependent changes in body 
weight of WT and α-gust-/-mice fed a western style diet (n= 21-23). (B) Plasma glucose levels during an OGTT 
(2g/kg) in WT and α-gust-/-mice fed a western style diet, 2 weeks before surgery (n=21-23).* P<0.05 compared 
to WT mice. 
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Figure S3. RYGB increased plasma total ghrelin levels in α-gust-/-mice. Number of (A-C) octanoyl ghrelin and 
(D-F) total ghrelin IR cells in the stomach (A, D), BPL (B, E),RL (C, F) and corresponding small intestine (sham 
groups) in ALF, PF and RYGB WT and α-gust-/-mice (n= 5-8). (G, H) Relative mRNA levels of GOAT in the 
stomach, BPL, RL (RYGB) or corresponding small intestine (sham groups) in PF and RYGB groups in WT and α-
gust-/-mice (n= 6-8). The dotted line indicates the mean relative GOAT mRNA levels in ALF mice. 
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Figure S4. RYGB increased L-cell density in the foregut, but not the distal gut of WT mice in an α-gustducin-
independent manner. (A) Morphometric analysis showing the mucosal height from sections of the distal colon 
from ALF, PF and RYGB groups in WT and α-gust-/-mice. Density of GLP-1 IR cells in sections of the RL (B) and 
distal colon (E) in RYGB groups or corresponding segments (ALF, PF groups) in WT and α-gust-/-mice (n= 5). 
Relative mRNA levels of neurogenin 3 in the RL (C, D) and distal colon (F, G) or corresponding segment (ALF-PF) 
in WT and α-gust-/-mice (n= 6-8). The dotted line indicates the mean relative neurogenin 3 mRNA levels in ALF 
mice. * P<0.05 compared to ALF groups. # P<0.05 compared to PF groups. £ P<0.05, ££ P<0.01 
genotype*operation effect between the indicated groups 
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Figure S5. α-gustducin plays a role in the RYGB-induced changes in ion transport across the epithelium 
(secretory and/or absorption properties) of the diverged small intestine. Equivalent short circuit current (Isc) 
in the (A, B) CL (RYGB groups) and (D, E) distal colon or corresponding segment (sham-operated groups) in ALF, 
PF and RYGB WT and α-gust-/-mice (n= 8-9). (C, F) Average equivalent short circuit current (Isc). *** P<0.001 
compared to ALF groups. ### P<0.001 compared to PF groups. ££ P<0.01 genotype*operation effect between 
the indicated groups. 
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Figure S6. RYGB improved colonic permeability in an α-gustducin-independent manner. (A, B) Colonic 
transepithelial electrical resistance (TEER) 7 weeks after surgery in ALF, PF and RYGB WT and α-gust-/-mice (n= 
6-8). (C, D) Colonic fluorescein passage 7 weeks after surgery in ALF, PF and RYGB WT and α-gust-/-mice (n= 6-
8). (E, F) Relative occludin mRNA levels in the distal colon in PF and RYGB WT and α-gust-/-mice (n= 6-9). The 
dotted line indicates the mean relative occluding mRNA levels in ALF mice * P<0.05, ** P<0.01, *** P<0.001 
compared to ALF groups. ## P<0.01, ### P<0.001 compared to PF group. 
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6 GENERAL DISCUSSION AND FUTURE PROSPECTS 
Several taste receptors (sweet, umami, bitter, fatty acid) and the taste receptor coupled G-protein, 
α-gustducin, are not only present on taste buds of the tongue but also on EECs and may tune gut 
hormone release according to the macronutrient composition of the meal. However, the 
physiological role of these taste receptors on EECs has not yet been fully elucidated. Targeting taste 
receptors to restore postprandial gut hormone levels (ghrelin, GLP-1, PYY), known to be dysregulated 
in obesity, may pose a new therapeutic strategy to combat obesity.  
This PhD project investigated the functional role of the sweet taste receptor on the ghrelin cell, the 
potential of targeting sweet/fatty acid taste receptors in the gut by prolonged treatment with 
artificial/prebiotic sweeteners to prevent body weight gain and the role of α-gustducin-mediated 
nutrient signaling in the restoration of postprandial gut hormone levels and metabolic improvements 
after Roux-en-Y gastric bypass (RYGB) surgery. 
6.1 Is the omnipresence of α-gustducin limiting its targetability? 
Taste signaling is omnipresent throughout the body. For instance, α-gustducin has been reported in 
several cell types in the gut epithelium including the brush cells, tuft cells and EECs (Sato, 2007, 
Sternini et al., 2008, Howitt et al., 2016) and in extra-oral sites like the choroid plexus, kidney, 
keratinocytes, brain, airways, testis, ureter, thyroids, pancreatic duct and adipose tissue (Tomas et 
al., 2016, Liu et al., 2015, Wolfle et al., 2015, Sternini et al., 2008, Kinnamon, 2012, Gong et al., 2016, 
Panneck et al., 2014, Hofer and Drenckhahn, 1998, Avau et al., 2015, Ren et al., 2009).  
Most of the tissues where the taste transduction machinery is active work as a barrier and it seems 
that the taste system behaves as a sensor to assess the composition of body fluids. This may then be 
used to trigger protective responses when hazardous compounds are sensed. For instance, taste 
receptors in the airways are thought to sense irritating bitter chemicals and to promote protective 
airway reflexes (Kinnamon, 2012). Furthermore the α-gustducin and TRPM5 dependent signaling 
pathway in tuft epithelial cells of the gut mediate type 2 cell immune responses during parasite 
infection to promote worm expulsion (Howitt et al., 2016, Gerbe et al., 2016, von Moltke et al., 
2016). 
Not only toxic compounds but also nutrients are sensed by extra-oral taste receptors. The sweet 
taste receptor and short-chain fatty acid receptors FFAR2 and FFAR3 are expressed in mouse and 
human pancreatic β-cells and our study showed expression of FFAR2 on adipose tissue (Kyriazis et al., 
2012, Tang et al., 2015). Kyriazis et al. demonstrated that fructose activated sweet taste receptors in 
isolated mouse islets and synergized with glucose to amplify insulin release. Genetic ablation of 
TAS1R2 abolished the potentiating effect of fructose on glucose-stimulated insulin release in vitro 
and in vivo. Studies in TRPM5-/- mice revealed that this taste receptor signaling pathway increased 
calcium levels which were dependent on phospholipase C and TRPM5 (Kyriazis et al., 2012). Tang et 
General discussion and future prospects
 
122 
 
al. showed that FFAR2 and FFAR3 mediate an inhibition of insulin secretion by coupling to Gi type 
proteins. Diet-induced obese mice with a genetic ablation of both receptors, on a whole body level or 
specifically in pancreatic beta cells, had a higher insulin secretion and improved glucose tolerance. 
However, FFAR2 or FFAR3 deletion in intestinal cells did not alter glucose tolerance (Tang et al., 
2015). SCFAs also reduced the intracellular lipolytic activity in differentiated murine 3T3-L1 
adipocytes via FFAR2 suggesting a role for FFAR2 on the adipocytes (Ge et al., 2008). 
Since α-gustducin and several elements of the chemosensory signaling pathway are so widely 
expressed throughout the body it is plausible to assume that during our studies signals derived from 
different sites could cancel each other out. For instance, the stimulatory effect of the gut-derived 
hormone ghrelin on adipogenesis, could get cancelled out by the increased heat production in α-
gustducin-/- mice (Avau et al., 2015). This might explain why the phenotype of WT and full body α-
gustducin knockout mice did not present many different features. Nevertheless, lean α-gustducin-/- 
mice did show lower basal ghrelin levels while diet-induced obese α-gustducin-/- mice tended to have 
lower GLP-1 and insulin levels.  
For the tongue it has been reported that the reduced preference to sweet compounds in two-bottle 
preference tests in α-gustducin-/- mice is accompanied by reduced responses of the chorda tympani 
and glossopharyngeal nerves to sweet compounds (Danilova et al., 2006). These nerves together 
with the vagus innervate the nucleus tractus solitarius. It is therefore tempting to speculate that their 
reduced signaling in α-gustducin-/- mice also translates in reduced activation of reflex circuits that 
contribute to the autonomic nerve activation of, for instance, the pancreas and EECs. A role for the 
autonomous nervous system in the regulation of gut peptide release has been shown for the cephalic 
insulin response to a meal (Herath et al., 1999) and the preprandial rise in ghrelin levels (Mundinger 
et al., 2006, Zhao et al., 2010). Thus, the interplay between oral taste perception and activation of 
the autonomic nervous sytem could contribute to the alterations in gut hormone levels in α-
gustducin-/- mice. 
6.2 Gut sweet taste receptors: the answer to obesity? 
In this PhD study we showed for the first time that the canonical sweet taste receptor signaling 
pathway does not play a functional role in the effect of sweeteners on ghrelin release. In contrast, an 
important role for sweet taste receptor signaling in glucose-induced GLP-1 release has been claimed 
from in vitro studies in the human NCI-H716 cell line, duodenal isolated villi and duodenal minced 
tissues from WT and α-gust-/- mice (Jang et al., 2007). In vivo, GLP-1 secretion was blunted in α-gust-/- 
and TAS1R3-/- mice after an intragastric or intraduodenal glucose administration, respectively (Jang et 
al., 2007, Kokrashvili et al., 2009a). Blocking sweet taste receptors in the gastro-intestinal tract of 
healthy volunteers with the sweet taste receptor antagonist lactisole also reduced GLP-1 and PYY 
secretion after an acute intragastric glucose infusion but to a lesser extent after intraduodenal 
General discussion and future prospects
 
123 
 
administration (Steinert et al., 2011b). Since the TAS1R2 subunit of the sweet taste receptor 
(TAS1R2-TAS1R3) is not present in the stomach of mice in our study, this is a somewhat 
counterintuitive result. Other studies using the TAS1R2-lacZ knock-in mouse did also not observe 
TAS1R2 expression in the stomach (Iwatsuki et al., 2010). In contrast, Koyama et al. showed a very 
low expression of TAS1R2 in the MGN3-1 cell line and primary gastric ghrelin cells using RNA 
sequencing (Koyama et al., 2016). This suggests that the process of glucose-induced gut hormone 
secretion is complex and likely to be the result of the summation of different processes, including 
feedback signals from the small intestine to the stomach. In addition, lactisole did not block the 
effect of a liquid meal consisting of proteins, fats, and other complex carbohydrates on GLP-1 and 
PYY release (Gerspach et al., 2011). Thus, although sweet taste receptors may play a role in the effect 
of glucose on GLP-1 and PYY release, it is likely that this is overruled by other macronutrients in a 
meal and that blocking sweet taste receptors might not be enough to modulate gut hormone 
release.  
In fact, targeting sweet taste receptors on EECs by acute intragastric administration of 
artificial/prebiotic sweeteners failed to affect ghrelin release in our study in mice. Similar findings 
have been reported with an acute intragastric administration of artificial sweeteners in rats (Fujita et 
al., 2009) and humans (Steinert et al., 2011a, Ma et al., 2009). These findings are at variance with in 
vitro studies in enteroendocrine cell lines where GLP-1 release from NCI-H716 cells was promoted by 
sucralose (an artificial sweetener) in a dose dependent manner, and blocked by the sweet taste 
receptor antagonist lactisole or siRNA for α-gustducin (Jang et al., 2007). In the current PhD we also 
showed effects with sucralose or oligofructose (OFS; a prebiotic sweetener) on ghrelin release in 
vitro in a ghrelinoma cell line and ex vivo in segments from both the stomach and jejunum of mice. 
These findings again underscore that acute activation of sweet taste receptors may not have an 
important functional role in vivo despite promising in vitro results.  
Long-term administration of sucralose did also not affect ghrelin, GLP-1 and PYY levels in mice on a 
high-fat diet and did not improve body weight gain nor glucose intolerance. Thus targeting sweet 
taste receptors on a long-term basis does not seem to be relevant from a therapeutic point of view. 
It is important to notice though that not all sweet compounds bind to the same binding pocket of the 
sweet taste receptor heterodimer (DuBois, 2016). Carbohydrates and artificial sweeteners are hence 
likely to activate a different signaling cascade and although artificial sweeteners may not induce 
physiological effects, carbohydrates may still signal via the sweet taste receptor. Therefore 
performing functional binding studies may be important before any conclusions are drawn on the 
possible effect of new sweeteners on metabolic parameters. 
Nevertheless, this does not exclude that sweet taste receptor expression might be altered during 
disease or that mutations can occur in sweet taste receptors that increase the risk to develop obesity 
or diabetes. On the tongue, several studies reported an increase in sweet taste threshold perception 
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in patients with T2DM (Gondivkar et al., 2009, Wasalathanthri et al., 2014) as well as in type 1 
diabetes (Khobragade et al., 2012). This taste abnormality may lead to a preference for sweet-tasting 
foods, thereby exacerbating hyperglycemia. In the gut, we showed that neither long-term 
administration of sweeteners, nor RYGB surgery affected TAS1R2 mRNA levels in mice. Young et al. 
showed that changes in basal glycemia do not change sweet taste receptor expression in humans. 
However, the expression of the sweet taste receptor subunit, TAS1R2, was increased in response to 
luminal glucose during euglycemia in both healthy volunteers and non-obese patients with T2DM. 
Furthermore, TAS1R2 was downregulated in response to luminal glucose during hyperglycemia in 
healthy volunteers but increased under the same conditions in non-obese patients with T2DM. This 
defect enhanced glucose absorption in type 2 diabetic patients and may exacerbate postprandial 
hyperglycemia (Young et al., 2013). 
Previous studies suggested a relationship between the activation of the TAS1R2-TAS1R3 receptor and 
the expression of SGLT1 (Margolskee et al., 2007). We reported that long-term (8 weeks) 
administration of equisweet concentrations of the sweetener OFS but not sucralose, followed by the 
administration of a single glucose bolus, decreased the expression of the glucose transporters in the 
small intestine. Surprisingly, this downregulation did not affect blood glucose levels. In contrast, 7 
weeks after RYGB surgery the expression levels of the glucose transporter were increased in the limb 
with increased exposure to undigested nutrients and thus also to carbohydrates. This upregulation 
was accompanied by increased peak glucose levels. Thus, it seems that an increased exposure to 
sweeteners and carbohydrates differentially regulate the expression levels of glucose transporters.  
The glucose transporter SGLT1 may play a role as a glucose-sensor on the L-cell, enabling this 
transporter to modulate gut hormone release (Reimann et al., 2008). This hypothesis is supported by 
both a pharmacological (by using the SGLT1 antagonist phloridzin) (Parker et al., 2012) and genetic 
loss-of function approach (SGLT1-/- mice) (Gorboulev et al., 2011). Recently the correlation between 
glucose transport, SGLT1 expression and gut hormone release has been investigated in lean and 
obese volunteers. Nguyen et al. showed that obese patients have a higher SGLT1 expression which 
was correlated with higher glucose absorption rates and plasma insulin and GIP levels compared to 
lean subjects. In contrast, obesity nor glucose infusion altered TAS1R2 levels (Nguyen et al.). 
Surprisingly the increase in glucose absorption and SGLT1 expression levels was associated with 
lower glucose-induced GLP-1 levels. This suggests that the increased proximal glucose absorption will 
result in a reduced glucose exposure in the distal intestine leading to a diminished glucose-
stimulated GLP-1 release.  
SGLT1-/- mice displayed decreased blood glucose levels, increased delivery of glucose to the distal 
small intestine/caecum and increased GLP-1 release, highlighting SGLT1 as a therapeutic target. 
However, these mice also suffer from glucose and galactose malabsorption, characterized by severe 
diarrhea (Powell et al., 2013a). To avoid gastro-intestinal side effects, most pharmaceutical 
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companies focused on the renal glucose transporter SGLT2, of which several selective inhibitors are 
approved for the treatment of T2DM (Rosenwasser et al., 2013). However, partial blockage of SGLT1, 
as observed in heterozygous SGLT1-/- mice, increased glucose disposal to the distal small intestine 
and caecum and increased GLP-1 secretion without inducing the gastro-intestinal side-effects (Powell 
et al., 2013a). These results opened a therapeutic window for achieving glycemic efficiency with a 
dual antagonist for SGLT1 and SGLT2. Indeed, treatment with Sotagliflozin/LX4211, a dual SGLT1 and 
SGLT-2 antagonist for 28 days improved glucose tolerance, increased plasma GLP-1 and PYY levels, 
and tended to decrease body weight in T2DM patients compared to placebo (Zambrowicz et al., 
2012). A longer, 12 week treatment with Sotagliflozin/LX4211, also improved glycemic control and 
decreased body weight in inadequately controlled type 2 diabetic patients on metformin 
monotherapy (Rosenstock and Ferrannini, 2015). Powell et al. showed that the effect of 
Sotagliflozin/LX4211 on glucose absorption and GLP-1 and PYY release is due to the blockage of 
SGLT1 and not SGLT2 in mice (Powell et al., 2013b).  
Collectively these findings suggest that intestinal glucose transporters, rather than sweet taste 
receptors play an important role in the regulation of gut hormone levels in response to glucose. 
Therefore pharmacological inhibitors for the intestinal SGLT1 transporter, or endoscopic devices that 
prevent carbohydrate exposure to the proximal intestine and induce a higher carbohydrate exposure 
to GLP-1 containing L-cells in the distal intestine, may pose potential strategies in the treatment of 
obesity and T2DM.  
We conclude that despite promising results in other models, our results and data in humans 
currently do not support the concept that acute consumption of low calorie sweeteners can reduce 
food intake through modulation of gastrointestinal hormones. In contrast, therapeutic modulation of 
glucose transporters may pose a new strategy for anti-obesity treatments. 
6.3 Gut sensing: the emerging role of the distal gut 
6.3.1 Short-chain fatty acids in the interplay between diet and energy balance 
Long-term administration of the prebiotic sweetener OFS, but not of “equisweet” concentrations of 
the artificial sweetener, sucralose, decreased body weight gain and the accumulation of fat pad mass 
in our study. These results highlighted that the effects observed after OFS administration were not 
mediated through sweet taste receptor activation but likely through the produced SCFAs and thus 
may involve FFAR2/3. SCFA supplementation may directly decrease fat storage since Lin et al. 
showed that dietary supplementation of butyrate and propionate in mice completely blocked HFD-
induced weight gain, while acetate supplementation led to a 40% suppression of excess weight gain 
(Lin et al., 2012, Lu et al., 2016). SCFAs have also been shown to reduce lipolysis and increase 
adipogenesis in cultured adipocytes of WT, but not of FFAR2-/- mice, indicating a role of FFAR2 
signaling in adipocyte metabolism (Hong et al., 2005, Ge et al., 2008). The reduced body fat after OFS 
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administration in our study was also accompanied by an increase in FFAR2 expression levels in fat 
depots, strengthening the hypothesis of a role for FFAR2 signaling on adipose tissue.  
FFAR2/3 signaling has also been shown to be mediate gut hormone release. Acetate and propionate 
inhibited ghrelin secretion through FFAR2 from gastric X/A cells, harvested from ghrelin-hrGFP 
reporter mice (Engelstoft et al., 2013).  
Tolhurst et al. showed that propionate and acetate trigger GLP-1 release from primary colonic 
cultures from WT mice, and that this effect was markedly or slightly diminished in cultures from 
FFAR2-/- mice and FFAR3-/- mice, respectively (Tolhurst et al., 2012). Furthermore, Brooks et al. 
showed that FFAR2 is important for the body weight loss after supplementation of inulin and that the 
prebiotic inulin can increase the density of PYY-containing cells and circulating PYY levels through 
FFAR2 activation (Brooks et al., 2017). In contrast, Lin et al. showed that an acute dose of butyrate, 
but not of acetate or propionate, increased GLP-1 and PYY levels in WT mice which was attenuated in 
FFAR3-/- mice (Lin et al., 2012). FFAR2-/- and FFAR3-/- mice also showed reduced basal and glucose-
induced GLP-1 levels (Tolhurst et al., 2012). 
However, the decreased body weight gain and fat pas mass after long-term OFS supplementation in 
our study was accompanied by a decrease in plasma GLP-1 levels and no effect on plasma PYY or 
ghrelin levels. The discrepancy between the SCFA-induced GLP-1 release in the acute experiments 
and the decreased glucose-induced GLP-1 release in our long-term study may indicate a time-related 
effect of SCFAs on gut hormone release. Indeed, Chambers et al. showed that in contrast to an acute 
colonic administration, long-term colonic administration of inulin-propionate in humans did not alter 
GLP-1 plasma levels. This indicates that the acute effects are not fully representative for the effects 
of long-term administration (Chambers et al., 2015). 
Furthermore, our results highlight the importance of the route and timing of SCFA administration. In 
our study, intragastric administration of a specific dose of OFS (300mg/day), one hour before lights 
off, improved body weight but not glucose tolerance in HFD fed mice, over a course of 8 weeks. In 
contrast, Cani et al. showed that continuous feeding of a HFD supplemented with 10% OFS 
(±300mg/day) for 4 weeks, improved both body weight and glucose homeostasis (Cani et al., 2006).  
Furthermore, feeding ob/ob mice a HFD while supplementing the drinking water with 300mg 
OFS/day for 8 weeks, improved glucose homeostasis but not body weight, although it did reduce fat 
mass and food intake (Everard et al., 2011). However, feeding diet-induced obese mice a HFD while 
supplementing the drinking water with 300mg OFS/day for 8 weeks, did improve glucose 
homeostasis and body weight (Everard et al., 2011). 
Targeted delivery could also be a useful strategy to supplement SCFAs since acute colonic infusion of 
propionate in rodents has been shown to stimulate the secretion of the satiety hormones GLP-1 and 
PYY through FFAR2 signaling (Psichas et al., 2015). Furthermore, Van der Beek et al. investigated the 
difference between acute proximal and distal colonic infusions of acetate on metabolic parameters in 
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overweight/obese men. Targeted distal colonic infusions of acetate increased fasting fat oxidation, 
peptide PYY levels and postprandial glucose and insulin concentrations, while proximal colonic 
infusions showed no effect on substrate metabolism or circulating hormones, highlighting the role of 
the delivery site (van der Beek et al., 2016). Inulin-propionate esters were developed and tested as 
site-specific delivery vehicles for colonic propionate delivery (Polyviou et al., 2016). This inulin-
propionate ester reduced weight gain, intra-abdominal adipose tissue distribution, 
intrahepatocellular lipid content and prevented the deterioration in insulin sensitivity compared to 
the inulin-control group after 24 weeks (Chambers et al., 2015). 
Targeted colonic delivery of acetate/propionate or selective agonists targeting FFAR2/3 in the distal 
colon or FFAR2 in the adipose tissue might be an alternative to treat obesity. 
6.3.2 Is our taste manipulated by the gut microbiota? 
Obesity and metabolic disorders are associated with an altered microbial composition and ecology 
(D'Aversa et al., 2013). Several (Turnbaugh et al., 2009, Ley et al., 2006), but not all (Walters et al., 
2014) studies reported a decrease in the fraction of Bacteroidetes species relative to Firmicutes 
species in obese versus lean individuals. These ratios depend on the caloric balance of the individuals 
studied, since weight loss increases the relative portion of Bacteroidetes species and microbial 
diversity (Ley et al., 2006, Cotillard et al., 2013).  
Both prebiotic treatment (Delzenne et al., 2011a) and RYGB surgery (Aron-Wisnewsky and Clement, 
2014, Kong et al., 2013) have been shown to have beneficial effects on gut microbiota composition. 
However, in contrast to prebiotic sweeteners, daily administration of artificial sweeteners in healthy 
volunteers who do not normally consume HIS or HIS-containing foods, induced dysbiosis resulting in 
a deteriorated glucose intolerance (Suez et al., 2014). Several studies in germ-free mice have shown 
that the presence and diversity of the different gut microbes plays an active role in the glucose- and 
energy homeostasis of the host; 1) germ-free mice are leaner than normal mice (Backhed et al., 
2004) and are resistant to diet induced obesity from a high-fat or western style diet (Rabot et al., 
2010, Backhed et al., 2007), 2) transfer of intestinal microbiota from lean mice to gnotobiotic mice 
results in weight (fat) gain despite decreased energy intake and increased EE (Backhed et al., 2004), 
3) colonization of germ-free mice with the microbiota from obese mice resulted in a greater increase 
in total body fat compared with germ-free mice colonized with the microbiota from lean mice 
(Turnbaugh et al., 2006), 4) artificial sweeteners induced dysbiosis causing glucose intolerance (Suez 
et al., 2014). 
This gut microbiota might also be able to modulate the expression of taste receptors on the tongue 
to alter food preference, and in the gut to alter gut hormone release. Germ-free mice showed an 
increased lingual CD36 expression, which correlated with an increased preference and caloric intake 
from fat (Duca et al., 2012). Furthermore, germ-free mice also consumed more of a sucrose solution 
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compared to control mice, although their preference for sucrose and lingual TAS1R3 and SGLT1 
expression was similar (Swartz et al., 2012). The increased consumption of fat and carbohydrates 
could be an adaptation to the chronic energy-deficient state. 
In the gut, germ-free mice showed reduced protein levels of the satiety peptides CCK, GLP-1 and PYY 
which were accompanied by a decreased intestinal expression of the fatty acid sensors FFAR1, 
FFAR2, FFAR3, FFAR4 and CD36 and an upregulation of the glucose/umami sensors TAS1R3 and 
SGLT1 (Swartz et al., 2012, Duca et al., 2012). These findings suggest an interaction between the gut 
microbiota, gut peptide levels and taste receptors. However, the exact link between these 
observations and the translation to therapeutically exploitable strategies remains to be investigated. 
6.4 The future role of gut hormones in the treatment of obesity 
6.4.1 Diet: friend or foe of enteroendocrine cells 
The restauration of gut hormone profiles after RYGB surgery is accompanied by structural changes in 
gut morphology and function due to enteroplasticity.  
Intestinal enteroplasticity can beneficially affect the glucose-and energy metabolism. Several 
mechanisms of action have been proposed for the observed metabolic improvements associated 
with intestinal enteroplasticity after bariatric surgery; 1) earlier work suggests that the 
enteroplasticity increases intestinal gluconeogenesis which may decrease food intake and restore 
glucose homeostasis by compensating for the blunted hepatic gluconeogenesis (Troy et al., 2008), 2) 
a study in rats suggested that the enteroplasticity results in a decreased glucose absorption in the 
roux limb after RYGB surgery, resulting in blunted postprandial glucose levels (Stearns et al., 2009) 
and 3) Saeidi et al. reported that after gastric bypass the intestine becomes an important tissue for 
glucose disposal to meet the anabolic demands of the intestinal tissue growth that occurs after 
bariatric surgery (Saeidi et al., 2013). 
Furthermore, this enteroplasticity seems to be extended to the enteroendocrine cell lineage in both 
the small intestine and distal part of the intestine. In the small intestine the enteroplasticity was 
accompanied by an increase in GLP-1 and PYY positive cells after RYGB surgery in our study. In 
previous studies in rats, RYGB surgery also increased the number of GLP-1, CCK, serotonin and PYY 
containing cells in the common limb (Mumphrey et al., 2013). Therefore this enteroplasticity might 
result in elevated nutrient-induced gut hormone secretion. Nutrient exposure seems to be able to 
influence this enteroplasticity since in our RYGB study, the limb which was overexposed to nutrients 
showed hypertrophy and an increased number of L-cells, while the limb that does not come into 
contact with nutrients anymore, did not.  
RYGB surgery did not increase L-cell density in the distal part of the colon, although it did increase 
the amount of L-cells in this tissue, which could be due to an increased colonic mucosal height. OFS 
supplementation also increased the colonic mucosal height in WT mice without affecting L-cell 
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density. This enteroplasticity might be due to the altered bacterial fermentation. Our results further 
indicate that gustducin-mediated signaling may play a role in these effects since the observed colonic 
hypertrophy after RYGB and OFS supplementation was absent in α-gustducin knockout mice.  
If nutrient sensors are involved in this enteroplasticity, specific diets might be able to alter intestinal 
glucose disposal and programming of EECs in order to regulate gut hormone levels. High-fat feeding 
stimulated the differentiation towards K-cells in the duodenum of Wistar rats (Gniuli et al., 2010). 
Furthermore, a previous study in mice highlighted the role of nutrient sensing in L-cell 
differentiation; ob/ob mice did not show altered L-cell density, while mice on a high-fat diet did in 
both the jejunum and colon. Thus, the lipid-rich diet is needed to trigger changes in L-cell number 
(Aranias et al., 2015).  
SCFAs have also been shown to increase intestinal differentiation of stem cells into L-cells in the 
lower part of the gut (Delzenne et al., 2007). Furthermore, using FFAR2-/- mice, Brooks et al. showed 
that the fermentable prebiotic inulin acts via FFAR2 to increase the density of PYY containing cells 
(Brooks et al., 2017). 
These results suggest that we might be able to modulate the gut through nutrient-induced intestinal 
enteroplasticity in both the small intestine and the distal part of the intestine. However, instead of 
ingesting a high-fat diet, targeting both short-chain and medium/long chain FFARs in the gut may 
pose an interesting therapeutic strategy to induce enteroplasticity.  
6.4.2 Going to the source: gut hormone multi-agonist drug candidates 
Obesity has been associated with altered meal-induced gut hormone release. Obese and overweight 
patients reported attenuated postprandial plasma GLP-1 (Adam and Westerterp-Plantenga, 2005, 
Verdich et al., 2001) and PYY levels (le Roux et al., 2006, Zwirska-Korczala et al., 2007), while fasting 
and postprandial plasma ghrelin levels were reported to be lower in obese individuals and show less 
pronounced meal-related fluctuations (Carlson et al., 2009). Restauration of these gut hormone 
profiles are thought to contribute to the superior weight loss and improvement in blood glucose 
levels observed after RYGB surgery. This suggests that gut hormones could be targets for novel 
obesity and diabetes therapies. 
Our study and previous reports highlighted that the metabolic improvements after RYGB surgery are 
associated with increased plasma GLP-1 and PYY levels, while the effect on plasma ghrelin levels is 
controversial (Sweeney and Morton, 2014). RYGB surgery is still an invasive technique but mimicking 
the sustained and enhanced release of GLP-1 and PYY might be a valuable, non-invasive alternative 
for bariatric surgery. 
GLP-1 is currently the most successful gut hormone to be exploited for therapeutic purposes in 
humans. Liraglutide, a long-working GLP-1 analogue is currently on the market for the treatment of 
obesity (Pi-Sunyer et al., 2015). PYY administration might also pose an interesting strategy to 
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decrease body weight, but it can lead to intolerable side effects like nausea and vomiting (Gantz et 
al., 2007). Ghrelin receptor antagonists and ghrelin-O acyl transferase inhibitors are another group of 
molecules which have received some interest for development as anti-obesity targets (Schellekens et 
al., 2010), but none of these candidates have yet been introduced on the market. 
A new treatment strategy may be polypharmaceutical agents. Co-administration of oral GLP-1 and 
PYY in healthy male volunteers reduced total energy intake and fullness at meal onset, but not 24-h 
energy intake (Steinert et al., 2010). Furthermore, IV co-infusion of GLP-1 and PYY in lean (Neary et 
al., 2005) and overweight men (Schmidt et al., 2014) reduced energy intake compared to placebo, 
although the mono-infusions of GLP-1 or PYY did not, demonstrating a synergistic effect.  
Preclinical results in rodents also showed that a triagonist binding the GLP-1 receptor, GIP receptor 
and glucagon receptor has better metabolic effects compared to the respective dual agonists and 
lowers body weight without a hypoglycemic risk (Finan et al., 2015). The rationale for this triagonist 
stems from the proven efficiency of GLP-1 agonists in T2DM and obesity, the ability of glucagon to 
increase lipolysis and thermogenesis (Davidson et al., 1957, Joel, 1966) and the potency of the 
incretin hormone GIP to enhance the glycemic benefits of GLP-1 (Finan et al., 2013). The metabolic 
contribution of each of the three independent agonists within the triagonist was demonstrated in 
genetic loss-of-function models for each of the three receptors (Finan et al., 2015). However, the 
magnitude of weight loss in a clinical setting and the speed with which it is achieved needs to be 
thoroughly established in subsequent work. A strategy combining the synergistic effects of GLP-1 and 
PYY with an antagonist of the ghrelin receptor may offer a future therapeutic approach to combat 
obesity. 
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7 SUMMARY 
The obesity rates continue to rise worldwide and are associated with adverse health problems, 
including increased risk of T2DM. Excessive weight gain is often considered to be the result of 
excessive food intake and/or insufficient physical activity. In addition, the food landscape has shifted 
dramatically over the past several decades and the increased consumption of soft drinks and other 
sugar-sweetened beverages is considered as a major contributor to the obesity epidemic. Not 
surprisingly, non-caloric sweeteners have increased in popularity over the years as a mean to 
facilitate weight loss by reducing the sugar content of meals without affecting its taste. Next to these 
non-caloric sweeteners, low-caloric prebiotic sweeteners (oligofructose; OFS) have been proposed as 
functional food ingredients that could improve lipid metabolism and body weight through beneficial 
effects ascribed to their fermentation products, the short-chain fatty acids (SCFAs). When dietary 
changes are insufficient, pharmacotherapy can be added, although the risks and modest nature of 
weight loss that can be achieved with these anti-obesity drugs highlights the need for new treatment 
strategies. The gastrointestinal tract is an obvious target for new anti-obesity treatment strategies as 
it coordinates the release of gut hormones, such as the ‘hunger hormone’ ghrelin and satiety 
hormones GLP-1 and PYY, to regulate energy uptake and utilization. Restoring postprandial gut 
hormone levels (ghrelin, GLP-1, PYY), known to be dysregulated in obesity, may play a role in the 
metabolic improvements after bariatric surgery such as Roux-en-Y gastric bypass (RYGB) surgery. 
RYGB surgery is an invasive technique that is associated with elevated GLP-1 and PYY levels. 
Mimicking the sustained and enhanced release of GLP-1 and PYY in a pharmacological manner might 
be a valuable, non-invasive alternative for bariatric surgery. The magnitude of postprandial gut 
hormone release depends on the meal composition. Several taste receptors (sweet, umami, bitter, 
fatty acid) and the taste receptor coupled G-protein, α-gustducin, are not only present on taste buds 
of the tongue but also on EECs and may tune gut hormone release according to the macronutrient 
composition of the meal. The physiological role of taste receptors on EECs has not been fully 
elucidated yet.  
In this thesis, we aimed to unravel whether α-gustducin coupled sweet taste receptors (TAS1R2-
TAS1R3) play a role in the sensing of carbohydrates and sweeteners by the ghrelin cell. In addition, 
we elucidated whether intragastric supplementation of artificial sweeteners (sucralose) or prebiotic 
sweeteners (OFS) can prevent the deleterious effects of a high-fat diet in mice by altering gut 
hormone release through gustducin-mediated taste receptor activation. As a last aim, we 
investigated the effect of nutrient rerouting during RYGB surgery on the α-gustducin-mediated 
signaling pathways that contribute to the metabolic improvements and physiological adaptations 
along the gut after RYGB surgery. 
 
Summary
 
134 
 
In the third chapter of this thesis we investigated if α-gustducin mediated sweet taste receptor 
signaling is involved in the sensing of sweeteners by the ghrelin cell in three different experimental 
models (a ghrelinoma cell line, ex vivo intestinal segments, in vivo experiments).  
The carbohydrate D-glucose and prebiotic sweetener OFS decreased ghrelin release from a gastric 
ghrelinoma cell line at concentrations physiological to the postprandial luminal fluid. In contrast, the 
artificial sweetener sucralose increased ghrelin release in vitro at a supraphysiological (200mM) 
concentration. Furthermore, by using pharmacological inhibitors we showed that neither sweet taste 
receptor activation, nor glucose transport (SGLT1, GLUT family) played a role in the effect of D-
glucose, OFS or sucralose on ghrelin release from the ghrelinoma cell line. Ghrelin release from 
gastric (only containing the TAS1R3 subunit) and jejunal (containing the TAS1R2 and TAS1R3 subunit) 
segments from WT and α-gust-/- mice, mimicked the in vitro effects of the sweeteners in the 
ghrelinoma cell line to a similar extent in both genotypes. These findings indicate that the effect of D-
glucose, OFS and sucralose on ghrelin release is neither α-gustducin nor region-dependent and thus 
does not involve the α-gustducin coupled TAS1R2-TAS1R3 heterodimer. Intragastric, but not 
intravenous administration of D-glucose decreased plasma octanoyl ghrelin levels in WT and α-gust-/- 
mice, indicating that the sensing of D-glucose is polarized and occurs via the luminal side of the X/A 
cell. In contrast, neither OFS nor sucralose at “equisweet” concentrations affected octanoyl ghrelin 
release after an intragastric administration in WT or α-gust-/- mice.  
In conclusion, our findings indicate that α-gustducin-mediated sweet taste receptor signaling does 
not play a functional role in the effect of sweeteners on ghrelin release. In contrast to the in vitro 
findings, only acute intragastric administration of D-glucose but not OFS or sucralose affected ghrelin 
release. 
In the fourth chapter of this thesis we studied whether daily intragastric administration of equisweet 
concentrations of an artificial sweetener (sucralose) or a prebiotic sweetener (OFS) for 8 weeks can 
prevent high-fat diet induced body weight gain, glucose intolerance and impairment of gut 
permeability, via activation of taste receptors coupled to α-gustducin, using WT and α-gust-/- mice.  
Sucralose administration did not modulate gut hormone release nor did it prevent body weight gain 
or glucose intolerance. Instead we provided evidence that OFS (300mg/day) administration 
decreased HFD-induced body weight gain with about 20% without improving glucose homeostasis. 
This effect was not accompanied by a reduced food intake. Furthermore, OFS induced a similar but 
delayed decrease in body weight gain in α-gust-/- mice, indicating that the α-gustducin mediated 
signaling pathway did not play a major role in this effect. OFS administration did not affect plasma 
levels of ‘the hunger hormone’ ghrelin and ‘satiety hormone’ PYY, but decreased plasma levels of 
‘the satiety hormone’ GLP-1 in WT mice. These changes in gut hormone levels cannot explain the 
beneficial effects on body weight. Neither OFS, nor sucralose administration altered the mRNA 
expression levels of the TAS1R2 or TAS1R3 subunit of the sweet taste receptor in the gastro-
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intestinal tract. However, OFS supplementation decreased cecal acetate and butyrate levels, 
downregulated colonic short chain fatty acid receptor (FFAR2/3) mRNA levels and upregulated FFAR2 
in peripheral adipose tissue. These findings suggest that, not sweet taste receptor activation, but 
enhanced uptake of SCFAs produced by the fermentation of OFS interacting with FFAR2 in peripheral 
adipose tissue may reduce adipogenesis and lead to the decrease (60%) in fat mass. Moreover, OFS 
improved the increased colonic permeability which results in metabolic complications in obesity, 
independent from taste receptors coupled to α-gustducin.  
In conclusion, this study provided evidence that despite the controversy in the field, artificial 
sweeteners are metabolically inert. Furthermore, neither OFS nor sucralose affected TAS1R2 or 
TAS1R3 mRNA levels, while OFS supplementation altered FFAR2/3 expression levels in the 
gastrointestinal tract and on adipose tissue. Therefore, not sucralose but OFS and especially the 
produced SCFAs, are interesting metabolites that could beneficially affect body weight gain. 
In the fifth chapter we studied the role of gustducin-mediated signaling in the metabolic 
improvements and intestinal adaptations along the gut after RYGB surgery in obese WT and α-gust-/- 
mice.  
We showed that RYGB surgery decreased body weight in WT and -gust-/- mice. Furthermore, pair-
feeding to the RYGB group induced similar blood glucose and plasma insulin profiles during an oral 
glucose tolerance test compared to RYGB surgery, indicating that the reduced food intake after RYGB 
surgery was responsible for the improved glucose homeostasis. Moreover, -gust-/- mice were 
partially protected from the diabetogenic properties of a western style diet, highlighting the 
importance of the gustatory signaling pathway in glucose homeostasis. RYGB surgery increased 
plasma GLP-1 levels in both genotypes and plasma PYY levels only in α-gust-/-mice. Plasma octanoyl 
ghrelin levels were not affected after surgery. The mechanism behind the postsurgical changes in gut 
hormone levels seemed to differ between WT and -gust-/- mice.  
In WT mice, nutrients act via α-gustducin to increase L-cell differentiation (in the Roux limb which 
comes in contact with more undigested nutrients) and L-cell number (Roux limb and colon) after 
RYGB surgery, in a region-dependent manner. However, this nutrient rerouting did not alter the 
mRNA expression levels of nutrient sensors in the Roux Limb, nor did it alter bacterial fermentation 
in the caecum of WT mice. In contrast, -gust-/- mice did not display an altered L-cell number or L-cell 
differentiation in the Roux limb or colon. However, -gust-/- mice did show increased mRNA 
expression levels of the glucose transporters (SGLT1 and GLUT2) and the protein sensor (LPAR5) in 
the Roux limb. Furthermore, RYGB surgery changed bacterial fermentation in the caecum of -gust-/- 
mice, which showed increased butyrate and propionate levels compared to WT mice. This resulted in 
decreased colonic FFAR2/3 mRNA levels in -gust-/- mice. These results suggest that a changed L-cell 
number and differentiation will be responsible for the increased plasma GLP-1 levels in WT mice. In 
contrast, alterations in nutrient signaling in the foregut, and altered bacterial fermentation and 
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short-chain fatty acid sensing in the distal gut of -gust-/- mice could explain the increased plasma 
GLP-1 and PYY levels in this genotype. Finally, signaling via α-gustducin plays a role in the increased 
ion transport of the foregut but not in the improvement in colonic barrier function.  
To summarize, our findings do not indicate a major contribution of α-gustducin-mediated signaling in 
the metabolic effects of RYGB. Nevertheless, RYGB activated several regulatory systems in which the 
gustducin mediated signaling pathway plays a role. This study highlights that nutrients cannot only 
serve as fuel but may regulate a number of physiological processes after RYGB surgery such as tuning 
of gut hormone release which is the result of multifaceted intestinal adaptations along the gut. 
Importantly, these gut hormones could contribute to the observed metabolic improvements after 
RYGB surgery.  
In conclusion our studies suggest that the canonical sweet taste receptor signaling pathway does not 
seem to play a major role in the sensing of carbohydrates or sweeteners by the ghrelin cell. 
Furthermore, in vivo targeting of sweet taste receptors on EECs by supplementing artificial 
sweeteners directly into the stomach for several weeks does not help to prevent the development of 
obesity nor T2DM. In contrast, prebiotic sweeteners seem to be more promising since their 
fermentation products target SCFA receptors. On a long term basis their effect on short-chain fatty 
acid induced gut hormone release does not seem to play a major role in the development of obesity 
but their capacity to alter expression levels of SCFA receptors on adipose tissue might be relevant. 
Finally, gustducin-mediated nutrient sensing does not play a role in the effect of RYGB surgery on the 
energy-and glucose homeostasis, but altered gut hormone levels might.  
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8 SAMENVATTING 
De prevalentie van obesitas blijft toenemen en is geassocieerd met comorbiditeiten zoals T2DM. 
Gewichtstoename is vaak te wijten aan een te hoge calorische inname en/of te lage fysieke activiteit. 
Hiernaast is ons voedselconsumptiepatroon over de laatste decennia sterk veranderd waarbij de 
toegenomen consumptie van frisdranken en andere met suiker gezoete dranken een belangrijke 
bijdrage levert aan de obesitas epidemie. Bijgevolg worden niet calorische zoetstoffen meer en meer 
gebruikt als een middel om gewichtsverlies te bekomen door de hoeveelheid suiker in de maaltijden 
te vervangen zonder aan smaak in te boeten. Naast deze niet calorische zoetstoffen worden laag 
calorische prebiotische zoetstoffen (oligofructose; OFS) voorgesteld als functionele voedingsstoffen 
die het vetmetabolisme en de energiehuishouding kunnen beïnvloeden via hun 
fermentatieproducten, de korteketenvetzuren. Wanneer veranderingen in voedingsgewoonten niet 
voldoende zijn in de strijd tegen obesitas, kan een farmacologische behandeling toegevoegd worden. 
De nevenwerkingen en beperkte efficiëntie van deze geneesmiddelen benadrukken echter de nood 
aan nieuwe therapeutische strategieën.  
Het gastro-intestinaal stelsel is een voor de hand liggend doelwit voor nieuwe anti-obesitas 
strategieën aangezien het de vrijstelling coördineert van maag-darmhormonen, zoals het 
‘hongerhormoon’ ghreline en de verzadigingshormonen GLP-1 en PYY, die onze energieopname- en 
verbruik regelen. Het herstellen van postprandiale plasmawaarden van maag-darmhormonen 
(ghreline, GLP-1 en PYY), die ontregeld zijn in de obese populatie, kan een belangrijke rol spelen in de 
metabole veranderingen na bariatrische chirurgie zoals Roux-en-Y maagbypass (RYGB). RYGB is een 
invasieve chirurgische techniek die gepaard gaat met een sterk verhoogde vrijstelling van GLP-1 en 
PYY. Het farmacologisch nabootsen van deze gewijzigde plasmawaarden van maag-darmhormonen 
kan een waardevol niet invasief alternatief zijn voor RYGB. De grootte van de postprandiale 
vrijstelling van maag-darmhormonen hangt af van de samenstelling van de maaltijd. Verschillende 
smaakreceptoren (zoet, umami, bitter en vetzuren) en het smaak G-proteïne, α-gustducine, zijn niet 
enkel aanwezig op de smaakpapillen op de tong, maar ook op enteroendocrine cellen (EEC) in het 
maag-darmstelsel en kunnen daar mogelijks de vrijstelling van maag-darmhormonen afstellen op de 
samenstelling van de maaltijd. De fysiologische rol van deze smaakreceptoren op EEC is echter nog 
niet volledig achterhaald.  
In dit doctoraatsproject werd nagegaan of zoetsmaakreceptoren (TAS1R2-TAS1R3) gekoppeld aan α-
gustducine een rol spelen in het waarnemen van koolhydraten en zoetstoffen door de ghrelinecel. 
Vervolgens werd nagegaan of intragastrische supplementatie van artificiële (sucralose) of 
prebiotische (oligofructose) zoetstoffen de nadelige effecten van een hoogvetdieet kunnen 
voorkomen door maag-darmhormonen vrij te stellen na activatie van gustducine-gekoppelde 
smaakreceptoren. Ten slotte onderzochten we of het omleiden van nutriënten na RYGB een effect 
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heeft op gustducine-gemedieerde signaalwegen en of deze bijdragen tot de metabole veranderingen 
en fysiologische aanpassingen van de darm na RYGB. 
In het derde hoofdstuk van dit doctoraatsproject werd, in drie verschillende experimentele modellen 
(een ghrelinoma cellijn, intestinale segmenten van muizen en in vivo experimenten) nagegaan, of 
gustducine-gekoppelde zoetsmaakreceptoren een rol spelen in het waarnemen van zoetstoffen door 
de ghrelinecel.  
De suiker D-glucose en het prebiotische koolhydraat OFS doen de ghrelinevrijstelling in een 
gastrische ghrelinoma cellijn dalen bij concentraties die fysiologisch zijn aan de postprandiale 
luminale inhoud, terwijl een suprafysiologische concentratie (200mM) van de artificiële zoetstof 
sucralose de ghrelinevrijstelling in dit model doet stijgen. Door farmacologische inhibitoren te 
gebruiken toonden we aan dat noch activatie van de zoetsmaakreceptor, noch glucose transport (via 
SGLT1, de GLUT familie) een rol spelen in het effect van D-glucose, OFS of sucralose op de 
ghrelinevrijstelling in de ghrelinoma cellijn. Het effect van glucose en zoetstoffen op de 
ghrelinevrijstelling van segmenten van de maag (bevat enkel de TAS1R3 subeenheid) en jejunum 
(bevat zowel de TAS1R2 als de TAS1R3 subeenheid) van zowel WT als α-gust-/-muizen was gelijkaardig 
aan deze bekomen in de ghrelinoma cellijn. Deze bevinding duidt erop dat het effect van D-glucose, 
OFS en sucralose op ghrelinevrijstelling niet afhankelijk is van α-gustducine, noch regiospecifiek is en 
bijgevolg niet gemedieerd is via het aan α-gustducine-gekoppelde TAS1R2-TAS1R3 heterodimeer. 
Intragastrische, maar niet intraveneuze, toediening van D-glucose veroorzaakte een daling van de 
plasma ghrelinewaarden van WT en α-gust-/- muizen. Hieruit kunnen we concluderen dat het 
waarnemen van D-glucose door de ghrelinecel gepolariseerd is en aan de luminale zijde van de X/A 
cel gebeurt. Aan concentraties met een gelijk zoetgehalte veroorzaakte noch OFS noch sucralose na 
intragastrische toediening een wijziging in de ghrelinewaarden van WT of α-gust-/- muizen. Deze 
studie toont aan dat activatie van gustducine-gekoppelde zoetreceptoren geen functionele rol speelt 
in het effect van zoetstoffen op ghrelinevrijstelling. In tegenstelling tot de in vitro resultaten kan 
enkel D-glucose, maar niet OFS of sucralose, de ghrelinevrijstelling in vivo beïnvloeden.  
In het vierde hoofdstuk van deze thesis bestudeerden we of dagelijkse intragastrische toediening 
van equizoete concentraties van een artificiële (sucralose) of prebiotische (oligofructose) zoetstof 
gedurende 8 weken het nadelige effect van een hoogvetdieet op lichaamsgewicht, T2DM en 
darmpermeabiliteit kan voorkomen via activatie van smaakreceptoren gekoppeld aan α-gustducine. 
Hiervoor werden WT en α-gust-/- muizen gebruikt. De artificiële zoetstof sucralose had geen effect op 
de vrijstelling van de maag-darmhormonen, noch voorkwam het de toename in lichaamsgewicht of 
de ontwikkeling van T2DM geïnduceerd door het hoogvetdieet. Desalniettemin deed een éénmaal 
dagelijkse toediening van OFS (300mg/dag) gedurende 8 weken de toename van lichaamsgewicht, 
geïnduceerd door een hoogvetdieet, met 20% afnemen, zonder de glucose homeostase te 
verbeteren. Dit effect ging niet gepaard met een gedaalde voedselinname. Verder induceerde OFS 
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een gelijkaardig maar vertraagd effect op de toename in lichaamsgewicht in α-gust-/- muizen. Dit 
wijst erop dat de gustducine-gemedieerde signaalweg geen belangrijke rol speelt in dit effect. OFS 
toediening beïnvloedde de plasmawaarden van het ‘hongerhormoon’ ghreline en het 
‘verzadigingshormoon’ PYY niet, maar deed de plasmawaarden van het ‘verzadigingshormoon’ GLP-1 
dalen in WT muizen. Een daling in verzadigingshormoon kan echter het lager lichaamsgewicht na OFS 
supplementatie niet verklaren.  
Daarboven hadden noch OFS noch sucralose een effect op de mRNA expressie van de TAS1R2 of 
TAS1R3 subeenheid van de zoetsmaakreceptor doorheen het maag-darmstelsel. OFS supplementatie 
veroorzaakte een daling in het acetaat en butyraat gehalte in het caecum en in de mRNA expressie 
van de korteketenvetzuurreceptoren, FFAR2/3, in het colon. Daarentegen werd de mRNA expressie 
van de FFAR2 in het vetweefsel verhoogd. Deze resultaten suggereren dat niet zoetreceptoractivatie, 
maar wel de toegenomen opname van korteketenvetzuren en hun interactie met FFAR2/3 in perifeer 
vetweefsel adipogenese kan reduceren om alzo een daling (60%) in vetmassa te induceren. 
Daarboven verbeterde OFS de gestegen permeabiliteit in het colon, onafhankelijk van 
smaakreceptoren gekoppeld aan α-gustducine.  
Deze studie toont aan dat, ondanks de tegenstrijdige resultaten in het onderzoeksveld, artificiële 
zoetstoffen toch metabool inert zijn. Daarnaast beïnvloedde noch OFS noch sucralose de mRNA 
expressieniveaus van TAS1R2 of TAS1R3. Daarentegen beïnvloedde OFS supplementatie wel de 
FFAR2/3 mRNA expressieniveaus in het maag-darmstelsel en in het vetweefsel. Hieruit kunnen we 
concluderen dat niet sucralose, maar OFS en voornamelijk de geproduceerde korteketenvetzuren 
interessante metabolieten zijn die mogelijks een voordelig effect op lichaamsgewicht kunnen 
hebben. 
In het vijfde hoofdstuk van dit doctoraatsproject onderzochten we de rol van de gustducine-
gemedieerde signaalweg in de metabole veranderingen en intestinale wijzigingen na RYGB in obese 
WT en α-gust-/- muizen. RYGB deed het lichaamsgewicht van WT en α-gust-/- muizen dalen. Daarnaast 
induceerde pair-feeding dezelfde verbetering in bloed glucose en plasma insuline profielen als RYGB, 
na een orale glucosetolerantietest. Dit duidt erop dat de gedaalde voedselinname na RYGB 
verantwoordelijk is voor de verbeterde glucose homeostase. Daarboven waren α-gust-/- muizen 
gedeeltelijk beschermd tegen het diabetogeen effect van een hoogvet-hoogsuikerdieet, wat het 
belang van de gustatorische signaaltransductieweg in de glucosehomeostase onderlijnt. RYGB 
verhoogde de plasmawaarden van GLP-1 in beide genotypes en van PYY enkel in de α-gust-/- muizen. 
De plasmawaarden van ghreline waren niet beïnvloed. Het mechanisme achter de postoperatieve 
veranderingen in de plasma waarden van deze maag-darmhormonen leek echter te verschillen 
tussen de WT en α-gust-/- muizen. 
In WT muizen verhoogden nutriënten via gustducine-gemedieerde signaalwegen de L-cel 
differentiatie (in de Roux limb, het deel van de darm dat in contact komt met meer onverteerd 
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voedsel) en het aantal L-cellen (in de Roux limb en distale deel van de darm) na RYGB in een regio-
afhankelijke manier. Deze veranderingen waren niet gecorreleerd met veranderingen in mRNA 
niveaus van de nutriënt sensoren in de Roux limb, noch met wijzigingen in de bacteriële fermentatie 
in het caecum van WT muizen. In tegenstelling tot de WT muizen, vertoonden α-gust-/- muizen geen 
veranderingen in het aantal of de differentiatie van de L-cellen in de Roux limb van het colon. 
Desalniettemin verhoogde RYGB de mRNA niveaus van de glucosetranssporters (SGLT1 en GLUT2) en 
de proteïnesensor (LPAR5) in de proximale darm van α-gust-/- muizen. Verder veranderde RYGB de 
bacteriële fermentatie in het caecum van α-gust-/- muizen, die verhoogde butyraat en propionaat 
niveaus vertoonden in vergelijking met WT muizen. Dit resulteerde in gedaalde FFAR2/3 mRNA 
niveaus in het colon van α-gust-/- muizen. Deze resultaten suggereren dat de verandering in het 
aantal en de differentiatie van L-cellen verantwoordelijk kunnen zijn voor de gestegen 
plasmawaarden van GLP-1 in WT muizen. In α-gust-/- muizen zal eerder de gewijzigde waarneming in 
de signaalweg van nutriënten in de proximale darm en de veranderde bacteriële fermentatie en 
korteketenvetzuur signaalweg in de distale darm de gestegen plasma GLP-1 en PYY waarden in dit 
genotype verklaren. Tenslotte speelt de gustducine-gemedieerde signaalweg een rol spelen in het 
toegenomen ionentransport in de proximale darm, maar niet in de verbeterde darmpermeabiliteit in 
het colon na RYGB.  
Samenvattend suggereren onze resultaten dat de gustducine-gemedieerde signaalweg geen 
belangrijke rol speelt in de metabole veranderingen na RYGB. Desalniettemin activeert RYGB wel 
verschillende regulatorische systemen waarin de gustatorische signaalweg een rol speelt. Verder 
toont deze studie aan dat nutriënten niet enkel kunnen dienen als brandstof, maar na RYGB ook een 
aantal fysiologische processen kunnen regelen zoals het afstemmen van de secretie van maag-
darmhormonen, welke het resultaat is van multifactoriële intestinale veranderingen in de darm. Het 
is belangrijk op te merken dat deze maag-darmhormonen kunnen bijdragen tot de metabole 
veranderingen na een RYGB operatie. 
In conclusie suggereren onze studies dat de zoetsmaakreceptor signaalweg geen belangrijke rol 
speelt in het waarnemen van koolhydraten of zoetstoffen door de ghreline cel. Verder gaat het in 
vivo beïnvloeden van zoetsmaakreceptoren op EEC, door gastrische toediening van zoetstoffen 
gedurende verschillende weken, niet bijdragen tot de preventie van obesitas en T2DM. Prebiotische 
zoetstoffen lijken echter veelbelovend te zijn aangezien hun fermentatieprodukten de 
korteketenvetzuurreceptoren kunnen activeren. Op lange termijn lijkt het effect van deze 
korteketenvetzuren op de vrijstelling van maag-darmhormonen geen belangrijke rol te spelen in de 
ontwikkeling van obesitas, maar hun capaciteit om vetzuurreceptoren op het vetweefsel te activeren 
kan relevant zijn. Tenslotte speelt de gustducine-gemedieerde signaalweg geen rol in het effect van 
RYGB op de energie-en glucose homeostase, alhoewel maag-darmhormonen hier mogelijks wel een 
rol in kunnen spelen. 
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